Topical neurological stimulation

Information

  • Patent Grant
  • 10307591
  • Patent Number
    10,307,591
  • Date Filed
    Friday, July 14, 2017
    6 years ago
  • Date Issued
    Tuesday, June 4, 2019
    5 years ago
Abstract
A topical nerve stimulator patch and system are provided comprising a dermal patch; an electrical signal generator associated with the patch; a signal receiver to activate the electrical signal generator; a power source for the electrical signal generator associated with the patch; an electrical signal activation device; and a nerve feedback sensor.
Description
COPYRIGHT NOTICE

© 2013 and 2014 GRAHAM CREASEY, MD, & HOO-MIN TOONG, PhD. This patent document contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever. 37 CFR § 1.71(d), (e).


TECHNICAL FIELD

This invention pertains to the activation of nerves by topical stimulators to control or influence muscles, tissues, organs, or sensation, including pain, in humans and mammals.


BACKGROUND

Nerve disorders may result in loss of control of muscle and other body functions, loss of sensation, or pain. Surgical procedures and medications sometimes treat these disorders but have limitations. This invention pertains to a system for offering other options for treatment and improvement of function.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a depiction of a neuron activating a muscle by electrical impulse.



FIG. 2 is a representation of the electrical potential activation time of an electrical impulse in a nerve.



FIG. 3 is a cross section of a penis.



FIG. 4 is an illustration of a Topical Nerve Stimulator/Sensor (TNSS) component configuration including a system on a chip (SOC).



FIG. 5 is an illustration of the upper side of a Smart Band Aid™ (SBA) implementation of a TNSS showing location of battery, which may be of various types.



FIG. 6 is a an illustration of the lower side of the SBA of FIG. 5.



FIG. 7 is TNSS components incorporated into a SBA.



FIG. 8 is examples of optional neural stimulator and sensor chip sets incorporated into a SBA.



FIG. 9 is examples of optional electrode configurations for a SBA.



FIG. 10 is an example of the use of TNSS with a Control Unit as a System, in a population of Systems and software applications.



FIG. 11 shows a method for forming and steering a beam by the user of a plurality of radiators.



FIG. 12 is an exemplary beam forming and steering mechanism.



FIG. 13 illustrates exemplary Control Units for activating a nerve stimulation device.



FIG. 14 are exemplary software platforms for communicating between the Control Units and the TNSS, gathering data, networking with other TNSSs, and external communications.



FIG. 15 represents TNSS applications for patients with spinal cord injury.



FIG. 16 shows an example TNSS system.



FIG. 17 shows communications among the components of the TNSS system of FIG. 16 and a user.



FIG. 18 shows an example electrode configuration for electric field steering and sensing.



FIG. 19 shows an example of stimulating and sensing patterns of signals in a volume of tissue.





DETAILED DESCRIPTION

A method for electrical, mechanical, chemical and/or optical interaction with a human or mammal nervous system to stimulate and/or record body functions using small electronic devices attached to the skin and capable of being wirelessly linked to and controlled by a cellphone, activator or computer network.


The body is controlled by a chemical system and a nervous system. Nerves and muscles produce and respond to electrical voltages and currents. Electrical stimulation of these tissues can restore movement or feeling when these have been lost, or can modify the behavior of the nervous system, a process known as neuro modulation. Recording of the electrical activity of nerves and muscles is widely used for diagnosis, as in the electrocardiogram, electromyogram, electroencephalogram, etc. Electrical stimulation and recording require electrical interfaces for input and output of information. Electrical interfaces between tissues and electronic systems are usually one of three types:


a. Devices implanted surgically into the body, such as pacemakers. These are being developed for a variety of functions, such as restoring movement to paralyzed muscles or restoring hearing, and can potentially be applied to any nerve or muscle. These are typically specialized and somewhat expensive devices.


b. Devices inserted temporarily into the tissues, such as needles or catheters, connected to other equipment outside the body. Health care practitioners use these devices for diagnosis or short-term treatment.


c. Devices that record voltage from the surface of the skin for diagnosis and data collection, or apply electrical stimuli to the surface of the skin using adhesive patches connected to a stimulator. Portable battery-powered stimulators have typically been simple devices operated by a patient, for example for pain relief. Their use has been limited by;


i. The inconvenience of chronically managing wires, patches and stimulator, particularly if there are interfaces to more than one site, and


ii. The difficulty for patients to control a variety of stimulus parameters such as amplitude, frequency, pulse width, duty cycle, etc.


Nerves can also be stimulated mechanically to produce sensation or provoke or alter reflexes; this is the basis of touch sensation and tactile feedback. Nerves can also be affected chemically by medications delivered locally or systemically and sometimes targeted to particular nerves on the basis of location or chemical type. Nerves can also be stimulated or inhibited optically if they have had genes inserted to make them light sensitive like some of the nerves in the eye. The actions of nerves also produce electrical, mechanical and chemical changes that can be sensed.


The topical nerve stimulator/sensor (TNSS) is a device to stimulate nerves and sense the actions of the body that can be placed on the skin of a human or mammal to act on and respond to a nerve, muscle or tissue. One implementation of the TNSS is the Smart Band Aid™ (SBA). A system, incorporating a SBA, controls neuro modulation and neuro stimulation activities. It consists of one or more controllers or Control Units, one or more TNSS modules, software that resides in Control Units and TNSS modules, wireless communication between these components, and a data managing platform. The controller hosts software that will control the functions of the TNSS. The controller takes inputs from the TNSS of data or image data for analysis by said software, The controller provides a physical user interface for display to and recording from the user, such as activating or disabling the TNSS, logging of data and usage statistics, generating reporting data. Finally, the controller provides communications with other Controllers or the Internet cloud.


The controller communicates with the neurostim module, also called TNSS module or SBA, and also communicates with the user. In at least one example, both of these communications can go in both directions, so each set of communications is a control loop. Optionally, there may also be a control loop directly between the TNSS module and the body. So the system optionally may be a hierarchical control system with at least four control loops. One loop is between the TNSS and the body; another loop is between the TNSS and the controller; another loop is between the controller and the user; and another loop is between the controller and other users via the cloud, which may be located in the TNSS, the controller or the cloud, has several functions including: (1) sending activation or disablement signals between the controller and the TNSS via a local network such as Bluetooth; (2) driving the user interface, as when the controller receives commands from the user and provides visual, auditory or tactile feedback to the user; (3) analyzing TNSS data, as well as other feedback data such as from the user, within the TNSS, and/or the controller and/or or the cloud; (4) making decisions about the appropriate treatment; (5) system diagnostics for operational correctness; and (6) communications with other controllers or users via the Internet cloud for data transmission or exchange, or to interact with apps residing in the Internet cloud.


The control loop is closed. This is as a result of having both stimulating and sensing. The sensing provides information about the effects of stimulation, allowing the stimulation to be adjusted to a desired level or improved automatically.


Typically, stimulation will be applied. Sensing will be used to measure the effects of stimulation. The measurements sensed will be used to specify the next stimulation. This process can be repeated indefinitely with various durations of each part. For example: rapid cycling through the process (a-b-c-a-b-c-a-b-c); prolonged stimulation, occasional sensing (aaaa-b-c-aaaa-b-c-aaaa-b-c); or prolonged sensing, occasional stimulation (a-bbbb-c-a-bbbb-c-a-bbbb). The process may also start with sensing, and when an event in the body is detected this information is used to specify stimulation to treat or correct the event, for example, (bbbbbbbbb-c-a-bbbbbbbb-c-a-bbbbbbbbb). Other patterns are possible and contemplated within the scope of the application.


The same components can be used for stimulating and sensing alternately, by switching their connection between the stimulating circuits and the sensing circuits. The switching can be done by standard electronic components. In the case of electrical stimulating and sensing, the same electrodes can be used for both. An electronic switch is used to connect stimulating circuits to the electrodes and electric stimulation is applied to the tissues. Then the electronic switch disconnects the stimulating circuits from the electrodes and connects the sensing circuits to the electrodes and electrical signals from the tissues are recorded.


In the case of acoustic stimulating and sensing, the same ultrasonic transducers can be used for both (as in ultrasound imaging or radar). An electronic switch is used to connect circuits to the transducers to send acoustic signals (sound waves) into the tissues. Then the electronic switch disconnects these circuits from the transducers and connects other circuits to the transducers (to listen for reflected sound waves) and these acoustic signals from the tissues are recorded.


Other modalities of stimulation and sensing may be used (e.g. light, magnetic fields, etc) The closed loop control may be implemented autonomously by an individual TNSS or by multiple TNSS modules operating in a system such as that shown below in FIG. 16. Sensing might be carried out by some TNSSs and stimulation by others.


Stimulators are protocol controlled initiators of electrical stimulation, where such protocol may reside in either the TNSS and/or the controller and/or the cloud. Stimulators interact with associated sensors or activators, such as electrodes or MEMS devices.


The protocol, which may be located in the TNSS, the controller or the cloud, has several functions including:


(1) Sending activation or disablement signals between the controller and the TNSS via a local network such as Bluetooth. The protocol sends a signal by Bluetooth radio waves from the smartphone to the TNSS module on the skin, telling it to start or stop stimulating or sensing. Other wireless communication types are possible.


(2) Driving the user interface, as when the controller receives commands from the user and provides visual, auditory or tactile feedback to the user. The protocol receives a command from the user when the user touches an icon on the smartphone screen, and provides feedback to the user by displaying information on the smartphone screen, or causing the smartphone to beep or buzz.


(3) Analyzing TNSS data, as well as other feedback data such as from the user, within the TNSS, and/or the controller and/or or the cloud. The protocol analyzes data sensed by the TNSS, such as the position of a muscle, and data from the user such as the user's desires as expressed when the user touches an icon on the smartphone; this analysis can be done in the TNSS, in the smartphone, and/or in the cloud.


(4) Making decisions about the appropriate treatment. The protocol uses the data it analyzes to decide what stimulation to apply.


(5) System diagnostics for operational correctness. The protocol checks that the TNSS system is operating correctly.


(6) Communications with other controllers or users via the Internet cloud for data transmission or exchange, or to interact with apps residing in the Internet cloud. The protocol communicates with other smartphones or people via the internet wirelessly; this may include sending data over the internet, or using computer programs that are operating elsewhere on the internet.


A neurological control system, method and apparatus are configured in an ecosystem or modular platform that uses potentially disposable topical devices to provide interfaces between electronic computing systems and neural systems. These interfaces may be direct electrical connections via electrodes or may be indirect via transducers (sensors and actuators). It may have the following elements in various configurations: electrodes for sensing or activating electrical events in the body; actuators of various modalities; sensors of various modalities; wireless networking; and protocol applications, e.g. for data processing, recording, control systems. These components are integrated within the disposable topical device. This integration allows the topical device to function autonomously. It also allows the topical device along with a remote control unit (communicating wirelessly via an antenna, transmitter and receiver) to function autonomously.


Referring to FIG. 1, nerve cells are normally electrically polarized with the interior of the nerve being at an electric potential 70 mV negative relative to the exterior of the cell. Application of a suitable electric voltage to a nerve cell (raising the resting potential of the cell from −70 mV to above the firing threshold of −55 mV) can initiate a sequence of events in which this polarization is temporarily reversed in one region of the cell membrane and the change in polarization spreads along the length of the cell to influence other cells at a distance, e.g. to communicate with other nerve cells or to cause or prevent muscle contraction.


Referring to FIG. 2, graphically represents a nerve impulse from a point of stimulation resulting in a wave of depolarization followed by a repolarization that travels along the membrane of a neuron during the measured period. This spreading action potential is a nerve impulse. It is this phenomenon that allows for external electrical nerve stimulation.


Referring to FIG. 3, the dorsal genital nerve on the back of the penis or clitoris just under the skin is a purely sensory nerve that is involved in normal inhibition of the activity of the bladder during sexual activity, and electrical stimulation of this nerve has been shown to reduce the symptoms of the Over Active Bladder. Stimulation of the underside of the penis may cause sexual arousal, erection, ejaculation and orgasm.


A Topical nerve stimulator/sensor (TNSS) is used to stimulate these nerves and is convenient, unobtrusive, self-powered, controlled from a smartphone or other control device. This has the advantage of being non-invasive, controlled by consumers themselves, and potentially distributed over the counter without a prescription.


Referring to FIG. 4, the TNSS has one or more electronic circuits or chips that perform the functions of: communications with the controller, nerve stimulation via one or more electrodes 408 that produce a wide range of electric field(s) according to treatment regimen, one or more antennae 410 that may also serve as electrodes and communication pathways, and a wide range of sensors 406 such as, but not limited to, mechanical motion and pressure, temperature, humidity, chemical and positioning sensors. One arrangement would be to integrate a wide variety of these functions into an SOC, system on chip 400. Within this is shown a control unit 402 for data processing, communications and storage and one or more stimulators 404 and sensors 406 that are connected to electrodes 408. An antenna 410 is incorporated for external communications by the control unit. Also present is an internal power supply 412, which may be, for example, a battery. An external power supply is another variation of the chip configuration. It may be necessary to include more than one chip to accommodate a wide range of voltages for data processing and stimulation. Electronic circuits and chips will communicate with each other via conductive tracks within the device capable of transferring data and/or power.


In one or more examples, a Smart Band Aid™ incorporating a battery and electronic circuit and electrodes in the form of adhesive conductive pads may be applied to the skin, and electrical stimuli is passed from the adhesive pads into the tissues. Stimuli may typically be trains of voltage-regulated square waves at frequencies between 15 and 50 Hz with currents between 20 and 100 mA. The trains of stimuli are controlled from a smartphone operated by the user. Stimuli may be either initiated by the user when desired, or programmed according to a timed schedule, or initiated in response to an event detected by a sensor on the Smart Band Aid™ or elsewhere. Another implementation for males may be a TNSS incorporated in a ring that locates a stimulator conductively to selected nerves in a penis to be stimulated.


Referring to FIG. 5, limited lifetime battery sources will be employed as internal power supply 412, to power the TNSS deployed in this illustration as a Smart Band Aid™. These may take the form of Lithium Ion technology or traditional non-toxic MnO2 technologies. FIG. 5 illustrates different battery options such as a printable Manganese Oxide battery 516 and a button battery 518. A TNSS of different shapes may require different battery packaging.



FIG. 6 shows an alternate arrangement of these components where the batteries 616-618 are positioned on the bottom side of the SBA between the electrodes 610 and 620. In this example, battery 616 is a lithium ion battery, battery 617 is a MnO2 battery and battery 618 is a button battery. Other types of batteries and other battery configurations are possible within the scope of this application in other examples.


Aside from the Controller, the Smart Band Aid™ Packaging Platform consists of an assembly of an adhesive patch capable of being applied to the skin and containing the TNSS Electronics, protocol, and power described above.


Referring to FIG. 7 is a TNSS deployed as a Smart Band Aid™ 414. The Smart Band Aid™ has a substrate with adhesive on a side for adherence to skin, the SOC 400 previously described in FIG. 4, or electronic package, and one or more electrodes 408 disposed between the dermis and the adhesive surface. The electrodes provide electrical stimuli through the dermis to nerves and other tissue and in turn may collect electrical signals from the body, such as the electrical signals produced by muscles when they contract (the electromyogram) to provide data about body functions such as muscle actions.


Referring to FIG. 8, different chips may be employed to design requirements. Shown are sample chips for packaging in a TNSS in this instance deployed as a SBA. For example, neural stimulator 800, sensor 802, processor/communications 804 are represented. The chips can be packaged separately on a substrate, including a flexible material, or as a system-on-chip (SOC) 400. The chip connections and electronics package are not shown but are known in the art.


Referring to FIG. 9 SBAs with variations on arrangements of electrodes are shown. Each electrode may consist of a plurality of conductive contacts that give the electrode abilities to adjust the depth, directionality, and spatial distribution of the applied electric field. For all the example electrode configurations shown, 901-904, the depth of the electrical stimulation can be controlled by the voltage and power applied to the electrode contacts. Electric current can be applied to various electrode contacts at opposite end of the SBA, or within a plurality of electrode contacts on a single end of the SBA. The phase relationship of the signals applied to the electrode contacts can vary the directionality of the electric field. For all configurations of electrodes, the applied signals can vary over time and spatial dimensions. The configuration on the left, 901, shows a plurality of concentric electrode contacts at either end of the SBA. This configuration can be used to apply an electric stimulating field at various tissue depths by varying the power introduced to the electrode contacts. The next configuration, 902, shows electrodes 404 that are arranged in a plurality of parallel strips of electrical contacts. This allows the electric field to be oriented perpendicular or parallel to the SBA. The next configuration, 903, shows an example matrix of electrode contacts where the applied signal can generate a stimulating field between any two or more electrode contacts at either end of the SBA, or between two or more electrode contacts within a single matrix at one end of the SBA. Finally, the next configuration on the far right, 904, also shows electrodes that are arranged in a plurality of parallel strips of electrical contacts. As with the second configuration, this allows the electric field to be oriented perpendicular or parallel to the SBA. There may be many other arrangements of electrodes and contacts.


One or more TNSSs with one or more Controllers form a System. Systems can communicate and interact with each other and with distributed virtualized processing and storage services. This enables the gathering, exchange, and analysis of data among populations of systems for medical and non-medical applications.


Referring to FIG. 10, a system is shown with two TNSS units 1006, with one on the wrist, one on the leg, communicating with its controller, a smartphone 1000 or other control device. The TNSS units can be both sensing and stimulating and can act independently and also work together in a Body Area Network (BAN). Systems communicate with each other over a communication bridge or network such as a cellular network. Systems also communicate with applications running in a distributed virtualized processing and storage environment generally via the Internet 1002. The purpose for communications with the distributed virtualized processing and storage environment is to communicate large amounts of user data for analysis and networking with other third parties such as hospitals, doctors, insurance companies, researchers, and others. There are applications that gather, exchange, and analyze data from multiple Systems 1004. Third party application developers can access TNSS systems and their data to deliver a wide range of applications. These applications can return data or control signals to the individual wearing the TNSS unit 1006. These applications can also send data or control signals to other members of the population who employ systems 1008. This may represent an individual's data, aggregated data from a population of users, data analyses, or supplementary data from other sources.


Referring to FIG. 11, shown is an example of an electrode array to affect beam forming and beam steering. Beam forming and steering allows a more selective application of stimulation energy by a TNSS to nerves and tissue. Beam steering also provides the opportunity for lower power for stimulation of cells including nerves by applying the stimulating mechanism directionally to a target. In the use of an electrical beam lower power demand lengthens battery life and allows for use of low power chip sets. Beam steering may be accomplished in multiple ways for instance by magnetic fields and formed gates. FIG. 11 shows a method for forming and steering a beam by the use of a plurality of radiators 1102 which are activated out of phase with each other by a plurality of phase shifters 1103 that are supplied power from a common source 1104. Because the radiated signals are out of phase they produce an interference pattern 1105 that results in the beam being formed and steered in varying controlled directions 1106. Electromagnetic radiation like light shows some properties of waves and can be focused on certain locations. This provides the opportunity to stimulate tissues such as nerves selectively. It also provides the opportunity to focus the transmission of energy and data on certain objects, including topical or implanted electronic devices, thereby not only improving the selectivity of activating or controlling those objects but also reducing the overall power required to operate them.



FIG. 12 is another example of a gating structure 1200 used for beam shaping and steering 1202. The gating structure 1200 shows an example of an interlocked pair of electrodes that can be used for simple beam forming through the application of time-varying voltages. The steering 1202 shows a generic picture of the main field lobes and how such beam steering works in this example. FIG. 12 is illustrative of a possible example that may be used.


The human and mammal body is an anisotropic medium with multiple layers of tissue of varying electrical properties. Steering of an electric field may be accomplished using multiple electrodes, or multiple SBAs, using the human or mammal body as an anisotropic volume conductor. Electric field steering will discussed below with reference to FIGS. 18 and 19.


Referring to FIG. 13, the controller is an electronics platform that is a smartphone 1300, tablet 1302, personal computer 1304, or dedicated module 1306 that hosts wireless communications capabilities, such as Near Field Communications, Bluetooth, or Wi-Fi technologies as enabled by the current set of communications chips, e.g. Broadcom BCM4334, TI WiLink 8 and others, and a wide range of protocol apps that can communicate with the TNSSs. There may be more than one controller, acting together. This may occur, for example, if the user has both a smartphone control app running, and a key fob controller in his/her pocket/purse.


TNSS protocol performs the functions of communications with the controller including transmitting and receiving of control and data signals, activation and control of the neural stimulation, data gathering from on board sensors, communications and coordination with other TNSSs, and data analysis. Typically the TNSS may receive commands from the controller, generate stimuli and apply these to the tissues, sense signals from the tissues, and transmit these to the controller. It may also analyze the signals sensed and use this information to modify the stimulation applied. In addition to communicating with the controller it may also communicate with other TNSSs using electrical or radio signals via a body area network.


Referring to FIG. 14, controller protocol executed and/or displayed on a smartphone 1400, tablet 1402 or other computing platform or mobile device, will perform the functions of communications with TNSS modules including transmitting and receiving of control and data signals, activation and control of the neuro modulation regimens, data gathering from on board sensors, communications and coordination with other controllers, and data analysis. In some cases local control of the neuro modulation regimens may be conducted by controller protocol without communications with the user.



FIG. 15 shows potential applications of electrical stimulation and sensing for the body, particularly for users who may suffer from paralysis or loss of sensation or altered reflexes such as spasticity or tremor due to neurological disorders and their complications, as well as users suffering from incontinence, pain, immobility and aging. Different example medical uses of the present system are discussed below.



FIG. 16 shows the components of one example of a typical TNSS system 1600. TNSS devices 1610 are responsible for stimulation of nerves and for receiving data in the form of electrical, acoustic, imaging, chemical and other signals which then can be processed locally in the TNSS or passed to the Control Unit 1620. TNSS devices 1610 are also responsible for analysis and action. The TNSS device 1610 may contain a plurality of electrodes for stimulation and for sensing. The same electrodes may be used for both functions, but this is not required. The TNSS device 1610 may contain an imaging device, such as an ultrasonic transducer to create acoustic images of the structure beneath the electrodes or elsewhere in the body that may be affected by the neural stimulation.


In this example TNSS system, most of the data gathering and analysis is performed in the Control Unit 1620. The Control Unit 1620 may be a cellular telephone or a dedicated hardware device. The Control Unit 1620 runs an app that controls the local functions of the TNSS System 1600. The protocol app also communicates via the Internet or wireless networks 1630 with other TNSS systems and/or with 3rd party software applications.



FIG. 17 shows the communications among the components of the TNSS system 1600 and the user. In this example, TNSS 1610 is capable of applying stimuli to nerves 1640 to produce action potentials in the nerves 1640 to produce actions in muscles 1670 or other organs such as the brain 1650. These actions may be sensed by the TNSS 1610, which may act on the information to modify the stimulation it provides. This closed loop constitutes the first level of the system 1600 in this example.


The TNSS 1610 may also be caused to operate by signals received from a Control Unit 1620 such as a cellphone, laptop, key fob, tablet, or other handheld device and may transmit information that it senses back to the Control Unit 1620. This constitutes the second level of the system 1600 in this example.


The Control Unit 1620 is caused to operate by commands from a user, who also receives information from the Control Unit 1620. The user may also receive information about actions of the body via natural senses such as vision or touch via sensory nerves and the spinal cord, and may in some cases cause actions in the body via natural pathways through the spinal cord to the muscles.


The Control Unit 1620 may also communicate information to other users, experts, or application programs via the Internet 1630, and receive information from them via the Internet 1630.


The user may choose to initiate or modify these processes, sometimes using protocol applications residing in the TNSS 1610, the Control Unit 1620, the Internet 1630, or wireless networks. This software may assist the user, for example by processing the stimulation to be delivered to the body to render it more selective or effective for the user, and/or by processing and displaying data received from the body or from the Internet 1630 or wireless networks to make it more intelligible or useful to the user.



FIG. 18 shows an example electrode configuration 1800 for Electric Field Steering. The application of an appropriate electric field to the body can cause a nerve to produce an electrical pulse known as an action potential. The shape of the electric field is influenced by the electrical properties of the different tissue through which it passes and the size, number and position of the electrodes used to apply it. The electrodes can therefore be designed to shape or steer or focus the electric field on some nerves more than on others, thereby providing more selective stimulation.


An example 10×10 matrix of electrical contacts 1860 is shown. By varying the pattern of electrical contacts 1860 employed to cause an electric field 1820 to form and by time varying the applied electrical power to this pattern of contacts 1860, it is possible to steer the field 1820 across different parts of the body, which may include muscle 1870, bone, fat, and other tissue, in three dimensions. This electric field 1820 can activate specific nerves or nerve bundles 1880 while sensing the electrical and mechanical actions produced 1890, and thereby enabling the TNSS to discover more effective or the most effective pattern of stimulation for producing the desired action.



FIG. 19 shows a example of stimulating and sensing patterns of signals in a volume of tissue. Electrodes 1910 as part of a cuff arrangement are placed around limb 1915. The electrodes 1910 are external to a layer of skin 1916 on limb 1915. Internal components of the limb 1915 include muscle 1917, bone 1918, nerves 1919, and other tissues. By using electric field steering for stimulation, as described with reference to FIG. 18, the electrodes 1910 can activate nerves 1919 selectively. An array of sensors (e.g. piezoelectric sensors or micro-electro-mechanical sensors) in a TNSS can act as a phased array antenna for receiving ultrasound signals, to acquire ultrasonic images of body tissues. Electrodes 1910 may act as an array of electrodes sensing voltages at different times and locations on the surface of the body, with software processing this information to display information about the activity in body tissues, e.g. which muscles are activated by different patterns of stimulation.


The SBA's ability to stimulate and collect organic data has multiple applications including bladder control, reflex incontinence, sexual stimulations, pain control and wound healing among others. Examples of SBA's application for medical and other uses follow.


Medical Uses


Bladder Management


1) Overactive bladder: When the user feels a sensation of needing to empty the bladder urgently, he or she presses a button on the Controller to initiate stimulation via a Smart Band Aid™ applied over the dorsal nerve of the penis or clitoris. Activation of this nerve would inhibit the sensation of needing to empty the bladder urgently, and allow it to be emptied at a convenient time.


2) Incontinence: A person prone to incontinence of urine because of unwanted contraction of the bladder uses the SBA to activate the dorsal nerve of the penis or clitoris to inhibit contraction of the bladder and reduce incontinence of urine. The nerve could be activated continuously, or intermittently when the user became aware of the risk of incontinence, or in response to a sensor indicating the volume or pressure in the bladder.


Erection, ejaculation and orgasm: Stimulation of the nerves on the underside of the penis by a Smart Band Aid™ (electrical stimulation or mechanical vibration) can cause sexual arousal and might be used to produce or prolong erection and to produce orgasm and ejaculation.


Pain control: A person suffering from chronic pain from a particular region of the body applies a Smart Band Aid™ over that region and activates electrically the nerves conveying the sensation of touch, thereby reducing the sensation of pain from that region. This is based on the gate theory of pain.


Wound care: A person suffering from a chronic wound or ulcer applies a Smart Band Aid™ over the wound and applies electrical stimuli continuously to the tissues surrounding the wound to accelerate healing and reduce infection.


Essential tremor: A sensor on a Smart Band Aid™ detects the tremor and triggers neuro stimulation to the muscles and sensory nerves involved in the tremor with an appropriate frequency and phase relationship to the tremor. The stimulation frequency would typically be at the same frequency as the tremor but shifted in phase in order to cancel the tremor or reset the neural control system for hand position.


Reduction of spasticity: Electrical stimulation of peripheral nerves can reduce spasticity for several hours after stimulation. A Smart Band Aid™ operated by the patient when desired from a smartphone could provide this stimulation.


Restoration of sensation and sensory feedback: People who lack sensation, for example as a result of diabetes or stroke use a Smart Band Aid™ to sense movement or contact, for example of the foot striking the floor, and the SBA provides mechanical or electrical stimulation to another part of the body where the user has sensation, to improve safety or function. Mechanical stimulation is provided by the use of acoustic transducers in the SBA such as small vibrators. Applying a Smart Band Aid™ to the limb or other assistive device provides sensory feedback from artificial limbs. Sensory feedback can also be used to substitute one sense for another, e.g. touch in place of sight.


Recording of mechanical activity of the body: Sensors in a Smart Band Aid™ record position, location and orientation of a person or of body parts and transmit this data to a smartphone for the user and/or to other computer networks for safety monitoring, analysis of function and coordination of stimulation.


Recording of sound from the body or reflections of ultrasound waves generated by a transducer in a Smart Band Aid™ could provide information about body structure, e.g. bladder volume for persons unable to feel their bladder. Acoustic transducers may be piezoelectric devices or MEMS devices that transmit and receive the appropriate acoustic frequencies. Acoustic data may be processed to allow imaging of the interior of the body.


Recording of Electrical Activity of the Body


Electrocardiogram: Recording the electrical activity of the heart is widely used for diagnosing heart attacks and abnormal rhythms. It is sometimes necessary to record this activity for 24 hours or more to detect uncommon rhythms. A Smart Band Aid™ communicating wirelessly with a smartphone or computer network achieves this more simply than present systems.


Electromyogram: Recording the electrical activity of muscles is widely used for diagnosis in neurology and also used for movement analysis. Currently this requires the use of many needles or adhesive pads on the surface of the skin connected to recording equipment by many wires. Multiple Smart Band Aids™ record the electrical activity of many muscles and transmit this information wirelessly to a smartphone.


Recording of optical information from the body: A Smart Band Aid™ incorporating a light source (LED, laser) illuminates tissues and senses the characteristics of the reflected light to measure characteristics of value, e.g. oxygenation of the blood, and transmit this to a cellphone or other computer network.


Recording of chemical information from the body: The levels of chemicals or drugs in the body or body fluids is monitored continuously by a Smart Band Aid™ sensor and transmitted to other computer networks and appropriate feedback provided to the user or to medical staff. Levels of chemicals may be measured by optical methods (reflection of light at particular wavelengths) or by chemical sensors.


Special Populations of Disabled Users


There are many potential applications of electrical stimulation for therapy and restoration of function. However, few of these have been commercialized because of the lack of affordable convenient and easily controllable stimulation systems. Some applications are shown in the FIG. 15.


Limb Muscle stimulation: Lower limb muscles can be exercised by stimulating them electrically, even if they are paralyzed by stroke or spinal cord injury. This is often combined with the use of a stationary exercise cycle for stability. Smart Band Aid™ devices could be applied to the quadriceps muscle of the thigh to stimulate these, extending the knee for cycling, or to other muscles such as those of the calf. Sensors in the Smart Band Aid™ could trigger stimulation at the appropriate time during cycling, using an application on a smartphone, tablet, handheld hardware device such as a key fob, wearable computing device, laptop, or desktop computer, among other possible devices. Upper limb muscles can be exercised by stimulating them electrically, even if they are paralyzed by stroke of spinal cord injury. This is often combined with the use of an arm crank exercise machine for stability. Smart Band Aid™ devices are applied to multiple muscles in the upper limb and triggered by sensors in the Smart Band Aids™ at the appropriate times, using an application on a smartphone.


Prevention of osteoporosis: Exercise can prevent osteoporosis and pathological fractures of bones. This is applied using Smart Band Aids™ in conjunction with exercise machines such as rowing simulators, even for people with paralysis who are particularly prone to osteoporosis.


Prevention of deep vein thrombosis: Electric stimulation of the muscles of the calf can reduce the risk of deep vein thrombosis and potentially fatal pulmonary embolus. Electric stimulation of the calf muscles is applied by a Smart Band Aid™ with stimulation programmed from a smartphone, e.g. during a surgical operation, or on a preset schedule during a long plane flight.


Restoration of Function (Functional Electrical Stimulation)


Lower Limb


1) Foot drop: People with stroke often cannot lift their forefoot and drag their toes on the ground. A Smart Band Aid™ is be applied just below the knee over the common peroneal nerve to stimulate the muscles that lift the forefoot at the appropriate time in the gait cycle, triggered by a sensor in the Smart Band Aid™


2) Standing: People with spinal cord injury or some other paralyses can be aided to stand by electrical stimulation of the quadriceps muscles of their thigh. These muscles are stimulated by Smart Band Aids™ applied to the front of the thigh and triggered by sensors or buttons operated by the patient using an application on a smartphone. This may also assist patients to use lower limb muscles when transferring from a bed to a chair or other surface.


3) Walking: Patients with paralysis from spinal cord injury are aided to take simple steps using electrical stimulation of the lower limb muscles and nerves. Stimulation of the sensory nerves in the common peroneal nerve below the knee can cause a triple reflex withdrawal, flexing the ankle, knee and hip to lift the leg, and then stimulation of the quadriceps can extend the knee to bear weight. The process is then repeated on the other leg. Smart Band Aids™ coordinated by an application in a smartphone produce these actions.


Upper Limb


1) Hand grasp: People with paralysis from stroke or spinal cord injury have simple hand grasp restored by electrical stimulation of the muscles to open or close the hand. This is produced by Smart Band Aids™ applied to the back and front of the forearm and coordinated by sensors in the Smart Band Aids™ and an application in a smartphone.


2) Reaching: Patients with paralysis from spinal cord injury sometimes cannot extend their elbow to reach above the head. Application of a Smart Band Aid™ to the triceps muscle stimulates this muscle to extend the elbow. This is triggered by a sensor in the Smart Band Aid™ detecting arm movements and coordinating it with an application on a smartphone.


Posture: People whose trunk muscles are paralyzed may have difficulty maintaining their posture even in a wheelchair. They may fall forward unless they wear a seatbelt, and if they lean forward they may be unable to regain upright posture. Electrical stimulation of the muscles of the lower back using a Smart Band Aid™ allows them to maintain and regain upright posture. Sensors in the Smart Band Aid™ trigger this stimulation when a change in posture was detected.


Coughing: People whose abdominal muscles are paralyzed cannot produce a strong cough and are at risk for pneumonia. Stimulation of the muscles of the abdominal wall using a Smart Band Aid™ could produce a more forceful cough and prevent chest infections. The patient using a sensor in a Smart Band Aid™ triggers the stimulation.


Essential Tremor: It has been demonstrated that neuro stimulation can reduce or eliminate the signs of ET. ET may be controlled using a TNSS. A sensor on a Smart Band Aid™ detects the tremor and trigger neuro stimulation to the muscles and sensory nerves involved in the tremor with an appropriate frequency and phase relationship to the tremor. The stimulation frequency is typically be at the same frequency as the tremor but shifted in phase in order to cancel the tremor or reset the neural control system for hand position.


Non-Medical Applications


Sports Training


Sensing the position and orientation of multiple limb segments is used to provide visual feedback on a smartphone of, for example, a golf swing, and also mechanical or electrical feedback to the user at particular times during the swing to show them how to change their actions. The electromyogram of muscles could also be recorded from one or many Smart Band Aids™ and used for more detailed analysis.


Gaming


Sensing the position and orientation of arms, legs and the rest of the body produces a picture of an onscreen player that can interact with other players anywhere on the Internet. Tactile feedback would be provided to players by actuators in Smart Band Aids on various parts of the body to give the sensation of striking a ball, etc.


Motion Capture for Film and Animation


Wireless TNSS capture position, acceleration, and orientation of multiple parts of the body. This data may be used for animation of a human or mammal and has application for human factor analysis and design.


Sample Modes of Operation


A SBA system consists of at least a single Controller and a single SBA. Following application of the SBA to the user's skin, the user controls it via the Controller's app using Near Field Communications. The app appears on a smartphone screen and can be touch controlled by the user; for ‘key fob’ type Controllers, the SBA is controlled by pressing buttons on the key fob.


When the user feels the need to activate the SBA s/he presses the “go” button two or more times to prevent false triggering, thus delivering the neuro stimulation. The neuro stimulation may be delivered in a variety of patterns of frequency, duration, and strength and may continue until a button is pressed by the user or may be delivered for a length of time set in the application.


Sensor capabilities in the TNSS, are enabled to start collecting/analyzing data and communicating with the controller when activated.


The level of functionality in the protocol app, and the protocol embedded in the TNSS, will depend upon the neuro modulation or neuro stimulation regimen being employed.


In some cases there will be multiple TNSSs employed for the neuro modulation or neuro stimulation regimen. The basic activation will be the same for each TNSS.


However, once activated multiple TNSSs will automatically form a network of neuro modulation/stimulation points with communications enabled with the controller.


The need for multiple TNSSs arises from the fact that treatment regimens may need several points of access to be effective.


While illustrative systems and methods as described herein embodying various aspects of the present disclosure are shown, it will be understood by those skilled in the art, that the invention is not limited to these embodiments. Modifications may be made by those skilled in the art, particularly in light of the foregoing teachings. For example, each of the elements of the aforementioned embodiments may be utilized alone or in combination or subcombination with elements of the other embodiments. It will also be appreciated and understood that modifications may be made without departing from the true spirit and scope of the present disclosure. The description is thus to be regarded as illustrative instead of restrictive on the present invention.

Claims
  • 1. A topical nerve stimulator system comprising: a flexible dermis conforming patch defining a surface and formed by a substrate;electrodes positioned on the patch proximal the surface and directly coupled to the substrate;electronic circuitry embedded in the patch comprising a system on a chip that is directly coupled to the substrate and comprising: an electrical signal generator configured to electrically activate the electrodes;a signal receiver in communication with the electrical signal generator;an antenna;a transmitter; anda receiver;a remote control device in wireless communication with the electronic circuitry, the remote control device configured to provide a signal to start stimulation on a user via the electrodes, the signal generated in response to the user interacting with the remote control device.
  • 2. The topical nerve stimulator system of claim 1, the surface further comprises adhesive.
  • 3. The topical nerve stimulator system of claim 1, further comprising a feedback sensor on the patch coupled to the substrate and configured to sense muscle and/or nerve activation and communicate data to the remote control device.
  • 4. The topical nerve stimulator system of claim 1, the remote control device is a smartphone and the signal is generated via a smartphone app.
  • 5. The topical nerve stimulator system of claim 1, the remote control device is a key fob controller comprising a button and the signal is generated via a pressing of the button.
  • 6. The topical nerve stimulator system of claim 3, the stimulation based on a stimulation pattern that is revised in response to the sensed muscle and/or nerve activation.
  • 7. The topical nerve stimulator system of claim 1, the electrodes configured to stimulate a mammalian nerve.
  • 8. The topical nerve stimulator system of claim 1, the remote control device comprising a user interface configured to provide visual, audio and tactile feedback to a user.
  • 9. A method for controlling a body function of a user comprising: applying a flexible dermis conforming patch to a dermis of the user in proximity to a selected nerve, the patch formed by a substrate and comprising electrodes directly coupled to the substrate, electronic circuitry embedded in the patch comprising a system on a chip that is directly coupled to the substrate and comprising an electrical signal generator configured to electrically activate the electrodes, a signal receiver in communication with the electric signal generator, an antenna, a transmitter and a receiver;applying an electrical signal generated by the flexible dermis conforming patch to the selected nerve; andsensing nerve stimulation response;the applying in response to a signal to start stimulation on the user via the electrodes from a remote control device in wireless communication with the electronic circuitry, the signal generated in response to the user interacting with the remote control device.
  • 10. The method of claim 9 further comprising monitoring the nerve response to the electrical signal and adjusting a nerve stimulation pattern that is revised in response to the nerve response.
  • 11. The method of claim 9 further comprising monitoring a muscle response to the nerve stimulation and adjusting a nerve stimulation pattern that is revised in response to the nerve response.
  • 12. The method of claim 9, the remote control device is a smartphone and the signal is generated via a smartphone app.
  • 13. The method of claim 9, the remote control device is a key fob controller comprising a button and the signal is generated via a pressing of the button.
  • 14. The method of claim 9 further comprising applying the flexible dermis conforming patch to the dermis with adhesive.
  • 15. The method of claim 9 further comprising applying more than one flexible dermis conforming patches to the dermis.
  • 16. The method of claim 9 further comprising stimulating more than one nerve with one or more flexible dermis conforming patches to create a nerve stimulation pattern.
  • 17. The method of claim 9 further comprising applying the electrical signal to a selected portion of a nerve.
  • 18. The method of claim 9 further comprising selectively adjusting a strength of the electrical signal.
  • 19. The method of claim 9 further comprising selectively adjusting a shape of the electrical signal.
  • 20. The method of claim 9 further comprising receiving a signal feedback from a stimulated nerve.
  • 21. The method of claim 9 further comprising receiving feedback from a stimulated nerve and adjusting the electrical signal based on the feedback.
  • 22. The method of claim 9, the remote control device comprising a user interface configured to provide visual, audio and tactile feedback to a user.
  • 23. A topical nerve stimulator patch comprising: a substrate;electrodes positioned on the patch proximal the surface and directly coupled to the substrate;electronic circuitry embedded in the patch comprising a system on a chip that is directly coupled to the substrate and comprising: an electrical signal generator configured to electrically activate the electrodes;a signal receiver in communication with the electrical signal generator;an antenna;a transmitter; anda receiver;the electrical circuitry configured to be in wireless communication with a remote control device, the remote control device configured to provide a signal to start stimulation on a user via the electrodes, the signal generated in response to the user interacting with the remote control device.
  • 24. The topical nerve stimulator patch of claim 23, further comprising a feedback sensor on the patch coupled to the substrate and configured to sense muscle and/or nerve activation and communicate data to the remote control device.
  • 25. The topical nerve stimulator patch of claim 24, the stimulation based on a stimulation pattern that is revised in response to the sensed muscle and/or nerve activation.
CLAIM OF PRIORITY

This application claims priority to and the benefit of the filing date of PCT application PCT/US2014/040240 filed on May 30, 2014, and U.S. provisional patent application U.S. Ser. No. 61/828,981 filed on May 30, 2013, and incorporates that application in its entirety herein.

US Referenced Citations (1201)
Number Name Date Kind
4277980 Coats et al. Jul 1981 A
4532930 Crosby et al. Aug 1985 A
4542753 Brenman et al. Sep 1985 A
4549556 Tarjan et al. Oct 1985 A
4553549 Pope et al. Nov 1985 A
4590949 Pohndorf May 1986 A
4614395 Peers-Trevarton Sep 1986 A
4658835 Pohndorf Apr 1987 A
4677989 Robblee Jul 1987 A
4690144 Rise et al. Sep 1987 A
4702254 Zabara Oct 1987 A
4706682 Stypulkowski et al. Nov 1987 A
4717581 Robblee Jan 1988 A
4759228 Butler et al. Jul 1988 A
4800898 Hess et al. Jan 1989 A
4817628 Zealear et al. Apr 1989 A
4881526 Johnson et al. Nov 1989 A
4883666 Sabel et al. Nov 1989 A
4919148 Muccio Apr 1990 A
4940453 Cadwell Jul 1990 A
4959532 Owechko Sep 1990 A
5031621 Grandjean et al. Jul 1991 A
5035242 Franklin et al. Jul 1991 A
5047005 Cadwell Sep 1991 A
5092332 Lee et al. Mar 1992 A
5092835 Schurig et al. Mar 1992 A
5095905 Klepinski Mar 1992 A
5211657 Yamada et al. May 1993 A
5265608 Lee et al. Nov 1993 A
5381801 McShane et al. Jan 1995 A
5476494 Edell et al. Dec 1995 A
5501703 Holsheimer et al. Mar 1996 A
5569307 Schulman et al. Oct 1996 A
5575813 Edell et al. Nov 1996 A
5584869 Heck et al. Dec 1996 A
5597381 Rizzo, III Jan 1997 A
5603726 Schulman et al. Feb 1997 A
5609616 Schulman et al. Mar 1997 A
5628769 Saringer May 1997 A
5643330 Holsheimer et al. Jul 1997 A
5679340 Chappel Oct 1997 A
5713922 King Feb 1998 A
5738625 Gluck Apr 1998 A
5741314 Daly et al. Apr 1998 A
5795790 Schinstine et al. Aug 1998 A
5824022 Zilberman et al. Oct 1998 A
5830651 Cauley et al. Nov 1998 A
5837236 Dinsmore Nov 1998 A
5853370 Chance et al. Dec 1998 A
5871534 Messick et al. Feb 1999 A
5876425 Gord et al. Mar 1999 A
5891437 Pietropaolo et al. Apr 1999 A
5916870 Lee et al. Jun 1999 A
5921245 O'Donnell, Jr. Jul 1999 A
5922012 Sakano Jul 1999 A
5937318 Warner, Jr. et al. Aug 1999 A
5938691 Schulman et al. Aug 1999 A
5948428 Lee et al. Sep 1999 A
5987361 Mortimer Nov 1999 A
5989445 Wise et al. Nov 1999 A
5992769 Wise et al. Nov 1999 A
6002960 Sternberger et al. Dec 1999 A
6011018 Crabtree et al. Jan 2000 A
6016449 Fischell et al. Jan 2000 A
6058331 King May 2000 A
6060048 Cherksey May 2000 A
6060054 Staerz May 2000 A
6066084 Edrich et al. May 2000 A
6067474 Schulman et al. May 2000 A
6085115 Weaver et al. Jul 2000 A
6096537 Chappel Aug 2000 A
6119071 Gorenflo et al. Sep 2000 A
6120538 Rizzo, III et al. Sep 2000 A
6140116 Dinsmore Oct 2000 A
6178349 Kieval Jan 2001 B1
6203792 Filbin Mar 2001 B1
6204053 Dinsmore Mar 2001 B1
6258353 Isacson et al. Jul 2001 B1
6264950 Staerz Jul 2001 B1
6265175 Gage et al. Jul 2001 B1
6270831 Kumar et al. Aug 2001 B2
6277372 Fraser et al. Aug 2001 B1
6284245 Edge Sep 2001 B1
6288527 Sugihara et al. Sep 2001 B1
6294383 Isacson et al. Sep 2001 B1
6304784 Allee et al. Oct 2001 B1
6304787 Kuzma et al. Oct 2001 B1
6359550 Brisebois et al. Mar 2002 B1
6374140 Rise Apr 2002 B1
6379393 Mavroidis et al. Apr 2002 B1
6392118 Hammang et al. May 2002 B1
6392550 Najor May 2002 B1
6393327 Scribner May 2002 B1
6415186 Chim et al. Jul 2002 B1
6421232 Sallam Jul 2002 B2
6427083 Owen et al. Jul 2002 B1
6444205 Dinsmore et al. Sep 2002 B2
6472181 Mineau-Hanschke Oct 2002 B1
6510347 Borkan Jan 2003 B2
6517833 Edge Feb 2003 B2
6533732 Urmey Mar 2003 B1
6537200 Leysieffer et al. Mar 2003 B2
6546291 Merfeld et al. Apr 2003 B2
6561975 Pool et al. May 2003 B1
6565503 Leysieffer et al. May 2003 B2
6575894 Leysieffer et al. Jun 2003 B2
6599695 Gage et al. Jul 2003 B2
6640118 Van Heerden et al. Oct 2003 B2
6640121 Telischi et al. Oct 2003 B1
RE38323 Sugihara et al. Nov 2003 E
6647297 Scribner Nov 2003 B2
6690974 Archer et al. Feb 2004 B2
6697674 Leysieffer Feb 2004 B2
6727696 Kruspe et al. Apr 2004 B2
6744367 Forster Jun 2004 B1
6788976 Gesotti Sep 2004 B2
6795737 Gielen et al. Sep 2004 B2
6807445 Baumann et al. Oct 2004 B2
6839596 Nelson et al. Jan 2005 B2
6850802 Holsheimer Feb 2005 B2
6879855 Schulman et al. Apr 2005 B2
6884122 Robinson et al. Apr 2005 B2
6892097 Holsheimer May 2005 B2
6893812 Woltering et al. May 2005 B2
6894616 Forster May 2005 B1
6902547 Aves et al. Jun 2005 B2
6931273 Groenewegen et al. Aug 2005 B2
6949251 Dalal et al. Sep 2005 B2
6970745 Scribner Nov 2005 B2
6976998 Rizzo et al. Dec 2005 B2
7001608 Fishman et al. Feb 2006 B2
7003335 Briancon Feb 2006 B2
7010351 Firlik et al. Mar 2006 B2
7027873 Pajunk et al. Apr 2006 B2
7030411 Krulevitch et al. Apr 2006 B2
7037603 Lasater May 2006 B2
7047080 Palanker et al. May 2006 B2
7058455 Huie, Jr. et al. Jun 2006 B2
7079882 Schmidt Jul 2006 B1
7101542 Vallera et al. Sep 2006 B1
7106190 Owens Sep 2006 B1
7107104 Keravel et al. Sep 2006 B2
7115071 Sunbeck Oct 2006 B1
7117034 Kronberg Oct 2006 B2
7120499 Thrope et al. Oct 2006 B2
7127301 Okandan et al. Oct 2006 B1
7155278 King et al. Dec 2006 B2
7167750 Knudson et al. Jan 2007 B2
7174223 Dalton et al. Feb 2007 B2
7181288 Rezai et al. Feb 2007 B1
7191018 Gielen et al. Mar 2007 B2
7193414 Kruspe et al. Mar 2007 B2
7206632 King Apr 2007 B2
7209787 DiLorenzo Apr 2007 B2
7218216 Uehran May 2007 B1
7218964 Hill et al. May 2007 B2
7228178 Carroll et al. Jun 2007 B2
7228727 Discenzo Jun 2007 B2
7239918 Strother et al. Jul 2007 B2
7249998 van Esbroeck et al. Jul 2007 B2
7283867 Strother et al. Oct 2007 B2
7297420 Jiang Nov 2007 B2
7299034 Kates Nov 2007 B2
7308303 Whitehurst et al. Dec 2007 B2
7308317 Okandan et al. Dec 2007 B1
7333851 Echauz et al. Feb 2008 B2
7337004 Classen et al. Feb 2008 B2
7349169 Lee et al. Mar 2008 B2
RE40209 Sugihara et al. Apr 2008 E
7376467 Thrope et al. May 2008 B2
7384145 Hetling et al. Jun 2008 B2
7392093 Khan Jun 2008 B2
7398255 Lauer et al. Jul 2008 B2
7415309 McIntyre Aug 2008 B2
7420760 Zhang et al. Sep 2008 B2
7422564 Parsons et al. Sep 2008 B2
7435443 Jiang Oct 2008 B2
7435585 Tykocinski et al. Oct 2008 B2
7437193 Parramon et al. Oct 2008 B2
7437196 Wyler et al. Oct 2008 B2
7483747 Gliner et al. Jan 2009 B2
7499745 Littrup et al. Mar 2009 B2
7499748 Moffitt et al. Mar 2009 B2
7502652 Gaunt et al. Mar 2009 B2
7519419 Jiang et al. Apr 2009 B2
7529582 DiLorenzo May 2009 B1
7553307 Bleich et al. Jun 2009 B2
7555343 Bleich Jun 2009 B2
7561919 Shalev et al. Jul 2009 B2
7565199 Sheffield et al. Jul 2009 B2
7565200 Wyler et al. Jul 2009 B2
7571002 Thrope et al. Aug 2009 B2
7571006 Gordon et al. Aug 2009 B2
7578819 Bleich et al. Aug 2009 B2
7584004 Caparso et al. Sep 2009 B2
7587238 Moffitt et al. Sep 2009 B2
7598031 Liew Oct 2009 B2
7599737 Yomtov et al. Oct 2009 B2
7620456 Gliner et al. Nov 2009 B2
7622303 Soykan et al. Nov 2009 B2
7636597 Gross et al. Dec 2009 B2
7657308 Miles et al. Feb 2010 B2
7658707 Topolev Feb 2010 B2
7662558 Liew Feb 2010 B2
7676274 Hung et al. Mar 2010 B2
7680526 McIntyre et al. Mar 2010 B2
7684866 Fowler et al. Mar 2010 B2
D613868 Lhuillery et al. Apr 2010 S
7699768 Kishawi et al. Apr 2010 B2
7704740 Schindler et al. Apr 2010 B2
7706888 Jolly Apr 2010 B2
7706893 Hung et al. Apr 2010 B2
7711416 Akkin et al. May 2010 B1
7715919 Osorio et al. May 2010 B2
7715924 Rezai et al. May 2010 B2
7725196 Machado et al. May 2010 B2
7732407 Hunter Jun 2010 B2
7738968 Bleich Jun 2010 B2
7738969 Bleich Jun 2010 B2
7740631 Bleich et al. Jun 2010 B2
7747318 John et al. Jun 2010 B2
7756583 Demarais et al. Jul 2010 B2
7756584 Sheffield et al. Jul 2010 B2
7769462 Meadows et al. Aug 2010 B2
7769470 Rezai et al. Aug 2010 B1
7798982 Zets et al. Sep 2010 B2
7799021 Leung et al. Sep 2010 B2
7801603 Westlund et al. Sep 2010 B2
7813809 Strother et al. Oct 2010 B2
7819801 Miles et al. Oct 2010 B2
7819869 Godara et al. Oct 2010 B2
7831305 Gliner Nov 2010 B2
7844340 Pawlowicz, III Nov 2010 B2
7877136 Moffitt et al. Jan 2011 B1
7892180 Epley Feb 2011 B2
7894911 Greenberg et al. Feb 2011 B2
7894914 Stahmann et al. Feb 2011 B2
7899542 Cowan et al. Mar 2011 B2
7914842 Greenberg et al. Mar 2011 B1
7917231 Farah et al. Mar 2011 B2
7918802 Urmey Apr 2011 B2
7943632 Katzman et al. May 2011 B2
7945330 Gliner et al. May 2011 B2
7947448 Couillard-Despres et al. May 2011 B2
RE42449 Forster Jun 2011 E
7959577 Schmitz et al. Jun 2011 B2
7963915 Bleich Jun 2011 B2
7967751 Goscha et al. Jun 2011 B2
7974689 Volpe et al. Jul 2011 B2
7981144 Geist et al. Jul 2011 B2
7988688 Webb et al. Aug 2011 B2
7991475 Tang et al. Aug 2011 B1
7991480 Stahmann et al. Aug 2011 B2
7992521 Bocquier Aug 2011 B2
8000782 Gharib et al. Aug 2011 B2
8000796 Tass et al. Aug 2011 B2
8000804 Wessendorf et al. Aug 2011 B1
8010202 Shah et al. Aug 2011 B2
8014868 Greenberg et al. Sep 2011 B2
8014878 Greenberg et al. Sep 2011 B2
8025632 Einarsson Sep 2011 B2
8027716 Gharib et al. Sep 2011 B2
8033996 Behar Oct 2011 B2
8060210 Carroll Nov 2011 B1
8065012 Firlik et al. Nov 2011 B2
8067173 Liew Nov 2011 B2
8073526 Graham et al. Dec 2011 B2
8073546 Sheffield et al. Dec 2011 B2
8075556 Betts Dec 2011 B2
8078252 Kipke et al. Dec 2011 B2
8090446 Fowler et al. Jan 2012 B2
8092398 Weinberg et al. Jan 2012 B2
8095209 Flaherty Jan 2012 B2
8101358 Liew Jan 2012 B2
8110358 Liew Feb 2012 B2
8114019 Miles et al. Feb 2012 B2
8114597 Liew Feb 2012 B2
8116875 Osypka et al. Feb 2012 B2
8126562 Fowler et al. Feb 2012 B2
8131376 Faraji et al. Mar 2012 B1
8133674 Liew Mar 2012 B2
8133675 Liew Mar 2012 B2
8135472 Fowler et al. Mar 2012 B2
8137258 Dennis et al. Mar 2012 B1
8137284 Miles et al. Mar 2012 B2
8140152 John et al. Mar 2012 B2
8140162 Jiang et al. Mar 2012 B1
8140170 Rezai et al. Mar 2012 B2
8148072 Liew Apr 2012 B2
8155757 Neisz et al. Apr 2012 B1
8160713 Greenberg et al. Apr 2012 B2
8162846 Epley Apr 2012 B2
8165685 Knutson et al. Apr 2012 B1
8170676 Greenberg et al. May 2012 B2
8174371 Schwieger May 2012 B2
8180453 Greenberg et al. May 2012 B2
8180460 Nevsmith et al. May 2012 B2
8192357 Miles et al. Jun 2012 B2
8195300 Gliner et al. Jun 2012 B2
8195307 Vilims Jun 2012 B2
8200338 Grennberg et al. Jun 2012 B2
8215773 Gibson-Horn et al. Jul 2012 B2
8216135 Goscha et al. Jul 2012 B2
8226661 Balling et al. Jul 2012 B2
8228202 Buchner et al. Jul 2012 B2
8239036 Shah et al. Aug 2012 B2
8255044 Miles et al. Aug 2012 B2
8257922 Liew Sep 2012 B2
8260428 Fink et al. Sep 2012 B2
8260439 DiUbaldi et al. Sep 2012 B2
8280516 Graupe Oct 2012 B2
8301266 Zilberman et al. Oct 2012 B1
8303516 Schmitz et al. Nov 2012 B2
8308665 Harry et al. Nov 2012 B2
8313443 Tom Nov 2012 B2
8323320 Lowry et al. Dec 2012 B2
8328354 Li et al. Dec 2012 B2
8332037 Imran Dec 2012 B2
8332044 McIntyre Dec 2012 B2
8346367 Carroll Jan 2013 B2
8352022 Akkin et al. Jan 2013 B2
8359083 Clark et al. Jan 2013 B2
8364257 Van Den Eerenbeemd et al. Jan 2013 B2
8364258 Della Rocca et al. Jan 2013 B2
8374698 Ok et al. Feb 2013 B2
8374701 Hyde et al. Feb 2013 B2
8382656 Brown Feb 2013 B1
8386032 Bachinski et al. Feb 2013 B2
8386053 Kornet Feb 2013 B2
8388678 Singhal et al. Mar 2013 B2
8391970 Tracey et al. Mar 2013 B2
8391986 Graupe et al. Mar 2013 B2
8391987 Faraji et al. Mar 2013 B2
8396556 Libbus et al. Mar 2013 B2
8403841 Miles et al. Mar 2013 B2
8406886 Gaunt et al. Mar 2013 B2
8412328 Whelan et al. Apr 2013 B2
8412335 Gliner et al. Apr 2013 B2
8417345 Machado et al. Apr 2013 B2
8419653 Bleich et al. Apr 2013 B2
8428732 Nishida et al. Apr 2013 B2
8428738 Valencia Apr 2013 B2
8428739 Ahuja et al. Apr 2013 B2
8430882 Lowry et al. Apr 2013 B2
8444640 Demarais et al. May 2013 B2
8457764 Ramachandran et al. Jun 2013 B2
8460167 Chornenky et al. Jun 2013 B2
8463383 Sakai et al. Jun 2013 B2
8473048 Greenberg et al. Jun 2013 B2
8494640 Peterson et al. Jul 2013 B2
8494642 Cowan et al. Jul 2013 B2
8498717 Lee et al. Jul 2013 B2
8498720 Pellinen et al. Jul 2013 B2
8506613 Webb et al. Aug 2013 B2
8509903 York et al. Aug 2013 B2
8512235 Miles et al. Aug 2013 B2
8515533 Rofougaran et al. Aug 2013 B2
8515543 Greenberg et al. Aug 2013 B2
8517961 Imran et al. Aug 2013 B2
8524311 Greenberg et al. Sep 2013 B1
8532776 Greenberg et al. Sep 2013 B2
8538537 Hulvershorn et al. Sep 2013 B2
8543210 Sharma Sep 2013 B2
8548600 Deem et al. Oct 2013 B2
8554328 Faraji et al. Oct 2013 B2
8554337 Barolat Oct 2013 B2
8556838 Moutray Oct 2013 B2
8560041 Flaherty et al. Oct 2013 B2
8562521 Miles et al. Oct 2013 B2
8565894 Vetter et al. Oct 2013 B2
8568331 Bertagnoli et al. Oct 2013 B2
8571665 Moffitt et al. Oct 2013 B2
8579837 Makower et al. Nov 2013 B1
8583238 Heldman et al. Nov 2013 B1
8588918 Bighetti Nov 2013 B2
8594798 Osorio et al. Nov 2013 B2
8600514 Carroll Dec 2013 B1
8608664 Kunitake et al. Dec 2013 B2
8612002 Faltys et al. Dec 2013 B2
8615308 Hung et al. Dec 2013 B2
8617808 Braesch-Andersen et al. Dec 2013 B2
8626265 Hempel et al. Jan 2014 B2
8626305 Nielsen et al. Jan 2014 B2
8628469 Miles et al. Jan 2014 B2
8634930 Dalal et al. Jan 2014 B2
8634932 Ye et al. Jan 2014 B1
8639344 Greenberg et al. Jan 2014 B2
8644900 Balberg et al. Feb 2014 B2
8644937 Greenberg et al. Feb 2014 B2
8644938 Craggs Feb 2014 B2
8647346 Bleich et al. Feb 2014 B2
8649845 McIntyre et al. Feb 2014 B2
8649868 Greenberg et al. Feb 2014 B2
8652129 Wu et al. Feb 2014 B2
8652187 Wells et al. Feb 2014 B2
8655455 Mann et al. Feb 2014 B2
8660655 Peterson et al. Feb 2014 B2
8666500 Greenberg et al. Mar 2014 B2
8667971 Makkar et al. Mar 2014 B2
8667972 Makkar et al. Mar 2014 B2
8669058 Liew Mar 2014 B2
8670837 Daneshvar et al. Mar 2014 B2
8674838 Konishi et al. Mar 2014 B2
8676274 Li Mar 2014 B2
8682443 Faraji et al. Mar 2014 B2
8698637 Raichman Apr 2014 B2
8702685 Schwartz et al. Apr 2014 B2
8706241 Firlik et al. Apr 2014 B2
8708899 Miles et al. Apr 2014 B2
8712517 Jolly Apr 2014 B2
8712538 Greenberg et al. Apr 2014 B2
8712549 Zdeblick et al. Apr 2014 B2
8721637 Zarins et al. May 2014 B2
8725251 Della Rocca et al. May 2014 B2
8734339 Rao et al. May 2014 B2
8740783 Gharib et al. Jun 2014 B2
8740896 Zarins et al. Jun 2014 B2
8744570 Lee et al. Jun 2014 B2
8750957 Tang et al. Jun 2014 B2
8753271 Miles et al. Jun 2014 B1
8755896 Humayun et al. Jun 2014 B2
8761889 Wingeier et al. Jun 2014 B2
8774922 Zarins et al. Jul 2014 B2
8774937 Mercanzini et al. Jul 2014 B2
8777942 Wu et al. Jul 2014 B2
8781603 Ye et al. Jul 2014 B2
8784461 Webb et al. Jul 2014 B2
8788064 Mercanzini et al. Jul 2014 B2
8788065 Rezai et al. Jul 2014 B2
8790338 Asirvatham et al. Jul 2014 B2
8798756 McClure et al. Aug 2014 B2
8801589 Peterchev et al. Aug 2014 B2
8805467 Yobas et al. Aug 2014 B2
8805517 Radivojevic et al. Aug 2014 B2
8805521 Carroll Aug 2014 B2
8821396 Miles et al. Sep 2014 B1
8831750 Ramachandran et al. Sep 2014 B2
8834545 Stafford et al. Sep 2014 B2
8835163 Zhao et al. Sep 2014 B2
8843201 Heldman et al. Sep 2014 B1
8843204 Garnham et al. Sep 2014 B2
8843210 Simon et al. Sep 2014 B2
8849412 Perryman et al. Sep 2014 B2
8855767 Faltys et al. Oct 2014 B2
8862236 Wolpaw et al. Oct 2014 B2
8864665 Rotondo et al. Oct 2014 B2
8864759 Godara et al. Oct 2014 B2
8866621 Wolfe et al. Oct 2014 B2
8868164 Kabakov et al. Oct 2014 B2
8868172 Leyde et al. Oct 2014 B2
8868216 Dunagan Oct 2014 B2
8870857 Seymour et al. Oct 2014 B2
8874216 Kim et al. Oct 2014 B2
8874239 Greenberg et al. Oct 2014 B2
8880189 Lipani Nov 2014 B2
8886324 Beuter et al. Nov 2014 B2
8888773 Chang et al. Nov 2014 B2
8892215 Lipani Nov 2014 B2
8903494 Goldwasser et al. Dec 2014 B2
8903501 Perryman Dec 2014 B2
8909343 Towe Dec 2014 B2
8909344 Arle et al. Dec 2014 B2
8909345 Danilov et al. Dec 2014 B1
8912149 Rawat et al. Dec 2014 B1
8915846 Miles et al. Dec 2014 B2
8915867 Imran et al. Dec 2014 B2
8918178 Simon et al. Dec 2014 B2
8921473 Hyman Dec 2014 B1
8926959 Deisseroth et al. Jan 2015 B2
8929990 Moffitt et al. Jan 2015 B2
8932196 Chornenky et al. Jan 2015 B2
8942797 Bartol et al. Jan 2015 B2
8942812 MacHado et al. Jan 2015 B2
8942821 Barolat Jan 2015 B2
8945004 Miles et al. Feb 2015 B2
8945216 Parker et al. Feb 2015 B2
8948884 Ramachandran et al. Feb 2015 B2
8951193 Ong et al. Feb 2015 B2
8954144 Anderson et al. Feb 2015 B2
8954150 Swanson et al. Feb 2015 B2
8954157 Faraji et al. Feb 2015 B2
8954167 Zarembo et al. Feb 2015 B2
8956387 Naghavi et al. Feb 2015 B2
8958862 Hetke et al. Feb 2015 B2
8958883 Mueller et al. Feb 2015 B2
8958890 Kipke et al. Feb 2015 B2
8965513 Wingeier et al. Feb 2015 B2
8969532 DeFrees et al. Mar 2015 B2
8972026 Kipke et al. Mar 2015 B2
8974402 Oddsson et al. Mar 2015 B2
8983593 Bartol et al. Mar 2015 B2
8983601 Fukamachi et al. Mar 2015 B2
8983628 Simon et al. Mar 2015 B2
8983629 Simon et al. Mar 2015 B2
8985057 Woodward Mar 2015 B2
8986294 Demarais et al. Mar 2015 B2
8992522 Pellegrino et al. Mar 2015 B2
8996131 Owen et al. Mar 2015 B1
8998894 Mauch et al. Apr 2015 B2
9002458 Pal et al. Apr 2015 B2
9002477 Burnett Apr 2015 B2
9005191 Azamian et al. Apr 2015 B2
9008784 Chan et al. Apr 2015 B2
9014810 Sauter-Starace et al. Apr 2015 B2
9014811 Pal et al. Apr 2015 B2
9014823 Simon et al. Apr 2015 B2
9019106 Alameh et al. Apr 2015 B2
9020598 Simon et al. Apr 2015 B2
9020612 Danilov et al. Apr 2015 B1
9023037 Zarins et al. May 2015 B2
9034640 Matos et al. May 2015 B2
9037268 Knight May 2015 B2
9042958 Karmarkar et al. May 2015 B2
9043001 Simon et al. May 2015 B2
9044596 Mahadevan-Jansen et al. Jun 2015 B2
9044611 Zhao et al. Jun 2015 B2
9056197 Kishawi et al. Jun 2015 B2
9061097 Holt et al. Jun 2015 B2
9061134 Askin, III et al. Jun 2015 B2
9061135 Keller et al. Jun 2015 B1
9072886 Gaunt et al. Jul 2015 B2
9072889 Guarraia et al. Jul 2015 B1
9072891 Rao Jul 2015 B1
9084550 Bartol et al. Jul 2015 B1
9084610 Goshgarian et al. Jul 2015 B2
9084895 Greenberg et al. Jul 2015 B2
9084900 Hershey et al. Jul 2015 B2
9089341 Chomas et al. Jul 2015 B2
9089687 Lee, II et al. Jul 2015 B2
9089691 Libbus et al. Jul 2015 B2
9095267 Halpern et al. Aug 2015 B2
9095320 Littrup et al. Aug 2015 B2
9095538 Yu et al. Aug 2015 B2
9101279 Ritchey et al. Aug 2015 B2
9113912 Mehta et al. Aug 2015 B1
9114261 Yonce Aug 2015 B2
9119628 Mehta et al. Sep 2015 B1
9119964 Marnfeldt Sep 2015 B2
9126197 Orwar et al. Sep 2015 B2
9132058 Imboden et al. Sep 2015 B2
9138579 Wolpaw et al. Sep 2015 B2
9144677 Garnham et al. Sep 2015 B2
9155887 Miller, III et al. Oct 2015 B2
9158890 Meredith et al. Oct 2015 B2
9162010 Lenarz et al. Oct 2015 B2
9162064 Faltys et al. Oct 2015 B2
9173585 Tsampazis et al. Nov 2015 B2
9179850 Wingeier et al. Nov 2015 B2
9179875 Hua Nov 2015 B2
9189613 Tuthill et al. Nov 2015 B1
9192757 Seymour Nov 2015 B2
9192767 Mercanzini et al. Nov 2015 B2
9199089 Perryman et al. Dec 2015 B2
9205275 Pan et al. Dec 2015 B2
9220897 Perryman et al. Dec 2015 B2
9220899 Cattaneo et al. Dec 2015 B2
9220900 Libbus et al. Dec 2015 B2
9221177 Herr et al. Dec 2015 B2
9227051 Fisk et al. Jan 2016 B1
9227056 Heldman et al. Jan 2016 B1
9254382 Ahmad et al. Feb 2016 B2
9895546 Jiang et al. Feb 2018 B2
20010034477 Mansfield et al. Oct 2001 A1
20010055776 Greenwalt Dec 2001 A1
20020009461 Isacson et al. Jan 2002 A1
20020031497 Fraser et al. Mar 2002 A1
20020034819 Smith et al. Mar 2002 A1
20020055779 Andrews May 2002 A1
20020090722 Dominko et al. Jul 2002 A1
20020136705 Dinsmore Sep 2002 A1
20020176849 Slepian Nov 2002 A1
20030002297 Nemtsev Jan 2003 A1
20030004547 Owen et al. Jan 2003 A1
20030049328 Dalal et al. Mar 2003 A1
20030088274 Gliner et al. May 2003 A1
20030097161 Firlik et al. May 2003 A1
20030100367 Cooke May 2003 A1
20030104993 Rueger et al. Jun 2003 A1
20030109901 Greatbatch Jun 2003 A1
20030125786 Gliner et al. Jul 2003 A1
20030149450 Mayberg Aug 2003 A1
20030157712 Daniel et al. Aug 2003 A1
20030195441 Firouzgar Oct 2003 A1
20030198664 Sullivan et al. Oct 2003 A1
20030232055 Medzhitov Dec 2003 A1
20040005291 Rogers et al. Jan 2004 A1
20040014662 Lindquist et al. Jan 2004 A1
20040028613 Quay Feb 2004 A1
20040030365 Rubin Feb 2004 A1
20040038888 Mercer et al. Feb 2004 A1
20040048279 Olek et al. Mar 2004 A1
20040048373 Gage et al. Mar 2004 A1
20040049134 Tosaya et al. Mar 2004 A1
20040054300 Hung et al. Mar 2004 A1
20040062755 Smith et al. Apr 2004 A1
20040064052 Chance et al. Apr 2004 A1
20040081652 Zack et al. Apr 2004 A1
20040093093 Andrews May 2004 A1
20040097401 Datta May 2004 A1
20040097839 Epley May 2004 A1
20040102525 Kozachuk May 2004 A1
20040106966 Scribner et al. Jun 2004 A1
20040121464 Rathjen et al. Jun 2004 A1
20040143170 DuRousseau Jul 2004 A1
20040147975 Popovic et al. Jul 2004 A1
20040156826 Dangond et al. Aug 2004 A1
20040162583 Bingham et al. Aug 2004 A1
20040172100 Humayun et al. Sep 2004 A1
20040172102 Leysieffer Sep 2004 A1
20040185557 Smith et al. Sep 2004 A1
20040199235 Younis Oct 2004 A1
20040212504 Forcier et al. Oct 2004 A1
20040219184 Brown et al. Nov 2004 A1
20040228831 Belinka et al. Nov 2004 A1
20040229702 Cooke Nov 2004 A1
20040230226 Bingham et al. Nov 2004 A1
20040243021 Murphy et al. Dec 2004 A1
20050003998 Bertilsson et al. Jan 2005 A1
20050015133 Ibrahim et al. Jan 2005 A1
20050020519 Albiston et al. Jan 2005 A1
20050020945 Tosaya et al. Jan 2005 A1
20050038473 Tamarkin et al. Feb 2005 A1
20050054096 Piniella Mar 2005 A1
20050054907 Page et al. Mar 2005 A1
20050070819 Poux et al. Mar 2005 A1
20050073649 Spector Apr 2005 A1
20050107859 Daglow et al. May 2005 A1
20050125044 Tracey Jun 2005 A1
20050165323 Montgomery et al. Jul 2005 A1
20050203366 Donoghue et al. Sep 2005 A1
20050203601 Palanker et al. Sep 2005 A1
20050222631 Dalal et al. Oct 2005 A1
20050226852 Toda et al. Oct 2005 A1
20050234370 Beal et al. Oct 2005 A1
20050267552 Conquergood et al. Dec 2005 A1
20050272097 Calenoff Dec 2005 A1
20050273890 Flaherty et al. Dec 2005 A1
20050277918 Shah et al. Dec 2005 A1
20060034767 Lum et al. Feb 2006 A1
20060047326 Wheeler Mar 2006 A1
20060049950 Lockhart Mar 2006 A1
20060049957 Surgenor et al. Mar 2006 A1
20060058627 Flaherty et al. Mar 2006 A1
20060118035 Lasater Jun 2006 A1
20060122458 Bleich Jun 2006 A1
20060122529 Tsau Jun 2006 A1
20060122864 Gottesman et al. Jun 2006 A1
20060140930 Rodriguez et al. Jun 2006 A1
20060149345 Boggs et al. Jul 2006 A1
20060161225 Sormann et al. Jul 2006 A1
20060167498 DiLorenzo Jul 2006 A1
20060167564 Flaherty et al. Jul 2006 A1
20060171933 Short Aug 2006 A1
20060184219 Pajunk et al. Aug 2006 A1
20060190056 Fowler et al. Aug 2006 A1
20060195146 Tracey et al. Aug 2006 A1
20060195153 Diubaldi et al. Aug 2006 A1
20060206167 Flaherty et al. Sep 2006 A1
20060206178 Kim Sep 2006 A1
20060234376 Mistry et al. Oct 2006 A1
20060263336 Caplan Nov 2006 A1
20060265037 Kuzma Nov 2006 A1
20060281130 Bock et al. Dec 2006 A1
20070005106 Adducci Jan 2007 A1
20070021803 Deem et al. Jan 2007 A1
20070043591 Meretei et al. Feb 2007 A1
20070049814 Muccio Mar 2007 A1
20070049842 Hill et al. Mar 2007 A1
20070067004 Boveja et al. Mar 2007 A1
20070073361 Goren et al. Mar 2007 A1
20070088335 Jolly Apr 2007 A1
20070100393 Whitehurst et al. May 2007 A1
20070102009 Wong et al. May 2007 A1
20070107071 Couillard-Despres May 2007 A1
20070123778 Kantorovich May 2007 A1
20070129769 Bourget et al. Jun 2007 A1
20070134657 Poznansky et al. Jun 2007 A1
20070135846 Knudson et al. Jun 2007 A1
20070165322 Strom et al. Jul 2007 A1
20070173893 Pitts Jul 2007 A1
20070173903 Goren et al. Jul 2007 A1
20070179558 Gliner et al. Aug 2007 A1
20070180542 Brinster et al. Aug 2007 A1
20070192881 Brinster et al. Aug 2007 A1
20070203533 Goren et al. Aug 2007 A1
20070208385 Carroll et al. Sep 2007 A1
20070219074 Pride Sep 2007 A1
20070239211 Lorincz et al. Oct 2007 A1
20070249952 Rubin et al. Oct 2007 A1
20070276449 Gunter et al. Nov 2007 A1
20070282396 Overstreet et al. Dec 2007 A1
20070287613 Adducci Dec 2007 A1
20070293893 Stolen et al. Dec 2007 A1
20070299483 Strother et al. Dec 2007 A1
20080002276 Strom et al. Jan 2008 A1
20080033520 Jolly Feb 2008 A1
20080040951 Kates Feb 2008 A1
20080057028 Alitalo et al. Mar 2008 A1
20080064946 Greenberg et al. Mar 2008 A1
20080071321 Boggs et al. Mar 2008 A1
20080074794 Lee et al. Mar 2008 A1
20080077192 Harry et al. Mar 2008 A1
20080095747 Rutishauser et al. Apr 2008 A1
20080097530 Muccio et al. Apr 2008 A1
20080120029 Zelek et al. May 2008 A1
20080125870 Carmichael et al. May 2008 A1
20080133016 Heinz Jun 2008 A1
20080139907 Rao et al. Jun 2008 A1
20080154335 Thrope et al. Jun 2008 A1
20080161879 Firlik et al. Jul 2008 A1
20080161882 Firlik et al. Jul 2008 A1
20080161887 Hagen Jul 2008 A1
20080170234 Kim Jul 2008 A1
20080170316 Kim Jul 2008 A1
20080195163 Scharmer Aug 2008 A1
20080200967 Ponomarev et al. Aug 2008 A1
20080208280 Lindenthaler et al. Aug 2008 A1
20080215112 Firlik et al. Sep 2008 A1
20080221653 Agrawal et al. Sep 2008 A1
20080241208 Shanley et al. Oct 2008 A1
20080242607 DeFrees Oct 2008 A1
20080243218 Bottomley et al. Oct 2008 A1
20080248959 DeFrees Oct 2008 A1
20080249439 Tracey et al. Oct 2008 A1
20080253992 DeFrees et al. Oct 2008 A1
20080255582 Harris Oct 2008 A1
20080262557 Brown Oct 2008 A1
20080262584 Bottomley et al. Oct 2008 A1
20080274958 DeFrees Nov 2008 A1
20080275546 Storey et al. Nov 2008 A1
20080280818 DeFrees Nov 2008 A1
20080312538 Shahar et al. Dec 2008 A1
20080318314 Fulga et al. Dec 2008 A1
20090012586 Kepecs Jan 2009 A1
20090012590 Inman et al. Jan 2009 A1
20090029912 Gronthos et al. Jan 2009 A1
20090036938 Shipley et al. Feb 2009 A1
20090054800 Martinerie et al. Feb 2009 A1
20090054950 Stephens Feb 2009 A1
20090076421 Grant Mar 2009 A1
20090076444 Machado et al. Mar 2009 A1
20090086015 Larsen et al. Apr 2009 A1
20090105149 Albrechtsen et al. Apr 2009 A1
20090112278 Wingeier et al. Apr 2009 A1
20090112279 Wingeier et al. Apr 2009 A1
20090118788 Firlik et al. May 2009 A1
20090124965 Greenberg et al. May 2009 A1
20090131995 Sloan et al. May 2009 A1
20090132018 DiUbaldi et al. May 2009 A1
20090149782 Cohen Jun 2009 A1
20090149900 Moffitt et al. Jun 2009 A1
20090157091 Buysman Jun 2009 A1
20090171381 Schmitz et al. Jul 2009 A1
20090182393 Bachinski Jul 2009 A1
20090201671 Huntley Aug 2009 A1
20090214474 Jennings Aug 2009 A1
20090215896 Morseman et al. Aug 2009 A1
20090220466 Ratajczak et al. Sep 2009 A1
20090226598 Feng et al. Sep 2009 A1
20090227025 Nichols et al. Sep 2009 A1
20090227965 Wijesiriwardana Sep 2009 A1
20090234265 Reid et al. Sep 2009 A1
20090258048 Ward et al. Oct 2009 A1
20090270958 Greenberg et al. Oct 2009 A1
20090292338 Gordon et al. Nov 2009 A1
20090299439 Mire et al. Dec 2009 A1
20090306728 Wright et al. Dec 2009 A1
20090306745 Parker et al. Dec 2009 A1
20090326612 Distler Dec 2009 A1
20100004654 Schmitz et al. Jan 2010 A1
20100010550 Ponomarev et al. Jan 2010 A1
20100016732 Wells et al. Jan 2010 A1
20100035299 DeFrees et al. Feb 2010 A1
20100037755 McMillen et al. Feb 2010 A1
20100042180 Mueller et al. Feb 2010 A1
20100042185 Curtis Feb 2010 A1
20100045595 Bakke Feb 2010 A1
20100047915 Soykan et al. Feb 2010 A1
20100092983 Liew Apr 2010 A1
20100092984 Liew Apr 2010 A1
20100094311 Jolly et al. Apr 2010 A1
20100099786 Dias et al. Apr 2010 A1
20100112026 Karp et al. May 2010 A1
20100114195 Burnes et al. May 2010 A1
20100124745 Liew May 2010 A1
20100124746 Liew May 2010 A1
20100145427 Gliner et al. Jun 2010 A1
20100168739 Wu et al. Jul 2010 A1
20100179284 Ward et al. Jul 2010 A1
20100185042 Schneider et al. Jul 2010 A1
20100189712 Heureux et al. Jul 2010 A1
20100203520 Liew Aug 2010 A1
20100204538 Burnett et al. Aug 2010 A1
20100204777 Storey et al. Aug 2010 A1
20100211172 Bellamkonda et al. Aug 2010 A1
20100222630 Mangrum et al. Sep 2010 A1
20100222844 Troosters et al. Sep 2010 A1
20100241195 Meadows et al. Sep 2010 A1
20100268055 Jung et al. Oct 2010 A1
20100268125 Epley Oct 2010 A9
20100280570 Sturm et al. Nov 2010 A1
20100280571 Sloan Nov 2010 A1
20100286067 DeFrees Nov 2010 A1
20100292759 Hahn et al. Nov 2010 A1
20100298916 Rabischong et al. Nov 2010 A1
20100304864 Johnson et al. Dec 2010 A1
20100305674 Zarembo et al. Dec 2010 A1
20100310529 Aizman Dec 2010 A1
20100324355 Spitaels et al. Dec 2010 A1
20100324626 Lefkovitz Dec 2010 A1
20110009959 Tiedtke Jan 2011 A1
20110014189 Soula et al. Jan 2011 A1
20110022105 Owen et al. Jan 2011 A9
20110022131 Giuliano Jan 2011 A1
20110028345 Fang et al. Feb 2011 A1
20110040204 Ivorra et al. Feb 2011 A1
20110040349 Graupe Feb 2011 A1
20110059447 Liew Mar 2011 A1
20110060266 Streeter et al. Mar 2011 A1
20110082531 Swanson et al. Apr 2011 A1
20110092863 Kim et al. Apr 2011 A1
20110098777 Silverstone Apr 2011 A1
20110106207 Cauller et al. May 2011 A1
20110106219 Cauller et al. May 2011 A1
20110112352 Pilla et al. May 2011 A1
20110118556 Siegel et al. May 2011 A1
20110124959 Murison May 2011 A1
20110137189 Kuo et al. Jun 2011 A1
20110158444 Waldmann Jun 2011 A1
20110177029 DeFrees Jul 2011 A1
20110184269 Sauter-Starace et al. Jul 2011 A1
20110190882 Parker et al. Aug 2011 A1
20110195106 McMurtrey Aug 2011 A1
20110196454 Strand et al. Aug 2011 A1
20110202120 Ball et al. Aug 2011 A1
20110208226 Fatone et al. Aug 2011 A1
20110218593 Rubinstein et al. Sep 2011 A1
20110224565 Ong et al. Sep 2011 A1
20110224754 Wei Sep 2011 A1
20110257501 Huys et al. Oct 2011 A1
20110257504 Hendricks et al. Oct 2011 A1
20110262501 Webster et al. Oct 2011 A1
20110264178 Mehregany et al. Oct 2011 A1
20110268776 Schapira et al. Nov 2011 A1
20110270345 Johnston et al. Nov 2011 A1
20110270361 Borsody Nov 2011 A1
20110295156 Arturi Dec 2011 A1
20110301662 Bar-Yoseph et al. Dec 2011 A1
20110313270 Neves et al. Dec 2011 A1
20110319703 Wiskerke et al. Dec 2011 A1
20120016431 Paul et al. Jan 2012 A1
20120016440 Muccio Jan 2012 A1
20120022616 Garnham et al. Jan 2012 A1
20120035684 Thompson et al. Feb 2012 A1
20120045487 Lahann et al. Feb 2012 A1
20120046702 Gibson Feb 2012 A1
20120059389 Larson et al. Mar 2012 A1
20120064628 Blick et al. Mar 2012 A1
20120076830 Sitharaman et al. Mar 2012 A1
20120078327 Sloan et al. Mar 2012 A1
20120089047 Ryba et al. Apr 2012 A1
20120095166 Ward et al. Apr 2012 A1
20120095524 Nelson et al. Apr 2012 A1
20120101326 Simon et al. Apr 2012 A1
20120101413 Beetel et al. Apr 2012 A1
20120109233 Lee et al. May 2012 A1
20120123508 Wentz et al. May 2012 A1
20120124470 West et al. May 2012 A1
20120130360 Buckley et al. May 2012 A1
20120134965 Kim et al. May 2012 A1
20120136232 Jeong et al. May 2012 A1
20120143293 Mauch et al. Jun 2012 A1
20120158095 Jolly Jun 2012 A1
20120158104 Huynh et al. Jun 2012 A1
20120158113 Jolly et al. Jun 2012 A1
20120158114 Debruyne et al. Jun 2012 A1
20120179076 Bavelier et al. Jul 2012 A1
20120185173 Yamamoto et al. Jul 2012 A1
20120191052 Rao Jul 2012 A1
20120191086 Moll et al. Jul 2012 A1
20120197092 Luo et al. Aug 2012 A1
20120197252 Deem et al. Aug 2012 A1
20120197374 Vogt et al. Aug 2012 A1
20120214737 Marchionni Aug 2012 A1
20120221072 Fukamachi et al. Aug 2012 A1
20120226331 Banna et al. Sep 2012 A1
20120237557 Lewitus et al. Sep 2012 A1
20120238924 Avni Sep 2012 A1
20120239363 Durrani et al. Sep 2012 A1
20120244503 Neveldine Sep 2012 A1
20120245534 Jolly Sep 2012 A1
20120253236 Snow et al. Oct 2012 A1
20120259255 Tomlinson et al. Oct 2012 A1
20120259390 Canion Oct 2012 A1
20120277825 Mawson et al. Nov 2012 A1
20120277842 Kunis Nov 2012 A1
20120282228 Bhasin Nov 2012 A1
20120283800 Perryman et al. Nov 2012 A1
20120296191 McGrath et al. Nov 2012 A1
20120296230 Davis et al. Nov 2012 A1
20120296444 Greenberg et al. Nov 2012 A1
20120302856 Chang et al. Nov 2012 A1
20120310140 Kramer et al. Dec 2012 A1
20120323288 Anderson et al. Dec 2012 A1
20130012831 Schmitz et al. Jan 2013 A1
20130018240 McCoy Jan 2013 A1
20130018444 Glenn et al. Jan 2013 A1
20130035745 Ahmed et al. Feb 2013 A1
20130041432 Tucker et al. Feb 2013 A1
20130052712 Cha et al. Feb 2013 A1
20130053853 Schmitz et al. Feb 2013 A1
20130053934 Gluckman et al. Feb 2013 A1
20130066147 Brown Mar 2013 A1
20130066216 Park Mar 2013 A1
20130066391 Hulvershorn et al. Mar 2013 A1
20130066392 Simon et al. Mar 2013 A1
20130066395 Simon et al. Mar 2013 A1
20130072808 Neves et al. Mar 2013 A1
20130072835 Harry et al. Mar 2013 A1
20130090542 Kipke et al. Apr 2013 A1
20130090711 Ramachandran et al. Apr 2013 A1
20130101635 Park et al. Apr 2013 A1
20130116685 Deem et al. May 2013 A1
20130116744 Blum et al. May 2013 A1
20130122528 Tyrell et al. May 2013 A1
20130123568 Hamilton et al. May 2013 A1
20130123570 Ly et al. May 2013 A1
20130131743 Yamasaki et al. May 2013 A1
20130131753 Simon et al. May 2013 A1
20130137955 Kong et al. May 2013 A1
20130144143 Kim et al. Jun 2013 A1
20130144369 Elias et al. Jun 2013 A1
20130144370 Debruyne et al. Jun 2013 A1
20130150653 Borsody Jun 2013 A1
20130154838 Alameh et al. Jun 2013 A1
20130157229 Lauritzen et al. Jun 2013 A1
20130178765 Mishelevich Jul 2013 A1
20130184792 Simon et al. Jul 2013 A1
20130184795 Kipke et al. Jul 2013 A1
20130184799 Kipke et al. Jul 2013 A1
20130204122 Hendler et al. Aug 2013 A1
20130204317 Sauter-Starace et al. Aug 2013 A1
20130210041 Anderberg et al. Aug 2013 A1
20130218456 Zelek et al. Aug 2013 A1
20130231725 Williams et al. Sep 2013 A1
20130238066 Joseph et al. Sep 2013 A1
20130238074 Zimmerling Sep 2013 A1
20130245480 Crockford Sep 2013 A1
20130245486 Simon et al. Sep 2013 A1
20130245711 Simon et al. Sep 2013 A1
20130245712 Simon et al. Sep 2013 A1
20130245717 Stohl et al. Sep 2013 A1
20130245765 Lowry et al. Sep 2013 A1
20130248226 Sime et al. Sep 2013 A1
20130253299 Weber et al. Sep 2013 A1
20130274540 Pilla et al. Oct 2013 A1
20130274658 Steinke et al. Oct 2013 A1
20130274842 Gaunt et al. Oct 2013 A1
20130280233 Kahn et al. Oct 2013 A1
20130282001 Hezi-Yamit et al. Oct 2013 A1
20130282090 Decré et al. Oct 2013 A1
20130288233 Murray Oct 2013 A1
20130289678 Clark et al. Oct 2013 A1
20130289686 Masson et al. Oct 2013 A1
20130296767 Zarins et al. Nov 2013 A1
20130309278 Peyman Nov 2013 A1
20130310909 Simon et al. Nov 2013 A1
20130317400 Ferezy Nov 2013 A1
20130317580 Simon et al. Nov 2013 A1
20130324994 Pellegrino et al. Dec 2013 A1
20130331869 Runge et al. Dec 2013 A1
20130338729 Spector Dec 2013 A1
20130341185 Collaert et al. Dec 2013 A1
20140003696 Taghva Jan 2014 A1
20140018792 Gang et al. Jan 2014 A1
20140022162 Yu et al. Jan 2014 A1
20140023999 Greder Jan 2014 A1
20140024981 Chun et al. Jan 2014 A1
20140025301 Storm et al. Jan 2014 A1
20140030735 Merali et al. Jan 2014 A1
20140046423 Rajguru et al. Feb 2014 A1
20140051938 Goldstein et al. Feb 2014 A1
20140058481 Perryman et al. Feb 2014 A1
20140058483 Zao et al. Feb 2014 A1
20140066924 Azamian et al. Mar 2014 A1
20140073883 Rao et al. Mar 2014 A1
20140074186 Faltys et al. Mar 2014 A1
20140081682 Perlmuter Mar 2014 A1
20140094674 Nurmikko et al. Apr 2014 A1
20140099352 Matheny Apr 2014 A1
20140107397 Simon et al. Apr 2014 A1
20140107398 Simon et al. Apr 2014 A1
20140114168 Block et al. Apr 2014 A1
20140127171 Nocera et al. May 2014 A1
20140128939 Embrey et al. May 2014 A1
20140135607 Lee et al. May 2014 A1
20140135680 Peyman May 2014 A1
20140142374 Makower et al. May 2014 A1
20140148649 Miles et al. May 2014 A1
20140148871 Southwell et al. May 2014 A1
20140148872 Goldwasser et al. May 2014 A1
20140155811 Gibson Jun 2014 A1
20140155973 Grigsby et al. Jun 2014 A1
20140163580 Tischendorf et al. Jun 2014 A1
20140163641 Yao et al. Jun 2014 A1
20140163658 Faraji et al. Jun 2014 A1
20140171807 Akkin et al. Jun 2014 A1
20140180036 Bukkapatnam et al. Jun 2014 A1
20140180196 Stone et al. Jun 2014 A1
20140180365 Perryman et al. Jun 2014 A1
20140187872 Stivoric et al. Jul 2014 A1
20140197937 Huang et al. Jul 2014 A1
20140200432 Banerji et al. Jul 2014 A1
20140200466 Sereno et al. Jul 2014 A1
20140200496 Hyde et al. Jul 2014 A1
20140200681 Kennedy et al. Jul 2014 A1
20140206947 Isserow et al. Jul 2014 A1
20140207292 Ramagem et al. Jul 2014 A1
20140213842 Simon et al. Jul 2014 A1
20140213971 Dolan et al. Jul 2014 A1
20140220555 Chen et al. Aug 2014 A1
20140222125 Glenn et al. Aug 2014 A1
20140225763 Kavaler et al. Aug 2014 A1
20140228901 Vogt Aug 2014 A1
20140228926 Santina et al. Aug 2014 A1
20140235950 Miles et al. Aug 2014 A1
20140236249 Rao et al. Aug 2014 A1
20140236847 Hamilton Aug 2014 A1
20140243616 Johnson Aug 2014 A1
20140243932 Libbus et al. Aug 2014 A1
20140249395 Zhou et al. Sep 2014 A1
20140255461 McMurtrey Sep 2014 A9
20140257063 Ong et al. Sep 2014 A1
20140257437 Simon et al. Sep 2014 A1
20140267123 Ludwig Sep 2014 A1
20140275737 Shore et al. Sep 2014 A1
20140276718 Turovskiy et al. Sep 2014 A1
20140276760 Bonyak et al. Sep 2014 A1
20140277031 Ballakur et al. Sep 2014 A1
20140277033 Taylor et al. Sep 2014 A1
20140277220 Brennan et al. Sep 2014 A1
20140277237 Maskara et al. Sep 2014 A1
20140277271 Chan et al. Sep 2014 A1
20140277310 Beetel et al. Sep 2014 A1
20140277582 Leuthardt et al. Sep 2014 A1
20140288379 Miles et al. Sep 2014 A1
20140296646 Wingeier et al. Oct 2014 A1
20140300490 Kotz et al. Oct 2014 A1
20140303525 Sitharaman Oct 2014 A1
20140303548 Jolly et al. Oct 2014 A1
20140304773 Woods et al. Oct 2014 A1
20140309548 Merz et al. Oct 2014 A1
20140316398 Kelly et al. Oct 2014 A1
20140320289 Raichman Oct 2014 A1
20140330337 Linke et al. Nov 2014 A1
20140336631 Wu et al. Nov 2014 A1
20140336722 Lima et al. Nov 2014 A1
20140350041 Yun et al. Nov 2014 A1
20140350633 Gustafson et al. Nov 2014 A1
20140357453 Tamanaha Dec 2014 A1
20140357933 Lee et al. Dec 2014 A1
20140360511 Mohler Dec 2014 A1
20140371547 Gartenberg et al. Dec 2014 A1
20140371564 Anikeeva et al. Dec 2014 A1
20140371622 Hausman et al. Dec 2014 A1
20140375457 Diaz Dec 2014 A1
20140378779 Freeman et al. Dec 2014 A1
20140378789 McKinley et al. Dec 2014 A1
20140378946 Thompson et al. Dec 2014 A1
20140379045 Rahimi et al. Dec 2014 A1
20140379049 Mashiach et al. Dec 2014 A1
20150005607 Cui et al. Jan 2015 A1
20150005680 Lipani Jan 2015 A1
20150005840 Pal et al. Jan 2015 A1
20150005841 Pal et al. Jan 2015 A1
20150005851 Bradley Jan 2015 A1
20150010607 Francis et al. Jan 2015 A1
20150012079 Goroszeniuk et al. Jan 2015 A1
20150016647 Martinez et al. Jan 2015 A1
20150017140 Bhatia et al. Jan 2015 A1
20150018659 Ware et al. Jan 2015 A1
20150032044 Peyman Jan 2015 A9
20150032178 Simon et al. Jan 2015 A1
20150032184 Muccio Jan 2015 A1
20150038886 Snow Feb 2015 A1
20150039055 Wagner et al. Feb 2015 A1
20150049325 Curtis Feb 2015 A1
20150051439 Hillbratt et al. Feb 2015 A1
20150051684 Greenberg et al. Feb 2015 A1
20150057736 Zachar Feb 2015 A1
20150059390 Hayes Mar 2015 A1
20150062018 Naidu et al. Mar 2015 A1
20150066126 Marx et al. Mar 2015 A1
20150067422 Hamilton Mar 2015 A1
20150073232 Ahmad et al. Mar 2015 A1
20150073520 Strahl et al. Mar 2015 A1
20150080709 Chaturvedi Mar 2015 A1
20150080926 Emery Mar 2015 A1
20150088030 Taylor Mar 2015 A1
20150088223 Blum et al. Mar 2015 A1
20150088224 Goldwasser et al. Mar 2015 A1
20150088225 Noble et al. Mar 2015 A1
20150102925 Foldyna et al. Apr 2015 A1
20150105794 Dhanasingh et al. Apr 2015 A1
20150105795 Lenarz et al. Apr 2015 A1
20150112234 McCaffrey et al. Apr 2015 A1
20150112321 Cadouri Apr 2015 A1
20150112359 Gillbe Apr 2015 A1
20150112360 Pellinen et al. Apr 2015 A1
20150112404 Holding et al. Apr 2015 A1
20150112405 Brown et al. Apr 2015 A1
20150112408 Kals Apr 2015 A1
20150119673 Pellinen et al. Apr 2015 A1
20150119790 Moffitt et al. Apr 2015 A1
20150119954 Bhadra et al. Apr 2015 A2
20150119989 Pimenta et al. Apr 2015 A1
20150126997 Beetel et al. May 2015 A1
20150133761 Vetter et al. May 2015 A1
20150133956 Dayan et al. May 2015 A1
20150135840 Sato et al. May 2015 A1
20150148643 Small et al. May 2015 A1
20150148644 Vaidyanathan et al. May 2015 A1
20150148736 Jolly et al. May 2015 A1
20150148869 Alan et al. May 2015 A1
20150148878 Yoo et al. May 2015 A1
20150150508 Glenn et al. Jun 2015 A1
20150157398 Zarins et al. Jun 2015 A1
20150157851 Sefkow et al. Jun 2015 A1
20150157854 Hetke et al. Jun 2015 A1
20150157862 Greenberg et al. Jun 2015 A1
20150164360 Kipke et al. Jun 2015 A1
20150164401 Toth et al. Jun 2015 A1
20150173673 Toth et al. Jun 2015 A1
20150173918 Herr et al. Jun 2015 A1
20150174403 Pal et al. Jun 2015 A1
20150174418 Tyler et al. Jun 2015 A1
20150182753 Harris et al. Jul 2015 A1
20150190635 Neuvonen et al. Jul 2015 A1
20150190636 Simon et al. Jul 2015 A1
20150190637 Simon et al. Jul 2015 A1
20150196767 Ahmed Jul 2015 A1
20150201855 Pellinen et al. Jul 2015 A1
20150202331 Blumenfeld et al. Jul 2015 A1
20150202437 Franke et al. Jul 2015 A1
20150209104 Tran et al. Jul 2015 A1
20150209577 Golestanirad et al. Jul 2015 A1
20150209586 Silva et al. Jul 2015 A1
20150217125 Chornenky et al. Aug 2015 A1
20150223731 Sahin Aug 2015 A1
20150224300 Hagr et al. Aug 2015 A1
20150224330 Kaib et al. Aug 2015 A1
20150230749 Gharib et al. Aug 2015 A1
20150231396 Burdick et al. Aug 2015 A1
20150235529 Deschamps Aug 2015 A1
20150238104 Tass Aug 2015 A1
20150238253 Wu et al. Aug 2015 A1
20150238764 Franke Aug 2015 A1
20150246072 Bhatia et al. Sep 2015 A1
20150248470 Coleman et al. Sep 2015 A1
20150251004 Imran et al. Sep 2015 A1
20150254992 Sethi Sep 2015 A1
20150257824 Mauch Sep 2015 A1
20150272805 Burnett et al. Oct 2015 A1
20150273206 Monteiro Oct 2015 A1
20150283365 Dacey et al. Oct 2015 A1
20150284416 Zhao Oct 2015 A1
20150290439 Eldredge et al. Oct 2015 A1
20150290450 Kolb et al. Oct 2015 A1
20150290464 Monteiro Oct 2015 A1
20150290472 Maguire et al. Oct 2015 A1
20150297104 Chen et al. Oct 2015 A1
20150297444 Tass Oct 2015 A1
20150297914 Hamid et al. Oct 2015 A1
20150305667 Durand Oct 2015 A1
20150305686 Coleman et al. Oct 2015 A1
20150310762 Seim et al. Oct 2015 A1
20150313498 Coleman et al. Nov 2015 A1
20150313512 Hausman et al. Nov 2015 A1
20150314017 Zhao Nov 2015 A1
20150320560 Mulliken et al. Nov 2015 A1
20150320588 Connor Nov 2015 A1
20150321000 Rosenbluth et al. Nov 2015 A1
20150321010 Marnfeldt Nov 2015 A1
20150321017 Perryman et al. Nov 2015 A1
20150322155 Zhao Nov 2015 A1
20150328454 Lambert Nov 2015 A1
20150328455 Meadows et al. Nov 2015 A1
20150335288 Toth et al. Nov 2015 A1
20150335876 Jeffery et al. Nov 2015 A1
20150335877 Jeffery et al. Nov 2015 A1
20150335883 Halpern et al. Nov 2015 A1
20150343196 Vasapollo Dec 2015 A1
20150343215 Ridder Dec 2015 A1
20150343242 Tyler et al. Dec 2015 A1
20150354922 Carriere Dec 2015 A1
20150359704 Imboden et al. Dec 2015 A1
20150364018 Mirov et al. Dec 2015 A1
20150374515 Meijer et al. Dec 2015 A1
20150379880 Sethi Dec 2015 A1
20170080216 Pham Mar 2017 A1
20170209693 An et al. Jul 2017 A1
Foreign Referenced Citations (8)
Number Date Country
101868279 Oct 2010 CN
107362447 Nov 2017 CN
2646779 Jul 1993 FR
2011502707 Jan 2011 JP
2013500080 Jan 2013 JP
2011011748 Jan 2011 WO
2011053607 May 2011 WO
2012129574 Sep 2012 WO
Non-Patent Literature Citations (768)
Entry
US 8,398,630 B2, 03/2013, Demarais et al. (withdrawn)
US 8,613,701 B2, 12/2013, Rao et al. (withdrawn)
US 8,652,133 B2, 02/2014, Zarins et al. (withdrawn)
Nijman, RJ; Role of antimuscarinics in the treatment of nonneurogenic daytime urinary incontinence in children; Urology; 2004; 45-50; 63.
Nilsson, KF, et al.; Estimation of endogenous adenosine activity at adenosine receptors in guinea-pig ileum using a new pharmacolofical method; Acta Physiol (Oxf); 2010; 231-241; 199.
Nitti, VW; Urodynamics, Incontinence, and Neurourology: Highlights from the Society for Urodynamics and Female Urology Annual Winter Meeting, Feb. 28-Mar. 2, 2008, Miami, FL; Rev Urol; 2008; 229-231; 10.
Noblett, K. et al.; Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder; Neurourol Urodyn; 2016; 246-251; 35.
Noblett, KL., et al.; Sacral nerve stimulation for the treatment of refractory voiding and bowel dysfunction: Am J Obstet Gynecol; 2014, 99-106; 210.
Nordling, J: Surgical treatment of painful bladder syndrome/interstitial cystitis: Womens Health (Lond Engl): 2006: 233-238: 2.
Nyarangi-Dix, JN, et al.; [Overactive bladder syndrome. Are there indications for surgical therapy?]: Urologe A; 2006; 1289-1290, 1292: 45.
Occhino, JA, et al.; Sacral nerve modulation in overactive bladder; Curr Urol Rep: 2010: 348-352: 11.
Oerlemans, DJ, et al.: Is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime?: Neurourol Urodyn: 2011: 1493-1496; 30.
Oerlemans, DJ. et al.: Sacral nerve stimulation for neuromodulation of the lower urinary tract: Neurourol Urodyn: 2008; 28-33; 27.
Offiah, I, et al.; Interstitial cystitis/bladder pain syndrome: diagnosis and management: Int Urogynecol J; 2013: 1243-1256: 24.
Oliver. S, et al.: Measuring the sensations of urge and bladder filling during cystometry in urge incontinence and the effects of neuromodulation; Neurourol Urodyn: 2003; 42567: 22.
Olivera, CK, et al.; Non-antimuscarinic treatment for overactive bladder: a systemactic review; Am J Obstet Gynecol: 2016:Abstract.
Olujide. LO, et al.: Female voiding dysfunction; Best Pract Res Clin Obstet Gynaecol: 2005; 807-828: 19.
Oom, DM. et al.; Anterior sphincteroplasty for fecal incontinence: a single center experience in the era of sacral neuomodulation; Dis Colon Rectum: 2009; 1681-1687: 52.
Oom, DM, et al; Is sacral neuromodulation for fecal incontinence worthwhile in patients with associated pelvic floor injury?; Dis Colon Rectum: 2010; 422-427: 53.
Ordia, JI, et al.; Continuous intrathecal baclofen infusion delivered by a programmable pump for the treatment of severe spasticity following traumatic brain injury: Neuromodulation; 2002: 103-107; 5.
O'Reilly, BA, et al.; A prospective randomised double-blind controlled trial evaluating the effect of trans-sacral magnetic stimulation in women with overactive bladder: Int Urogynecol J Pelvic Floor Dysfunct; 2008; 497-502; 19.
Osman, NI, et al.: Fowler's syndrome—a cause of unexplained orinary retention in young women?; Nat Rev Urol; 2014; 87-98: 11;Abstract.
Osman, NI, et al.: Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches; Arab J Urol; 2013; 313-318; 11.
Otto, W, et al.; [Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a German high-volume clinic]: Aktuelle Urol: 2012; 162-166; 43;Abstract.
Ozyalcin, NS, et al.; [Sacral nerve stimulation in fecal incontinence: efficacy and safety]; Agri: 2004; 35-44; 16;Abstract.
Panicker, JN, et al.; Lower urinary tract dysfuntion in the neurological patient; clinical assessment and management; Lancet Neurol; 2015: 720-732; 14.
Pannek, J, et al.; [Initial results of Stoller peripheral neuromodulation in disorders of bladder function]; Urologe A; 2003; 1470-1476; 42.
Parija, SC, et al.; Adenosine- and alpha,beta-methylene ATP-induced differential inhibition of cholinergic and non-cholinergic neurogenic responses in a rat urinary bladder; Br J Pharmacol; 1991; 396-400; 102.
Park, SH, et al.; Overactive bladder; treatment options for the aging woman; Int J Fertil Womens Med; 2005; 37-44; 50;Abstract.
Parnell, BA, et al.; The effect of sacral neuromodulation on pudendal nerve function and female sexual function; Neurourol Urodyn; 2015; 456-460; 34.
Pascual, I, et al.; Sacral nerve stimulation for fecal incontinence; Rev Esp Enferm Dig; 2011; 355-359; 103.
Patidar, N. et al.; Transcutaneous posterior tibial nerve stimulation in pediatric overactive bladder; A preliminary report; J Pediatr Urol; 2015; 351.e351-356; 11.
Pauls, RN, et al.; Effects of sacral neuromodulation on female sexual function; Int Urogynecol J Pelvic Floor Dysfunct; 2007; 391-395; 18.
Peeters, K, et al.; Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction; BJU Int; 2014; 789-794; 113.
Peirce, C, et al.; Central representation of the inferior rectal nerve of the rat; Dis Colon Rectum; 2010; 315-320; 53.
Pelaez, E. et al.; [Epidural spinal cord stimulation for interstitial cystitis]; Rev Esp Anestesiol Reanim; 2004; 549-552; 51;Abstract.
Pelliccioni, G, et al.; External and sphincter responses after S3 spinal root electrical stimulation; Neurourol Urodyn; 2006; 788-791; 25.
Pena, G, et al.; Cholinergic regulatory lymphocyles re-establish neuromodulation of innate immune responses in sepsis; J Immunol. 2011; 718-725; 187.
Peng, CW, et al.; Pudendal neuromodulation with a closed-loop control strategy to improve bladder functions in the animal study; Conf Proc IEEE Eng Med Biol Soc; 2013; 3626-3629; 2013.
Penson, DF; Re: Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin a treatment for patients with idiopathis overactive bladder; J Urol; 2012; 2157-2158; 187.
Penson, DF; Re: Physician Use of Sacral Neuromodulation among Medicare Beneficiaries with Overactive Bladder and Urinary Retention; J Urol; 2016; 689; 195.
Perissinotto et al.; Transcutaneous Tibial Nerve Stimulation in the Treatment of Lower UrinaryTract Symptoms and its Impact on Health-Related Quality of Life in Patients With ParkinsonDisease; J Wound, Ostomy and Continence Nurses Society; 2015; 94-89: 42.
Perrigot, M. et al.; [Perineal electrical stimulation and rehabilitation in urinary incontinence and other symptoms of non-neurologic origin]; Ann Readapt Med Phys; 2008: 479-480; 51;Abstract.
Pescatori, LC, et al.; Sphincteroplasty for anal incontinence; Gastroenterol Rep (Oxf); 2014; 92-97; 2.
Peters, KM, et al.; Characterization of a clinical cohort of 87 women with interstitial cystitis/painful bladder syndrome; Urology: 2008; 634-640; 71.
Peters, KM, et al.; Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptons; Neurourol Urodyn; 2010; 1267-1271; 29.
Peters, KM, et al.; Clinical outcomes of sacral neuromodulation in patients with neurologic conditions; Urology, 2013; 738-743; 81.
Peters, KM, et al.; Does patient age impact outcomes of neuromodulation?; Neurourol Urodyn; 2013; 30-36; 32.
Peters, KM, et al.; Effect of Sacral neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome Patients: Low Urin Tract Symptoms; 2015: 77-83: 7.
Peters, KM, et al.; Effect of Sacral Neuromodulation Rate on Overactive Bladder Symptoms; A Randomized Crossover Feasibility Study; Low Urin Tract Symptoms; 2013; 129-133; 5.
Peters, KM, et al.; Is sensory testing during lead placement crucial for achieving positive outcomes after sacral neuromodulation?; Neurourol Urodyn; 2011; 1489-1492; 30.
Peters, KM, et at.; Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder; 3-year results of the STEP study; J Urol; 2013; 2194-2201; 189.
Peters, KM, et al.; Predictors of reoperation after sacral neuromodulation: A single institution evaluation of over 400 patients; Neurourol Urodyn; 2015;Abstract.
Van Wunnik, BP, et al.; Patient experience and satisfaction with sacral neuromodulation; results of a single-center sample survey; Dis Colon Rectum; 2011; 95-100; 54.
Van Wunnik, BP, et al.; Sacral neuromodulation therapy; a promising treatment for adolescents with refractory functional constipation; Dis Colon Rectum; 2012; 278-285; 5.
Vasavada, SP, et al.; Neuromodulation techniques; a comparison of available and new therapies; Curr Urol Rep; 2007; 455-460; 8.
Vasdev, N, et al.; The surgical management of the refractory overactive bladder; Indian J Urol; 2010; 263-269; 26.
Veeratterapillay, R, et al.; Augmentation cystoplasty; Contemporary indications, techniques and complications; Indian J Urol; 2013; 322-327; 29.
Veit-Rubin, N, et al.; [Overactive bladder syndrome—a public health challenge]; Rev Med Suisse; 2015; 2016-2021; 11;Abstract.
Vigil, HR, et al.; Urinary tract infection in the neurogenic bladder; Transl Androl Urol; 2016; 72-87; 5.
Vignes, JR, et al.; Animal models of sacral neuromodulcation for detrusor overactivity; Neurourol Urodyn; 2009; 42594; 28.
Vignes, JR, et al.; Sacral neuromodulation as a functional treatment of bladder overactivity; Acta Neurochir Suppl; 2007; 315-322; 97;Abstract.
Vignes, JR, et al.; Sacral neuromodulation in lower urinary tract dysfunction; Adv Tech Stand Neurosurg; 2005; 177-224; 30;Abstract.
Wallace, JL, et al.; Lack of beneficial effect of a tachykinin receptor antagonist in experimental colitis; Regul Pept; 1998; 95-101; 73.
Walsh, IK, et al.; Non-invasive antidromic neurostimulation; a simple effective method for improving bladder storage; Neurourol Urodyn; 2001; 73-84; 20.
Walter, S; [Duloxetine. A new preparation for patients with urinary incontinence]; Ugeskr Laeger; 2005; 4553-4555; 167;Abstract.
Wang, Y, et al.; Neuromodulation reduces c-fos gene expression in spinalized rats; a double-blind randomized study; J Urol; 2000; 1966-1970; 163.
Wang, Y, et al.; Neuromodulation reduces uriniary frequency in rats with hydrochloric acid-induced cystitis; BJU Int; 2000; 726-730; 86.
Wark, HA, et al.; Restoration from acute urinary dysfunction using Utah electrode arrays implanted into the feline pudendal nerve: Neuromodulation; 2015: 317-323; 18.
Watanabe, JH, et al.; Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder; Urology; 2010; 835-840; 76.
Wehbe, SA, et al.; Minimally invasive therapies for chronic pelvic pain syndrome; Curr Urol Rep; 2010; 276-265; 11.
Wehbe, SA, et al.; Sacral neuromodulations for female lower urinary tract, pelvic floor, and bowel disorders; Curr Opin Obstet Gynecol; 2010; 414-419; 22.
Weil, EH, et al.; Sacral root neuromodulation in the treatment of refractory urinary urge incontinence; a prospective randomized clinical trial; Eur Urol; 2000; 161-171; 37;Abstract.
Wein, AJ, et al.; Overactive bladder; a better understanding of pathophysiology, diagnosis and management; J Urol; 2006; S5-10; 175.
Wein, AJ; Diagnosis and treatment of the overactive bladder; Urology; 2003; 20-27; 62.
Wein, AJ; Re; inhibition of bladder overactivity by a combination of tibial neuromodulation and tramadol treatment in cats; J Urol; 2014; 868-869; 191.
Wein, AJ; Re; is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime?; J Urol; 2013; 610-611; 189.
Wein, AJ; Re; Results of a Prospective, Randomized, Multicenter Study Evaluating Sacral Neuromodulation with InterStim Therapy Compared to Standard Medical Therapy at 6-Months in Subjects with Mild Symptoms of Overactive Bladder; J Urol; 2015; 1051-1052; 194.
Wenzler, DL, et al.; Proof of concept trial on changes in current perception threshold after sacral neuromodulation; Neuromodulation; 2015; 228-231; discussion 232; 18.
Wexner, SD. et al.; Current surgical strategies to treat fecal incontinence; Expert Rev Gastroenterol Hepatol; 2015; 1577-1589; 9;Abstract.
White, N, et al.; Overactive Bladder; Obstet Gynecol Clin North Am; 2016; 59-68; 43.
Whitmore, KE; Complementary and alternative therapies as treatment approaches for interstitial cystitis; Rev Urol; 2002; S28-35; 4 Suppl 1.
Wiklund CU, et al.; Modulation of cholinergic and substance P-like neurotransmission by nitric oxide in the guinea-pig ileum; Br J Pharmacol; 1993: 833-839: 110.
Wiklund, NP, et al.; Cholinergic neuromodulation by endothelin in guinea pig ileum; Neurosci Lett; 1989; 342-346; 101.
Wiklund, NP, et al.; Neuromodulation by adenine nucleotides, as indicated by experiments with inhibitors of nucleotide inactivation; Acta Physiol Scand; 1988; 217-223; 126:Abstract.
Williams, MJ, et al.; Self-Reported Medication Costs in Patients Receiving Sacral Neuromodulation for Overactive Bladder; Value Health; 2015; A352; 18.
Withington, J, et al.; The changing face of urinary continence surgery in England: a perspective from the Hospital Episode Statistics database; BJU Int; 2014; 268-277; 114.
Wolff, K, et al.; Function outcome and quality of life after stapled transanal rectal resection for obstructed defecation syndrome: Dis Colon Rectum; 2010; 881-888; 53.
Wood, LN, et al.; Urinary incontinence in women; Brnj; 2014; g4531; 349.
Wooldridge, LS; Percutaneous tibial nerve stimulation for the treatment of urinary frequency, urinary urgency, and urge incontinence; results from a community-based clinic; Urol Nurs; 2009; 177-185; 29.
Worsoe, J, et al., Turning off sacral nerve stimulation does not affect gastric and small intestinal motility in patients treated for faecal incontinence; Colorectal Dis; 2012; e713-720; 14.
Wosnitzer, MS, et al.; The use of sacral neuromodulation for the treatment of non-obstructive urinary retention secondary to Guillain-Barre syndrome; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 1145-1147; 20.
Wu, JM, et al.; Patient preferences for different severities of and treatments for overactive bladder; Female Pelvic Med Reconstr Surg; 2011; 184-189; 17;Abstract.
Wyndaele, JJ, et al,; Conservative treatment of the neuropathic bladder in spinal cord injured patients; Spinal Cord; 2001; 294-300; 39.
Wyndaele, JJ, et al.; Influence of sacral neuromodulation on electrosensation of the lower urinary tract; J Urol; 2000; 221-224; 163.
Wyndaele, JJ; Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms; Spinal Cord; 2009; 427; 47.
Xiao, Z. et al.; Role of spinal GABAA receptors in pudendal inhibition of nociceptive and nonnociceptive bladder reflexes in cats; Am J Physiol Renal Physiol; 2014; F781-789, 306.
Xiao, Z, et al.; Somatic modulation of spinal reflex bladder activity mediated by nociceptive bladder afferent nerve fibers in cats; Am J Physiol Renal Physiol; 2014; F673-679; 307.
Yamanishi, T, et al.; Neuromodulation for the Treatment of Lower Urinary Tract Symptoms; Low Urin Tract Symptoms; 2015; 121-132; 7.
Yamanouchi, M. et el.; Integrative control of rectoanal reflex in guinea pigs through lumbar colonic nerves; Am J Physiol Gastrointest Liver Physiol; 2002; G148-156; 283.
Yang, G, et al.; Pudendal nerve stimulation and block by a wireless-controlled implantable stimulator in cats; Neuromodulation; 2014; 490-496; discussion 496; 17.
Yazdany, T, et al., Determing outcomes, adverse events, and predictors of success after sacral neuromodulation for lower urinary disorders in women; Int Urogynecol J; 2011; 1549-1554; 22.
Yih, JM, et al.; Changes in sexual functioning in women after neuromodulation for voiding dysfunction; J Sex Med; 2013; 2477-2483; 10.
Yoong, W, et al.; Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability; outcomes following a shortened 6-week protocol; BJU Int; 2010; 1673-1676; 106.
Yun, AJ, et al.; Opening the floodgates: benign prostatic hyperplasia may represent another disease in the compendium of ailments caused by the global sympathetic bias that emerges with aging; Med Hypotheses; 2006; 392-394; 67.
Zabihi, N, el al.; Short-term results of bilateral S2-S4 sacral neuromodulation for the treatment of refractory interstitial cystitis, painful bladder syndrome, and chronic pelvic pain; Int Urogynecol J Pelvic Floor Dysfunct; 2008; 553-557; 19.
Zariffa, J, et al.; A Phase-Based Electrical Plethysmography Approach to Bladder Volume Measurement; Ann Biomed Eng; 2015.
Zecca, C, et al., Motor and sesensory responses after percutaneous tibial nerve stimulation in multiple sclerosis patients with lower urinary tract symptoms treated in daily practice: Eur J Neurol; 2014; 506-511; 21.
Zecca, C, et al.; Posterior tibial nerve stimulation in the management of lower urinary tract symptoms in patients with multiple sclerosis; Int Urogynecol J; 2015.
Zempleni, MZ, et al.; Cortical substrate of bladder control in SCI and the effect of peripheral pudendal stimulation; Neuroimage; 2010; 2983-2994; 49.
Zhang, F, et al.; Inhibition of bladder overactivity by a combination of tibial neuromodulation and tramadol treatment in cats; Am J Physiol Renal Physiol; 2012; F1576-1582; 302.
Zhang, F, et al,; Neural pathways involved in sacral neuromodulation of reflex bladder activity in cats; Am J Physiol Renal Physiol; 2013; F710-717; 304.
Zhang, N, et al,; Transcutaneous Neuromodulation at Posterior Tibial Nerve and ST36 for Chronic Constipation; Evid Based Complement Alternat Med; 2014; 560802; 2014.
Zhao, X. et al.; Diffused and sustained inhibitory effects of intestinal electrical stimulation on intestinal motility mediated via sympathetic pathway: Neuromodulation; 2014; 373-379; discussion 380; 17.
Zheng, J, et al.; [Sacral neuromodulation in the treatment of intractable constipation]; Zhonghua Wei Chang Wai Ke Za Zhi; 2014; 1175-1178; 17;Abstract.
Zhou, Y, et al.; Change of vanilloid receptor 1 following neuromodulation in rats with spinal cord injury; J Surg Res; 2002; 140-144; 107.
Zullo, MA, et al.; Sacral neuromodulation after stabilization of L2-S1 vertebrae with metallic fixation devices; is it feasible?; Int Urogynecol J; 2011; 373-375; 22.
Zvara, P, et al.; An animal model for the neuromodulation of neurogenic bladder dysfunction; Br J Urol. 1998; 267-271; 82.
Jezernik, S. et al.; Electrical stimulation for the treatment of bladder dysfunction: current status and future possibilities; Neurol Res; 2002; 413-430; 24;Abstract.
Jiang, CH; Modulation of the micturition reflex pathway by intravesical electrical stimulation: an experimental study in the rat; Neurourol Urodyn; 1998; 543-553; 17.
Jimenez-Toscano, M, et al.; Efficacy and quality of life after transcutaneous posterior tibial neuromodulation for faecal incontinence; Colorectal Dis; 2015; 718-723; 17.
Jin, H. et al.; Electrical neuromodulation at acupoint ST36 normalizes impaired colonic motility induced by rectal distenseion in dogs; Am J Physiol Gastrointest Liver Physiol; 2015; G368-376; 309.
Johnsen, NV, et al.; The role of electrical stimulation techniques in the management of the male patient with urgency incontinence; Curr Opin Urol; 2014; 560-565; 24.
Johnston, TE, et al.; Implantable FES system for upright mobility and bladder and bowel function for individuals with spinal cord injury; Spinal Cord; 2005; 713-723; 43.
Joussain, C, et al.; Electrical management of neurogenic lower urinary tract disorders; Ann Phys Rehabil Med; 2015; 245-250; 58.
Julius. F. et al.; Catheter tip granuloma associate with sacral region intrathecal drug administration; Neuromodulation; 2003; 225-228; 6.
Kachur, JF, et al.; Neuromodulation of guinea pig intestinal electrolyte transport by cholecystokinin octapeptide; Gastroenterology; 1991; 344-349; 100;Abstract.
Kacker, R, et al.; Electrical and mechanical office-based neuromodulation; Urol Clin North Am; 2013; 581-589; 40.
Kacker, R, et al.; Selection of ideal candidates for neuromodulation in refractory overactive bladder; Curr Urol Rep; 2010; 372-378; 11.
Kantartzis, K, et al.; Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder; Curr Opin Obstet Gynecol; 2012; 331-336; 24.
Kantartzis, KL, et al.; Cost-effectiveness of test phase implantation strategies for InterSlim(R) sacral neuromodulation; Female Pelvice Med Reconstr Surg; 2013; 322-327; 19;Abstract.
Kapoor, DS, et al.; Combined urinary and faecal incontinence; Int Urogynecol J Pelvic Floor Dysfunct; 2005; 321-328; 16.
Karademir, K, et al.; A peripheric neuromodulation technique for curing detrusor overactivity; Stoller afferent neurostimulation; Scand J Urol Nephrol; 2005; 230-233; 39.
Karam, R, et al.; Real-Time Classification of Bladder Events for Effective Diagnosis and Treatment of Urinary Incontinence; IEEE Trans Biomed Eng; 2015.
Karmarkar, R, et al.; Emerging drugs for overactive bladder; Expert Opin Emerg Drugs; 2015; 613-624; 20;Abstract.
Karram, MM; Sacral neuromodulation: emerging technology with expanding indications; Int Urogynecol J; 2010; 1443;21.
Karsenty, G, et al.; Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux; J Urol; 2007; 1011-1014; 177.
Karsenty, G, et al.; Understanding detrusor sphincter dyssynergia—significance of chronology; Urology; 2005; 763-768; 66.
Katsuragi, T, et al.; Cholinergic neuromodulation by ATP, adenosine and its N6-substituted analogues in guinea-pig ileum; Clin Exp Pharmacol Physiol; 1985; 73-78; 12;Abstract.
Katsuragi, T. et al.; Involvement of dihydropyridine-sensitive Ca2+ channels in adenosine-evoked inhibition of acetylcholine release from guinea pig ileal preparation; J Neurochem; 1990; 363-369; 55.
Katsuragi, T, et al.; Possible transsynaptic cholinergic neuromodulation by ATP released from ileal longitudinal muscles of guinea pigs; Life Sci; 1993; 911-918; 53.
Kaufmann, S. et al.; Unilateral vs bilateral sacral neuromodulation in pigs with formalin-induced detrusor hyperactivity; BJU Int; 2009; 260-263; 103.
Kavia, R, et al.; A functional magnetic resonance imaging study of the effect of sacral neuromodulation on brain responses in women with Fowler's syndrome; BJU Int; 2010; 366-372; 105.
Kavia, R, et al.; Overactive bladder; J R Soc Promot Health; 2005; 176-179; 125;Abstract.
Kenefick, NJ; Sacral nerve neuromodulation for the treatment of lower bowel motility disorders; Ann R Coll Surg Engl; 2006; 617-623; 86.
Keppene, V, et al.; [Neuromodulation in the management of neurogenic lower urinary tract dysfunction]; Prog Urol; 2007; 609-615; 17;Abstract.
Kessler, TM, et al.; [Sacral neuromodulation for neurogenic bladder dysfunction]; Urologe A; 2012; 179-183; 51.
Kessler, TM, et al.; [Urodynamic phenomena in the aging bladder]; Urologe A; 2004; 542-546; 43.
Kessler, TM, et al.; Prolonged sacral neuromodulation testing using permanent leads: a more reliable patient selection methods?; Eur Urol; 2005; 660-665; 47.
Kessler, TM, et al.; Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland; Eur Urol; 2007; 1357-1363; 51.
Kessler. TM, et al.; Urologists' referral attitude for sacral neuromodulation for treating refractory idiopathic overactive bladder syndrome: discrete choice experiment; Neurourol Urodyn; 2014; 1240-1246; 33.
Killinger, KA, et al.; Secondary changes in bowel function after successful treatment of voiding symptoms with neuromodulation; Neurourol Urodyn; 2011; 133-137; 30.
Kim, JH, et al.; Sacral nerve stimulation for treatment of intractable pain associated with cauda equina syndrome; J Korean Neurosurg Soc; 2010; 473-476; 47.
Kinder, MV, et al.; Neuronal circuitry of the lower urinary tract; central and peripheral neuronal control of the micturition cycle; Anat Embryol (Berl); 1995; 195-209; 192.
Kirkham, AP, et al.; Neuromodulation through sacral nerve roots 2 to 4 with a Finetech-Brindley sacral posterior and anterior root stimulator; Spinal Cord; 2002; 272-281; 40.
Kirkham, AP, et al.; The acute effects of continuous and conditional neuromodulation on the bladder in spinal cord injury; Spinal Cord; 2001; 420-428; 39.
Klingler, HC, et al.; Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study; Urology; 2000; 766-771; 56.
Knowles; CH, et al.; Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial, Lancet: 2015; 1640-1648; 386.
Knupfer, S, et al.; [Therapy-refractory overactive bladder: alternative treatment approaches]; Urologe A; 2011; 806-809; 50.
Knupfer, SC, et al.; Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction; BMC Urol; 2014; 65; 14.
Kocjancic, E, et al.; Sacral neuromodulation for urinary retention in a kidney-transplant patient; Urol Int; 2005; 187-188; 75.
Kohli, N, et al.; InterStim Therapy: A Contemporary Approach to Overactive Bladder; Rev Obstet Gynecol. 2009; 18-27; 2.
Kohli, N, et al.; Neuromodulation techniques for the treatment of the overactive bladder; Clin Obstet Gynecol; 2002; 218-232; 45.
Koldewijn, EL; [What to do if pills do not work fo urge incontinence—still many questions and ambiguities]; Ned Tijdschr Geneeskd; 2012; A5099; 156;Abstract.
Kosan, M, et al.; Alteration in contractile responses in human detrusor smooth muscle from obstructed bladders with overactivity; Urol Int: 2008; 193-200; 80.
Kovacevic, M, et al.; Reflex neuromodulation of bladder function elicited by posterior tibial nerve stimulation in anesthetized rats; Am J Physiol Renal Physiol; 2015; F320-329; 308.
Krames, E, et al.; Spinal cord stimulation reverses pain and diarrheal episodes of irritable bowel syndrome: a case report; Neuromodulation; 2004; 82-88; 7.
Krivoborodov, GG, et al.; [Afferent stimulation of the tibial nerve in patients with hyperactive bladder]; Urologiia; 2002; 36-39; ;Abstract.
Peters, KM, et al.; Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial; J Urol; 2010; 1438-1443; 183.
Peters, KM; Alternative approaches to sacral nerve stimulation; Int Urogynecol J; 2010; 1559-1563; 21.
Peters, KM; Sacral neuromodulation is an effective treatment for interstitial cystitis/bladder pain syndrome: pro; J Urol; 2012; 2043-2044; 188.
Pettit, PD, et al.; Sacral neuromodulation: new applications in the treatment of female pelvic floor dysfunction; Curr Opin Obstet Gynecol; 2002; 521-525; 14.
Peyronnet, B, et al.; [Management of overactive bladder in women]; Prog Urol; 2015; 877-883; 25;Abstract.
Phe, V, et al.; How to define a refractory idiopathic overactive bladder?; Neurourol Urodyn; 2015; 42411; 34.
Possover, M, et al.; Neuromodulation of the Superior hypogastric plexus: a new option to treat bladder atonia secondary to radical pelvic surgery?; Surg Neurol; 2009; 573-576; 72.
Possover, M, et al.; Risks. symptoms, and management of pelvic nerve damage secondary to surgery for pelvic organ prolapse: a report of 95 cases; Int Urogynecol J; 2011; 1485-1490; 22.
Possover, M; A novel implantation technique for pudendal nerve stimulation for treatment of overactive bladder and urgency incontinence; J Minim Invasive Gynecol; 2014; 888-892; 21.
Possover M; Laparoscopic management of endopelvic etiologies of pudendal pain in 134 consecutive patients; J Urol; 2009; 1732-1736; 181.
Possover, M; The laparoscopic implantation of neuroprothesis to the sacral plexus for therapy of neurogenic bladder dysfunctions after failure of percutaneous sacral nerve stimulation; Neuromodulation; 2010; 141-144; 13.
Possover, M; The sacral LION procedure for recovery of bladder/rectum/sexual functions in paraplegic patients after explantation of a previous Finetech-Brindley controller; J Minim Invasive Gynecol; 2009; 98-101; 16.
Powell, CR, et al.; Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures; J Urol; 2010; 173-176; 183.
Pucciani, F; A review on functional results of sphincter-saving surgery for rectal cancer: the anterior resection syndrome; Updates Surg; 2013; 257-263; 65.
Puccini, F, et al.; Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis, Int Urogynecol J; 2016; 347-354; 27.
Qin, C, et al.; Is constant current or constant voltage spinal cord stimulation superior for the suppression of nociceptive visceral and somatic stimuli? A rat model; Neuromodulation; 2012: 132-142; discussion 143; 15.
Rahnama'i, MS, et al.; Evidence for prostaglandin E2 receptor expression in the intramural ganglia of the guinea pig urinary bladder; J Chem Neuroanat; 2015; 43-47; 64-65.
Rai, BP, et al.; Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults: Cochrane Database Syst Rev; 2012; Cd003193; 12;Abstract.
Ramage, L, et al.; A systematic review of sacral nerve stimulation for low anterior resection syndrome; Colorectal Dis; 2015; 762-771: 17.
Ramundo, JM, et al.; State of the science: pathology and management of the patient with overactive bladder; Ostomy Wound Manage; 2002; 22-27; 48.
Rana, MV, et al.; Tripolar spinal cord stimulation for the treatment of abdominal pain associated with irritable bowel syndrome; Neuromodulation; 2013; 73-77; discussion 77; 16.
Rashid, TG, et al.; Male incontinence: onabotulinum toxin A and sacral nerve stimulation; Curr Opin Urol; 2013; 545-551; 23.
Rasmussen, NT, et al.; Successful use of sacral neuromodulation after failed bladder augmentation: Can Urol Assoc J: 2009; E49-50; 3.
Ratto, C, et al.; Minimally invasive sacral neuromodulation implant technique: modifications to the conventional procedure; Dis Colon Rectum; 2003; 414-417; 46.
Ratto, C, et al.; Sacral neuromodulation in the treatment of defecation disorders; Acta Neurochir Suppl; 2007; 341-350; 97;Abstract.
Rawashdeh, YF, et al.; International Children's Continence Society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children; Neurourol Urodyn; 2012; 615-620; 31.
Reese, JN, et al.; Role of spinal metabotropic glutamate receptor 5 in pudendal inhibition of the nociceptive bladder reflex in cats; Am J Physiol Renal Physiol; 2015; F832-838; 308.
Reitz, A, et al.; Topographic anatomy of a new posterior approach to the pudendal nerve for stimulation; Eur Urol; 2007; 1350-1355; discussion 1355-1356; 51.
Reyblat, P. et al.; Augmentation enterocystoplasty in overactive bladder; is there still a role?; Curr Urol Rep; 2010; 432-439; 11.
Riazimand, SH, et al.; A rat model for studying effects of sacral neuromodulation on the contractile activity of a chronically inflamed bladder; BJU Int; 2004; 158-163; 94.
Riazimand, SH, et al.; Interaction between neurotransmitter antagonists and effects of sacral neuromodulation in rats with chronically hyperactive bladder; BJU Int; 2005; 900-908; 96.
Richter, EO, et al.; Percutaneous cephalocaudal implantation of epidural stimulation electrodes over sacral nerve roots—a technical note on the importance of the lateral approach; Neuromodulation; 2011; 62-67; discussion 67; 14.
Ridout, AE, et al.; Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy; J Obstet Gynaecol; 2010; 111-114; 30.
Rigaud, J, et al.; [Specific treatments for painful bladder syndrome]; Prog Urol; 2010; 1044-1053; 20;Abstract.
Rimmer, CJ, et al.; Short-term Outcomes of a Randomized Pilot Trial of 2 Treatment Regimens of Transcutaneous Tibial Nerve Stimulation for Fecal Incontinence; Dis Colon Rectum; 2015; 974-985; 58.
Ripetti, V, et al.; Sacral nerve neuromodulation improves physical, psychological and social quality of life in patients with fecal incontinence; Tech Coloproctol; 2002; 147-152; 6.
Rittenmeyer. H; Sacral nerve neuromodulation (InterStim). Part 1. Review of the InterStim system; Urol Nurs; 2008; 15-20; 28.
Robaina Padron, FJ; [Surgical neuromodulation; new frontiers in neurosurgery]; Neurocirugia (Astur); 2008; 143-155; 19;Abstract.
Robinson, D, et al.; Overactive bladder: diagnosis and management; Maturitas; 2012; 188-193; 71.
Robinson, D, et al.; The management of overactive bladder refractory to medical therapy; Maturitas; 2013; 101-104; 75.
Robinson, D, et al.; The medical management of refractory overactive bladder; Maturitas; 2013; 386-390; 74.
Rogers, MJ, et al.; Propranolol, but not naloxone, enhances spinal reflex bladder activity and reduces pudendal inhibition in cats; Am J Physiol Regul Integr Comp Physiol; 2015; R42-49; 308.
Rogers, MJ, et al.; Role of glycine in nociceptive and non-nociceptive bladder reflexes and pudendal afferent inhibition of these reflexes in cats; Neurourol Urodyn; 2015;Abstract.
Romero Maroto, J, et al.; [Techniques and current practice of urodynamics, Problems and traps]; Acias Urol Esp; 2003; 75-91; 27;Abstract.
Roth, TM; Blunt trauma leafding to delayed extrusion of sacral nerve implant; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 735-737; 20.
Roth, TM; Sacral neuromodulation and cardiac pacemakers; Int Urogynecol J; 2010; 1035-1037; 21.
Roth, TM; Safe Simultaneous Use of Sacral Neuromodulation and Vagal Nerve Stimulation; Female Pelvic Med Reconstr Surg; 2016; e1-2; 22;Abstract.
Roth, TM; Subcapsular relocation for sacral neuromodulation pulse generator implant revision; Neuromodulation; 2010; 145-146; 13.
Roupret, M, et al.; Sacral neuromodulation for refractory detrusor overactivity in women with an artificial urinary sphincter; J Urol; 2004; 236-239; 172.
Rovner, ES; Treatment of urinary incontinence; Curr Urol Rep; 2000; 235-244; 1.
Ruffion, A, et al.; [Sacral root neuromodulation for the treatment of urinary incontinence reported to detrusor hyperactivity]; Neurochirurgie; 2003; 377-382; 49;Abstract.
Ruffion, A. et al., [Two indications for bilateral neuromodulation]; Prog Urol; 2003; 1394-1396; 13;Abstract.
Saber-Khalaf, M, et al.; Sacral neuromodulation outcomes in male patients with chronic urinary retention; Neuromodulation; 2015; 329-334; discussion 334; 18.
Sadiq, A, et al.; Management of neurogenic lower urinary tract dysfuntion in multiple sclerosis patients; Curr Urol Rep; 2015; 44; 16.
Sahai, A, et al.; Neurogenic detrusor overactivity in patients with spinal cord injury; evaluation and management; Curr Urol Rep; 2011; 404-412; 12.
Sajadi, KP, et al.; Bladder augmentation and urinary diversion for neurogenic LUTS: current indications; Curr Urol Rep; 2012; 389-393; 13.
Sajadi, KP, et al.; Overactive bladder after sling surgery; Curr Urol Rep; 2010; 366-371; 11.
Sakas, DE, et al., An introduction to operative neuromodulation and functional neuroprosthetics, the new frontiers of clinical neuroscience and biotechnology; Acta Neurochir Suppl; 2007; 42439; 97;Abstract.
Sancaktar, M. et .; The outcome of adding peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe overactive bladder; Gynecol Endocrinol; 2010; 729-732; 26.
Sanford, MT, et al.; Neuromodulation in neurogenic bladder; Transl Androl Urol; 2016; 117-126; 5.
Scaglia, M, et al.; Fecal incontinence treated with acupuncture—a pilot study; Auton Neurosci; 2009; 89-92; 145.
Scheepens, WA, et al.; [Neuromodulation and neurostimulation in urology]; Ned Tijdschr Geneeskd; 2001; 1730-1734; 145;Abstract.
Scheepens, WA, et al.; Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction; Urology; 2002; 598-602; 60.
Scheepens, WA, et al.; Unilateral versus bilateral sacral neuromodulation in patients with chronic voiding dysfunction; J Urol; 2002; 2046-2050; 168.
Scheepens, WA, et al.; Urodynamic results of sacral neuromodulation correlate with subjective improvement in patients with an overactive bladder; Eur Urol; 2003; 282-287; 43.
Scheiner, DA, et al.; [Interstitial cystitis/bladder pain syndrome (IC/BPS)]; Praxis (Bern 1994); 2015; 909-918; 104.
Schijns, O. et al.; Development and characterization of [123l]iodotiagabine for in-vivo GABA-transporter imaging; Nucl Med Commun; 2013; 175-179; 34;Abstract.
Schmidt, RA, et al.; Neurostimulation and neuromodulation: a guide to selecting the right urologic patient; Eur Urol; 1998; 23-26; 34 Suppl 1;Abstract.
Schneider, MP, et al.; Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review: Eur Urol; 2015; 859-887; 68.
Schonberger, B; [Bladder dysfunction and surgery in the small pelvis. Therapeutic possibilities]; Urologe A; 2003; 1569-1575; 42.
Schreiber, KL, et al.; Evidence for neuromodulation of enteropathogen invasion in the intestinal mucosa; J Neuroimmune Pharmacol; 2007; 329-337; 2.
Schultz-Lampel, D, et al.; Experimental results on mechanisms of action of electrical neuromodulation in chronic urinary retention; World J Urol; 1983; 301-304; 16.
Schurch, B, et al.; Dysfunction of lower urinary tract in patients with spinal cord injury; Handb Clin Neurol; 2015; 247-267; 130.
Schurch, B, et al.; Electrophysiological recordings during the peripheral nerve evaluation (PNE) test in complete spinal cord injury patients; World J Urol; 2003; 319-322; 20.
Schwalenberg, T, et al.; [Sacral neuromodulation in urology—development and current status]; Aktuelle Urol; 2012; 39-48; 43;Abstract.
Schwen, Z, et al.; Combination of foot stimulation and tolterodine treatment eliminates bladder overactivity in cats; Neurourol Urodyn; 2014; 1266-1271; 33.
Schwen, Z, et al.; Inhibition of bladder overactivity by duloxetine in combination with foot stimulation of WAY-100635 treatment in cats: Am J Physiol Renal Physiol; 2013; F1663-1668; 305.
Schwen, Z, et al.; Involvement of 5-HT3 receptors in pudendal inhibition of bladder overactivity in cats; Am J Physiol Renal Physiol; 2013; F663-671; 305.
Seif, C, et al.; [Pudendal nerve stimulation therapy of the overactive bladder—an alternative to sacral neuromodulation?]; Aktuelle Urol; 2005; 234-238; 36;Abstract.
Seif, C, et al.; [Use of permanent electrodes in the peripheral nerve evaluation test (PNE-Test) in comparison to conventional wire electrodes]; Aktuelle Urol; 2006; 277-280; 37;Abstract.
Seif, C, et al.; Findings with Bilateral Sacral Neurostimulation: Sixty-two PNE-Tests in Patients with Neurogenic and Idiopathic Bladder Dysfunctions; Neuromodulation; 2004; 141-145; 7.
Seif, C, et al.; Improved sacral neuromodulation in the treatment of the hyperactive detrusor: signal modification in an animal model; BJU Int; 2003; 711-715; 91.
Seth, A, et al.; What's new in the diagnosis and management of painful bladder syndrome/interstitial cystitis?; Curr Urol Rep; 2008; 349-357; 9.
Sevcencu, C; A review of electrical stimulation to treat motility dysfunctions in the digestive tract: effects and stimulation patterns; Neuromodulation; 2007; 85-99; 10.
Sevcencu, C; Gastrointestinal mechanisms activated by electrical stimulation to treat motility dysfunctions in the digestive tract: a review; Neuromodulation; 2007; 100-112; 10.
Shafik, A, et al.; Percutaneous peripheral neuromodulation in the treatment of fecal incontinence: Eur Surg Res; 2003; 103-107; 35.
Shah, P, et al.; Unique spatiotemporal neuromodulation of the lumbosacral circuitry shapes locomotor success after spinal cord injury; J Neurotrauma; 2016;Abstract.
Shaker, H, et al.; Role of C-afferent fibres in the machanism of action of sacral nerve root neuromodulation in chronic spinal cord injury; BJU Int: 2000; 905-910; 85.
Shaker, H, et ai.; Sacral root neuromodulation in the treatment of various voiding and storage problems; Int Urogynecol J Pelvic Floor Dysfunct; 1999; 336-343; 10;Abstract.
Shaker, HS, et al.; Sacral nerve root neuromodulation: an effective treatment for refractory urge incontinence J Urol; 1998; 1516-1519; 159.
Shaker, HS, et al.; Sacral root neuromodulation in idiopathic nonobstructive chronic urinary retention: J Urol; 1998; 1476-1478; 159.
Shalmon, DF, et al.; Sacral nerve stimulation reduces elevated urinary nerve growth factor levels in women with symptomatic detrusor overactivity; Am J Obstet Gynecol: 20014; 561,e561-565; 211.
Shamliyan, T, et al.; Prevention of urinary and fecal incontinence in adults; Evid Rep Technol Assess (Full Rep); 2007; 1-379; ;Abstract.
Sharma, A, et al.; Review of sacral neuromodulation for management of constipation; Surg Innov; 2013; 614-624; 20.
Sharma, A, et al.; Sacral neuromodulation for the management of severe constipation; development of a constipation treatment protocol; Int J Colorectal Dis; 2011; 1583-1587; 26.
Shen, B, et al.; Neuromodulation of bladder activity by stimulation of feline pudendal nerve using a transdermal amplitude modulated signal (TAMS); Neurourol Urodyn; 2011; 1686-1694; 30.
Shepherd, JP, et al.; InterStim Sacral Neuromodulation and Botox Botulinum-A Toxin Intradetrusor Injections for Refractory Urge Urinary Incontinence: A Decision Analysis Comparing Outcomes Including Efficacy and Complications; Female Pelvic Med Reconstr Surg; 2011; 199-203; 17;Abstract.
Sherif, H, et al.; Posterior tibial nerve stimulation as treatment for the overactive bladder; Arab J Urol; 2013; 131-135; 11.
Sheriff, MK, et al.; Neuromodulation of detrusor hyper-reflexia by functional magnetic stimulation of the sacral roots; Br J Urol; 1996; 39-46; 78;Abstract.
Sherman, ND, et al.; Current and future techniques of neuromodulation by bladder dysfunction; Curr Urol Rep; 2007; 448-454; 8.
Tai, C, et al.; Irritation induced bladder overactivity is suppressed by tibial nerve stimulation in cats; J Urol; 2011; 326-330; 186.
Tai, C, et al.; Prolonged poststimulation inhibition of bladder activity induced by tibial nerve stimulation in cats; Am J Physiol Renal Physiol; 2011; F385-392; 300.
Takahashi, S, et al.; Overactive bladder: magnetic versus electrical stimulation: Curr Opin Obstet Gynecol; 2003; 429-433; 15.
Tanagho, EA; Concepts of neuromodulation: Neurourol Urodyn; 1993; 487-488; 12.
Tanagho, EA; Neuromodulation in the management of voiding dysfunction in children; J Urol; 1992; 655-657; 148;Abstract.
Tang, H, et al.; Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women; a clinical trial; Urol J; 2014; 1800-1805; 11.
Taweel, WA, et al.; Neurogenic bladder in spinal cord injury patients; Res Rep Urol; 2015; 85-99; 7.
Thin, NN, et al.; Randomized clinical trial of sacral versus percutaneous tibial nerve stimulation in patients with faecal incontinence; Br J Surg; 2015; 349-358; 102.
Thin, NN, et al.; Systematic review of the clinical effectiveness of neuromodulation in the treatment of faecal incontinence; Br J Surg: 2013; 1430-1447; 100.
Thomas, GP, et al.; A pilot study of transcutaneous sacral nerve stimulation for faecal incontinence; Colorectal Dis; 2013; 1406-1409; 15.
Thomas, GP, et al.; Sacral nerve stimulation for faecal incontinence secondary to congenital imperforate anus; Tech Coloproctol; 2013; 227-229; 17.
Thompson, JH, et al.; Sacral neuromodulation: Therapy evolution; Indian J Urol; 2010; 379-384; 26.
Thoua, NM, et al.; Internal anal sphincter atrophy in patients with systemic sclerosis; Rheumatology (Oxford); 2011; 1596-1602; 50.
Tian, Y, et al.; Inhibitory Effect and Possible Mechanism of Intraurethral Stimulation on Overactive Bladder in Female Rats; Int Neurourol J; 2015; 151-157; 19.
Tirlapus, SA, et al.; Nerve stimulation for chronic pelvic pain and bladder pain syndrome: a systematic review; Acta Obstet Gynecol Scand; 2013; 881-887; 92.
Tjandra, JJ, et al.; Sacral nerve stimulation is more effective than optimal medical therapy for severe fecal incontinence: a randomized. controlled study; Dis Colon Retum; 2008; 494-502; 51.
Tomonori Yamanishi et al.; Neuromodulation for the Treatment of Lower Urinary TractSymptoms; Low Urin Tract Symptoms; 2015; 121-132; 7.
Traynor, TR, et al.; Neuromodulation of ion transport in porcine distal colon: NPY reduces secretory actions of leukotrienes; Am J Physiol. 1995; R426-431; 269;Abstract.
Trevizol, AP, et al.; Trigeminal Nerve Stimulation (TNS) for the Treatment of Irritable Bowel Syndrome in an Elderly Patient with Major Depressive Disorder: A Case Study; Brain Stimul; 2015; 1235-1236; 8.
Turner, WH, et al.; Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment; Pharmacol. Ther; 1997; 77-110; 75.
Ullah, S, et al.; Temporary gastric neuromodulation for intractable nausea and vomiting; Ann R Coll Surg Engl; 2011; 624-628; 93.
Uludag, O, et al.; [Sacral neuromodulation is effective in the treatment of fecal incontinence with intact sphincter muscles: a prospective study]; Ned Tijdschr Geneeskd; 2002; 989-993; 146;Abstract.
Uludag, O, et al.; Sacral neuromodulation in patients with fecal incontinence: a single-center study; Dis Colon Rectum; 2004; 1350-1357; 47.
Uludag, O, et al.; Sacral neuromodulation: does it affect the rectoanal angle in patients with fecal incontinence?; World J Surg; 2010; 1109-1114; 34.
Uludag, O, et al.; Sacral neuromodulation: long-term outcome and quality of life in patients with faecal incontinence; Colorectal Dis; 2011; 1162-1166; 13.
Uludag, O, et al.; Sacral neuromodulation; does it affect colonic transit time in patients with faecal incontinence?; Colorectal Dis; 2006; 318-322; 8.
Unger, CA, et al.; Fecal incontinence: the role of the urologist; Curr Urol Rep; 2014; 388; 15.
Unwala, DJ, et al.; Repeated botulinum toxin injection for idiopathic overactive bladder: will chemodenervation become a long-term solution?: Curr Urol Rep; 2007; 419-424; 8.
Uranga, A, et al.; An integrated implantable electrical sacral root stimulator for bladder control; Neuromodulation; 2002; 238-247; 5.
Vaarala, MH, et al.; Sacral neuromodulation in urological indications: the Finnish experience; Scand J Urol Nephrol; 2011; 46-51; 45.
Vaizey, CJ, et al.; Effects of short term sacral nerve stimulation on anal and rectal function in patients with anal incontinence; Gut; 1999; 407-412; 44.
Vallet, C, et al.; Sacral nerve stimulation for faecal incontinence: response rate, satisfaction and the value of preoperative investigation in patient selection; Colorectal Dis; 2010; 247-253; 12.
Van Balken, MR, et al.; Prognostic factors for successful percutaneous tibial nerve stimulation; Eur Urol; 2006; 360-365; 49.
Van Balken, MR, et al.; Sexual functioning in patients with lower urinary tract dysfunction improves after percutaneous tibial nerve stimulation; Int J Impot Res: 2006; 470-475; discussion 476; 18.
Van Balken, MR, et al.; The use of electrical devices for the treatment of bladder dysfunction: a review of methods; J Urol; 2004; 846-851; 172.
Van Balken, MR; Percutaneous tibial nerve stimulation: the Urgent PC device; Expert Rev Med Devices; 2007; 693-698; 4.
Van Der AA, HE, et al.; Sacral anterior root stimulation for bladder control: clinical results; Arch Physiol Biochem; 1999; 248-256; 107.
Van Der Pal, F, et al.; Current opinion on the working mechanisms of neuromodulation in the treatment of lower urinary tract dysfunction; Curr Opin Urol, 2006; 261-267; 16.
Van Der Pal, F, et al.; Implant-Driven Tibial Nerve Stimulation in the Treatment of Refractory Overactive Bladder Syndrome; 12-Month Follow-up; Neuromodulation; 2006; 163-171; 9.
Van Kerrebroeck, P; Editorial comment re: Killinger et al. “Secondary changes in bowel function after successful treatment of voiding symptoms with neuromodulation”; Neurourol urodyn; 2011; 1403; 30.
Van Kerrebroeck, PE. et al.; Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study; J Urol; 2007; 2029-2034; 178.
Van Kerrebroeck, PE; Advances in the role of sacral nerve neuromodulation in lower urinary tract symptoms; Int Urogynecol J: 2020; S467-474; 21 Suppl 2.
Van Kerrebroeck, PE; Neuromodulation and other electrostimulatory techniques; Scand J Urol Nephrol Suppl; 2002; 82-86.
Van Kerrebroeck, PE; The role of electrical stimulation in voiding dysfunction; Eur Urol. 1998; 27-30; 34 Suppl 1;Abstract.
Van Koeveringe, GA, et al.; Detrusor underactivity: a plea for new approaches to a common bladder dysfunction; Neurourol Urodyn; 2011; 723-728; 30.
Van Ophoven, A, et al.; [The future of invasive neuromodulation: new techniques and expanded indications]; Urologe A; 2012; 212-216; 51.
Van Voskuilen, AC, et al.; Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study; Eur Urol; 2006; 366-372; 49.
Van Voskuilen, AC, et al.; Medium-term experience of sacral neuromodulation by tined lead implantation; BJU Int; 2007; 107-110; 99.
Van Wunnik, BP, et al.; Cost-effectiveness analysis of sacral neuromodulation for faecal incontinence in The Netherlands, Colorectal Dis; 2012; e807-814; 14.
Van Wunnik, BP, et al.; Neuromodulation for constipation: sacral and transcutaneous stimulation; Best Pract Res Clin Gastroenterol; 2011; 181-191; 25.
Desrosiers, L, et al.; Urogynecologic conditions: interstitial cystitis/painful bladder syndrome; FP Essent; 2015; 17-22; 430;Abstract.
Devane, LA, et al.; Acute lumbosacral nerve stimulation does not affect anorectal motor function in a rodent model; Neurogastroenterol Motil; 2016; 358-363; 28.
Devroede, G, et al.; Quality of life is markedly improved in patients with fecal incontinence after sacral nerve stimulation; Female Pelvic Med Reconstr Surg; 2012; 103-112; 18;Abstract.
Di Giovangiulio, M, et al.; The Neuromodulation of the Intestinal Immune System and Its Relevance in Inflammatory Bowel Disease; Front Immunol; 2015; 590; 6.
Dijkema, HE, et al.; [Initial experiences with neuromodulation as treatment for incontinence and micturition disorders in The Netherlands]; Ned Tijdschr Geneeskd; 1992; 88-90; 136;Abstract.
Dijkema, HE, et al.; Neuromodulation of sacral nerves for incontinence and voiding dysfunctions. Clinical results and complications; Eur Urol; 1993; 72-76; 24;Abstract.
Dmochowski, R; Neuromodulation and the urinary tract—are we over the rainbow or have we simply stepped through the looking glass?; J Urol; 2007; 1844-1845; 178.
Donon, L, et al.; [Sacral neuromodulation: results of a monocentric study of 93 patients]; Prog Urol; 2014; 1120-1131; 24;Abstract.
Dorflinger, A, et al.; Voiding dysfunction; Curr Opin Obstet Gynecol; 2001; 507-512; 13.
Doumouchtsis, SK, et al.; Female voiding dysfunction; Obstet Gynecol Surv; 2008; 519-526; 63.
Drake, MJ; Management and rehabilitation of neurologic patients with lower urinary tract dysfunction; Handb Clin Neurol; 2015; 451-468; 130.
Drossaerts, J, et al.; Screening for depression and anxiety in patients with storage or voiding dysfunction: A retrospective cohort study predicting outcome of sacral neuromodulation; Neurourol Urodyn; 2015;Abstract.
Drossaerts, J, et al.; The value of urodynamic tools to guide patient selection in sacral neuromodulation; World J Urol; 2015; 1889-1895; 33.
Dudding, TC, et al.; Sacral nerve stimulation for faecal incontinence: optimizing outcome and managing complications; Colorectal Dis; 2011; e196-202; 13.
Dudding, TC, et al.; Sacral nerve stimulation for faecal incontinence: patient selection, service provision and operative technique; Colorectal Dis; 2011; e187-195; 13.
Dudding, TC, et al.; Sacral nerve stimulation: an effective treatment for chronic functional anal pain?; Colorectal Dis; 2013; 1140-1144; 15.
Dudding, TC; Future indications for sacral nerve stimulation; Colorectal Dis; 2011; 23-28; 13 Suppl 2.
Duelund-Jakobsen, J, et al.; Baseline factors predictive of patient satisfaction with sacral neuromodulation for diopathic fecal incontinence; Int J Colorectal Dis; 2014; 793-798; 29.
Duthie, J, et al.; Botulinum toxin injections for adults with overactive bladder syndrome; Cochrane Database Syst Rev; 2007; Cd005493; ;Abstract.
Duthie, JB, et al.; Botulinum toxin injections for adults with overactive bladder syndrome; Cochrane Database Syst Rev; 2011; Cd005493.
Duve H, et al.; Distribution and functional significance of Leu-callatostatins in the blowfly Calliphora vomitoria; Cell Tissue Res; 1994; 367-379; 276.
Dwyer, ME, et al.; The dysfunctional elimination syndrome in children—is sacral neuromodulation worth the trouble?; J Urol; 2012; 1076-1077; 188.
Elkelini, MS, et al.; Mechanism of action of sacral nerve stimulation using a transdermal amplitude-modulated signal in a spinal cord injury rodent model; Can Urol Assoc J; 2012; 227-230; 6.
Elkelini, MS, et al.; Safety of MRI at 1.5Tesla in patients with implanted sacral nerve neurostimulator; Eur Urol; 2006; 311-316; 50.
Ellsworth, P, et al.; Neurogenic detrusor overactivity: an update on management options; R I Med J (2013); 2013; 38-40; 96.
Ellsworth, P, et al.; Update on the pharmacologic management of overactive bladder: the present and the future; Urol Nurs; 2010; 29-38, 53; 30.
Elneil, S, et al.; Optimizing the duration of assessment of stage-1 sacral neuromodulation in nonobstructive chronic urinary retention; Neuromodulation; 2014; 66-70; discussion 70-61; 17.
Elneil, S; Urinary retention in women and sacral neuromodulation; Int Urogynecol J; 2010; S475-483; 21 Suppl 2.
Elser, DM; Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management; Postgrad Med; 2012; 42-49; 124;Abstract.
Evans, RJ; Sacral neuromodulation is an effective treatment for interstitial cystitis/bladder pain syndrome: con; J Urol; 2012; 2044-2045; 188.
Everaert, K, et al.; Sacral nerve stimulation for pelvic floor and bladder dysfunction in adults and children; Neuromodulation; 2005; 186-187; 8.
Everaert, K, et al.; The urodynamic evaluation of neuromodulation in patients with voiding dysfunction; Br J Urol; 1997; 702-707; 79.
Evers, J, et al.; Effects of stimulation frequency and intensity in sacral neuromodulation on anorectal inputs to the somatosensory cortex in an experimental model; Br J Surg; 2014; 1317-1328; 101.
Evers, J, et al.; Reversal of sensory deficit through sacral neuromodulation in an animal model of fecal incontinence; Neurogastroenterol Motil; 2016;Abstract.
Fall, M, et al.; EAU guidelines on chronic pelvic pain; Eur Urol; 2004; 681-689; 46.
Fall, M, et al.; EAU guidelines on chronic pelvic pain; Eur Urol; 2010; 35-48; 57.
Falletto, E, et al.; Is sacral nerve stimulation an effective treatment for chronic idiopathic anal pain?; Dis Colon Rectum; 2009; 456-462; 52.
Falletto, E, et al.; Sacral neuromodulation for bowel dysfunction: a consensus statement from the Italian group; Tech Coloproctol; 2014; 53-64; 18.
Fang, Q, et al.; [Morphological study on the role of ICC-like cells in detrusor neuro-modulation of rat urinary bladder]; Zhonghua Wai Ke Za Zhi; 2008; 1542-1545; 46.
Fariello, JY, et al.; Sacral neuromodulation stimulation for IC/PBS, chronic pelvic pain, and sexual dysfunction; Int Urogynecol J; 2010; 1553-1558; 21.
Faucheron, JL, et al.; Sacral neuromodulation for bowel dysfunction; Tech Coloproctol; 2014; 42433; 18.
Faucheron, JL; [Anal incontinence]; Presse Med; 2008; 1447-1462; 37;Abstract.
Feler, CA, et al.; Sacral neuromodulation for chronic pain conditions; Anesthesiol Clin North America; 2003; 785-795; 21.
Felt-Bersma, RJ, et al.; Temperature-controlled radiofrequency energy (SECCA) to the anal canal for the treatment of faecal incontinence offers moderate improvement; Eur J Gastroenterol Hepatol; 2007; 575-580; 19;Abstract.
Ferhi, K, et al.; [Results of sacral posterior neuromodulation on voiding disorders and impact on sexuality based on a single-center study]; Prog Urol; 2008; 160-166; 18;Abstract.
Ferroni, MC, et al.; Role of the brain stem in tibial inhibition of the micturition reflex in cats; Am J Physiol Renal Physiol; 2015; F242-250; 309.
Ferulano, GP, et al.; [Sacral neuromodulation in fecal continence disorders]; Recenti Prog Med; 2002; 403-409; 93; Abstract.
Finazzi-Agro, E, et al.; Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials; Neurourol Urodyn; 2009; 320-324; 28.
Findlay, JM, et al.; Peripheral neuromodulation via posterior tibial nerve stimulation—a potential treatment for faecal incontinence?; Ann R Coll Surg Engl; 2010; 385-390; 92.
Firoozi, F, et al.; Increasing patient preparedness for sacral neuromodulation improves patient reported outcomes despite leaving objective measures of success unchanged; J Urol; 2013; 594-597; 190.
Fjorback, MV, et al.; A portable device for experimental treatment of neurogenic detrusor overactivity; Neuromodulation; 2003; 158-165; 6.
Foditsch, EE, et al.; Laparoscopic placement of a tined lead electrode on the pudendal nerve with urodynamic monitoring of bladder function during electrical stimulation: an acute experimental study in healthy female pigs; Springerplus; 2014; 309; 3.
Foon, R, et al.; The overactive bladder; Ther Adv Urol; 2010; 147-155; 2.
Ford, AP, et al.; P2X3 receptors and sensitization of autonomic reflexes; Auton Neurosci; 2015; 16-24; 191.
Fowler, CJ; The perspective of a neurologist on treatment-related research in fecal and urinary incontinence; Gastroenterology; 2004; S172-174; 126.
Franzen, K, et al.; Surgery for urinary incontinence in women 65 years and older: a systematic review; Int Urogynecol J; 2015; 1095-1102; 26.
Fraser, MO, et al.; Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence; BJU Int; 2003; 743-748; 91.
Freeman, RM, et al.; Overactive bladder; Best Pract Res Clin Obstet Gynaecol; 2005; 829-841; 19.
French, JS, et al.; What do spinal cord injury consumers want? A review of spinal cord injury consumer priorities and neuroprosthesis from the 2008 neural interfaces conference; Neuromodulation; 2010; 229-231; 13.
Frokjaer, JB, et al.; Modulation of vagal tone enhances gastroduodenal motility and reduces somatic pain sensitivity; Neurogastroenterol Motil; 2016.
Fu, G, et al.; [Neuromodulation for treatment for neurogenic bowel dysfunction]; Zhonghua Wai Ke Za Zhi; 2009; 128-131; 47.
Gaj, F, et al.; [Chronic pelvic pain treatment with posterior tibial nerve stimulation]; Clin Ter; 2011; e111-114; 162; Abstract.
Gajewski, JB, et al.; The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre; BJU Int; 2011; 1258-1264; 107.
Game, X, et al.; [Alternative treatments for interstitial cystitis]; Prog Urol; 2009; 357-363; 19;Abstract.
Game, X, et al.; Outcome after treatment of detrusor-sphincter dyssynergia by temporary stent; Spinal Cord; 2008; 74-77; 46.
Game, X; [Sacral neuromodulation and sexuality]; Prog Urol; 2008; 167; 18;Abstract.
Ganio, E, et al.; Neuromodulation for fecal incontinence: outcome in 16 patients with definitive implant. The initial Italian Sacral Neurostimulation Group (GINS) experience; Dis Colon Rectum; 2001; 965-970; 44.
George, E, et al.; Use of combined anticholinergic medication and sacral neuromodulation in the treatment of refractory overactive bladder; Female Pelvic Med Reconstr Surg; 2011; 97-99; 17;Abstract.
Ghazwani, YQ, et al.; Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up; Neurourol Urodyn; 2011; 1271-1275; 30.
Ghiselli, R, et al.; Nitric oxide synthase expression in rat anorectal tissue after sacral neuromodulation; J Surg Res; 2012; 29-33; 176.
Giarenis, I, et al.; Management of refractory overactive bladder; Minerva Ginecol; 2013; 41-52; 65;Abstract.
Giarenis, I, et al.; Managing urinary incontinence: what works?; Climacteric; 2014; 26-33; 17 Suppl 2;Abstract.
Gibbons, SJ, et al.; Review article: carbon monoxide in gastrointestinal physiology and its potential in therapeutics; Aliment Pharmacol Ther; 2013; 689-702; 38.
Gill, BC, et al.; Improved sexual and urinary function in women with sacral nerve stimulation; Neuromodulation; 2011; 436-443; discussion 443; 14.
Gill, BC, et al.; Improvement of bowel dysfunction with sacral neuromodulation for refractory urge urinary incontinence; Int Urogynecol J; 2012; 735-741; 23.
Gleason, JL, et al.; Sacral neuromodulation effects on periurethral sensation and urethral sphincter activity; Neurourol Urodyn; 2013; 476-479; 32.
Glinski, RW, et al.; Refractory overactive bladder: Beyond oral anticholinergic therapy; Indian J Urol; 2007; 166-173; 23.
Gonzalez-Chamorro, F, et al.; [Current status of neurostimulation and neuromodulation for vesicourethral dysfunction]; Arch Esp Urol; 1997; 687-694; 50;Abstract.
Gonzalez-Chamorro, F, et al.; [Neurostimulation and neuromodulation in urinary incontinence]; Rev Med Univ Navarra; 2004; 75-84; 48;Abstract.
Gormley, EA, et al.; Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment; J Urol; 2015; 1572-1580; 193.
Gottwald, T, et al.; [Sex differences in neuromodulation of mucosal mast cells in the rat jejunum]; Langenbecks Arch Chir; 1997; 157-163; 382;Abstract.
Govaert, B, et al.; Neuromodulation for functional bowel disorders; Best Pract Res Clin Gastroenterol; 2009; 545-553; 23.
Govier, FE, et al.; Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study; J Urol; 2001; 1193-1198; 165.
Green, BT, et al.; Neuromodulation of enteropathogen internalization in Peyer's patches from porcine jejunum; J Neuroimmunol; 2003; 74-82; 141.
Griffin, KM, et al.; Sacral nerve stimulation increases activation of the primary somatosensory cortex by anal canal stimulation in an experimental model; Br J Surg; 2011; 1160-1169; 98.
Grill, WM; Electrical activation of spinal neural circuits: application to motor-system neural prostheses; Neuromodulation; 2000; 97-106; 3.
Groen, J, et al.; Chronic pudendal nerve neuromodulation in women with idiopathic refractory detrusor overactivity incontinence: results of a pilot study with a novel minimally invasive implantable mini-stimulator; Neurourol Urodyn; 2005; 226-230; 24.
Groen, J, et al.; Computerized assessment of detrusor instability in patients treated with sacral neuromodulation; J Urol; 2001; 169-173; 165.
Groen, J, et al.; Neuromodulation techniques in the treatment of the overactive bladder; BJU Int; 2001; 723-731; 87.
Groen, J, et al.; Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding; J Urol; 2006; 1005-1009; discussion 1009; 175.
Groen, LA, et al.; Sacral neuromodulation with an implantable pulse generator in children with lower urinary tract symptoms: 15-year experience; J Urol; 2012; 1313-1317; 188.
Groenendijk, PM, et al.; Five-Year Follow-up After Sacral Neuromodulation: Single Center Experience; Neuromodulation; 2007; 363-368; 10.
Groenendijk, PM, et al.; Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence; BJU Int; 2008; 325-329; 101.
Gross, T, et al.; Transcutaneous Electrical Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review; Eur Urol; 2016;Abstract.
Grossi, U, et al.; Sacral neuromodulation for anorectal dysfunction secondary to congenital imperforate anus: report of two cases; Int J Colorectal Dis; 2014; 889-890; 29.
Grunewald, V; Neuromodulation/neurostimulation; World J Urol; 1998; 299-300; 16.
Guerci, B, et al.; Gastric electrical stimulation for the treatment of diabetic gastroparesis; Diabetes Metab; 2012; 393-402; 38.
Gulur, DM, et al.; Management of overactive bladder; Nat Rev Urol; 2010; 572-582; 7.
Gupta, P, et al.; Percutaneous tibial nerve stimulation and sacral neuromodulation: an update; Curr Urol Rep; 2015; 4; 16.
Guys, JM, et al.; [Neurogenic bladder in children: basic principles in diagnosis and treatment]; Ann Urol (Paris); 2006; 15-27; 40;Abstract.
Bernstein, AJ, et al.; Expanding indications for neuromodulation; Urol Clin North Am; 2005; 59-63; 32.
Bertapelle, MP, et al.; Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System; World J Urol; 2015; 1109-1117; 33.
Beusterien, K, et al.; Use of best-worst scaling to assess patient perceptions of treatments for refractory overactive bladder; Neurourol Urodyn; 2015;Abstract.
Biemans, JM, et al.; Efficacy and effectiveness of percutaneous tibial nerve stimulation in the treatment of pelvic organ disorders: a systematic review; Neuromodulation; 2013; 25-33; discussion 33; 16.
Bleier, JI, et al.; Surgical management of fecal incontinence; Gastroenterol Clin North Am; 2013; 815-836; 42.
Blok, BF, et al.; Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators; BJU Int; 2006; 1238-1243; 98.
Bolton, JF, et al.; Neuromodulation 10 years on: how widely should we use this technique in bladder dysfunction?; Curr Opin Urol; 2009; 375-379; 19.
Bosch, JL, et al.; Neuromodulation: urodynamic effects of sacral (S3) spinal nerve stimulation in patients with detrusor instability or detrusor hyperflexia; Behav Brain Res; 1998; 141-150; 92.
Bosch, JL, et al.; Sacral nerve neuromodulation in the treatment of patients with refractory motor urge incontinence: long-term results of a prospective longitudinal study; J Urol; 2000; 1219-1222; 163.
Bosch, JL, et al.; What treatment should we use if drugs fail for OAB; and, what really works after drugs?; Neurourol Urodyn; 2010; 658-661; 29.
Bosch, JL; An update on sacral neuromodulation: where do we stand with this in the management of lower urinary tract dysfunction in 2010?; BJU Int; 2010; 1432-1442; 106.
Bosch, JL; Sacral neuromodulation in the treatment of the unstable bladder; Curr Opin Urol; 1998; 287-291; 8.
Bosch, JL; Sacral neuromodulation: treatment success is not just a matter of optimal electrode position; BJU Int; 2000; 20-21; discussion 22-23; 85 Suppl 3.
Bouchelouche, K, et al.; Recent developments in the management of interstitial cystitis; Curr Opin Urol; 2003; 309-313; 13.
Bouguen, G, et al.; Effects of transcutaneous tibial nerve stimulation on anorectal physiology in fecal incontinence: a double-blind placebo-controlled cross-over evaluation; Neurogastroenterol Motil; 2014; 247-254; 26.
Bower, WF, et al.; A pilot study of the home application of transcutaneous neuromodulation in children with urgency or urge incontinence; J Urol; 2001; 2420-2422; 166.
Bower, WF, et al.; A review of non-invasive electro neuromodulation as an intervention for non-neurogenic bladder dysfunction in children; Neurourol Urodyn; 2004; 63-67; 23.
Bower, WF, et al.; A urodynamic study of surface neuromodulation versus sham in detrusor instability and sensory urgency; J Urol; 1998; 2133-2136; 160.
Braun, PM, et al.; [Chronic sacral bilateral neuromodulation. Using a minimal invasive implantation technique in patients with disorders of bladder function]; Urologe A; 2002; 44-47; 41.
Braun, PM, et al.; Alterations of cortical electrical activity in patients with sacral neuromodulator; Eur Urol; 2002; 562-566; discussion 566-567; 41.
Braun, PM, et al.; Stimulation signal modification in a porcine model for suppression of unstable detrusor contractions; Urology; 2003; 839-844; 61.
Braun, PM, et al.; Tailored laminectomy: a new technique for neuromodulator implantation; J Urol; 1999; 1607-1609; 162.
Brink, TS, et al.; A Chronic, Conscious Large Animal Platform to Quantify Therapeutic Effects of Sacral Neuromodulation on Bladder Function; J Urol; 2015; 252-258; 194.
Bristow, SE, et al.; TENS: a treatment option for bladder dysfunction; Int Urogynecol J Pelvic Floor Dysfunct; 1996; 185-190; 7.
Brooks, DR, et al.; The Caenorhabditis elegans orthologue of mammalian puromycin-sensitive aminopeptidase has roles in embryogenesis and reproduction; J Biol Chem; 2003; 42795-42801; 278.
Brosa, M, et al.; Cost-effectiveness analysis of sacral neuromodulation (SNM) with Interstim for fecal incontinence patients in Spain; Curr Med Res Opin; 2008; 907-918; 24.
Bross, S, et al.; [Sacral neuromodulation in patients with nonobstructive, chronic urinary retention: relevance of the carbachol test and influence of associated nerve lession]; Aktuelle Urol; 2003; 157-161; 34;Abstract.
Bross, S, et al.; The role of the carbachol test and concomitant diseases in patients with nonobstructive urinary retention undergoing sacral neuromodulation; World J Urol; 2003; 346-349; 20.
Brouwer, R, et al.; Sacral nerve neuromodulation is effective treatment for fecal incontinence in the presence of a sphincter defect, pudendal neuropathy, or previous sphincter repair; Dis Colon Rectum; 2010; 273-278; 53.
Brown, DR, et al.; Delta-opioid receptor mRNA expression and immunohistochemical localization in porcine ileum; Dig Dis Sci; 1998; 1402-1410; 43.
Brown, ET, et al.; New evidence in the treatment of overactive bladder; Curr Opin Obstet Gynecol; 2015; 366-372; 27.
Brown, SR, et al.; Surgery for faecal incontinence in adults; Cochrane Database Syst Rev; 2013; Cd001757; 7.
Buback, D; The use of neuromodulation for treatment of urinary incontinence; Aorn j; 2001; 176-178, 181-177, 189-190; quiz 191-176; 73;Abstract.
Bugbee, M, et al.; An implant for chronic selective stimulation of nerves; Med Eng Phys; 2001; 29-36; 23.
Buhmann, H, et al.; [Update on fecal incontinence]; Praxis (Bern 1994); 2014; 1313-1321; 103.
Burks, FN, et al.; Neuromodulation and the neurogenic bladder; Urol Clin North Am; 2010; 559-565; 37.
Burks, FN, et al.; Neuromodulation versus medication for overactive bladder: the case for early intervention; Curr Urol Rep; 2009; 342-346; 10.
Burnstock, G, et al.; P2X receptors in health and disease; Adv Pharmacol; 2011; 333-372; 61;Abstract.
Burnstock, G; Innervation of bladder and bowel; Ciba Found Symp; 1990; 2-18; discussion 18-26; 151;Abstract.
Burnstock, G; Introduction and perspective, historical note; Front Cell Neurosci; 2013; 227; 7.
Burnstock, G; Introductory overview of purinergic signalling; Front Biosci (Elite Ed); 2011; 896-900; 3;Abstract.
Burnstock, G; Purinergic cotransmission; F1000 Biol Rep; 2009; 46; 1.
Burnstock, G; Purinergic signalling in the gastrointestinal tract and related organs in health and disease; Purinergic Signal; 2014; 18323; 10.
Burnstock, G; Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future; Bioessays; 2012; 218-225; 34.
Burnstock, G; Purinergic signalling: past, present and future; Braz J Med Biol Res; 2009; 42437; 42.
Burnstock, G; The journey to establish purinergic signalling in the gut; Neurogastroenterol Motil; 2008; 42601; 20 Suppl 1.
Cadish, LA, et al.; Stimulation latency and comparison of cycling regimens in women using sacral neuromodulation; Neurourol Urodyn; 2016;Abstract.
Cameron, AP, et al.; Battery explantation after sacral neuromodulation in the Medicare population; Neurourol Urodyn; 2013; 238-241; 32.
Campbell, JD, et al.; Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence; BMC Urol; 2009; 18; 9.
Campin, L, et al.; [Urinary functional disorders bound to deep endometriosis and to its treatment: review of the literature]; J Gynecol Obstet Biol Reprod (Paris); 2014; 431-442; 43;Abstract.
Sherman, ND, et al.; Sacrel neuromodulation for the treatment of refractory urinary urge incontinence after stress incontinence surgery; Am J Obstet Gynecol, 2005; 2083-2087,193.
Sherman, ND, et al.; The current use of neuromodulation for bladder dysfuntion: Minerva Ginecol; 2000; 283-293; 58:Abstract.
Shi, P. et al.; Bladder response to acute sacral neuromodulation while treating rats in different phases of complete spinal cord injury: a preliminary study; Int Braz J Urol; 2015; 1194-1201; 41.
Shi, P, et al.: Effects of acute sacral neuromodulation on bladder reflex in complete spinal ori injury rats; Neuromodulation: 2013; 583-589; discussion 589; 16.
Shvarts, PG, et al.; [The modern methods of the electrical stimulation for the management of neurogenic disturbances of urination]; Vopr Kurortol Fizioter Lech Fiz Kult; 2015; 18-21; 92.
Siegel, S, et al.; Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medial therapy at 6-months in subjects with mild syptoms of overactive bladder; Neurourol Urodyn: 2015; 224-230; 34.
Sievert, KD, et al.; [Unconventional treatment procedures of the bladder in paraplegia and myelomeningocele]; Urologe A; 2012; 1692-1696; 51.
Sievert, KD, et al.; Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury; Ann Neurol; 2010; 74-84; 67.
Sievert, KD; Neuromodulation; Neurourol Urodyn; 2005; 310; 24.
Signorello, D, et al.; Impact of sacral neuromodulation on female sexual function and his correlation with clinical outcome and quality of life indexes: a monocentric experience; J Sex Med; 2011; 1147-1155; 8.
Sillen, U, et al.; Effects of transcutaneous neuromodulation (TENS) on overactive bladder symptoms in children: a randomized controlled trial; J Pediatr Urol; 2014; 1100-1105; 10.
Silveri, M, et al.; Voiding dysfunction in x-linked adrenoleukodystrophy: symptom score and urodynamic findings; J Urol; 2004; 2651-2653; 171.
Sivalingam, N, et al.; Concepts in the management of the overactive bladder in women; Med J Malaysia; 2012; 137-141; quiz 142; 67.
Skobejko-Wlodarska, L; [Non-neurogenic lower urinary tract dysfuntion]; Pol Merkur Lekarski; 2008; 131-137; 24 Suppl 4;Abstract.
Smaldone, MC, et al.; Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neurotoxin: Nat Clin Pract Urol; 2008; 120-121; 5.
Smith, AL, et al.; Contemporary management of overactive bladder; Postgrad Med; 2012; 104-116; 124;Abstract.
Smits, MA, et al.; [Neuromodulation as a treatment for overactive bladder syndrome]; Ned Tijdschr Geneeskd; 2012; A4135; 156;Abstract.
Smits, MA, et al.; Sacral neuromodulation in patients with idiopathic overactive bladder after intial botulinum toxin therapy: J Urol; 2013; 2148-2158; 190.
Snellings, AE, et al.; Effects of stimulation site and stimulation parameters on bladder inhibition by electrical nerve stimulation; BJU Int; 2012; 136-143; 110.
South, MM, et al.; Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation; Int Urogynecol J Pelvic Floor Dysfunct: 2007; 1395-1398; 18.
Speer, LM, et al.; Chronic Pelvic Pain in Women; Am Fam Physician, 2016; 380-387; 93.
Spinelli, M, et al.; A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder: description of the method and preliminary data; Neurourol Urodyn; 2005; 305-309; 24.
Spinelli, M, et al.; Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety; Eur Urol; 2008; 1287-1296; 54.
Spinelli, M, et al.; New sacral neuromodulation lead for percutaneous implantation using local anesthesia: description and first experience; J Urol; 2003; 1905-1907; 170.
Srivastava, D; Efficacy of sacral neuromodulation in treating chronic pain related to painful bladder syndrome/interstitial cystitis in adults; J Anaesthesiol Clin Pharmacol; 2012; 428-435; 28.
Starkman, JS, et al.; Management of refractory urinary urge incontienence following urogynecological surgery with sacral neuromodulation; Neurourol Urodyn; 2007; 29-35; discussion 36; 26.
Starkman, JS, et al.; Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation; Int Urogynecol J Pelvic Floor Dysfunct; 2008; 277-282; 19.
Starkman, JS, et al.; Surgical options for drug-refractory overactive bladder patients; Rev Urol: 2010; e97-e110; 12.
Starkman, JS, et al.; The evolution of obstruction induced overactive bladder symptoms following urethrolysis for female bladder outlet obstruction; J Urol; 2008; 1018-1023; 179.
Steanu, ID, et al.; The Place of the Ice Water Test (IWT) in the Evaluation of the Patients with Traumatic Spinal Cord Injury, Maedica (Buchar); 2012; 125-130; 7.
Stephany, HA, et al.; Prospective evaluation of sacral nerve modulation in children with validated questionnaires; J Urol; 2013; 1516-1522; 190.
Stoffel, JT: Contemporary management of the neurogenic bladder for multiple sclerosis patients; Urol Clin North Am; 2010; 547-557; 37.
Su, X, et al.; Comparison of neural targets for neuromodulation of bladder micturition reflex in the rat; Am J Physiol Renal Physiol; 2012; F1196-1206; 303.
Su, X, et al.; Differentiation and interaction of tibial versus spinal nerve stimulation for micturition control in the rat; Neurourol Urodyn; 2015; 92-97; 34.
Su, X, et al.; Neuromodulation attenuates bladder hyperactivity in a rat cystitis model; BMC Urol; 2013; 70; 13.
Su, X, et al.; Neuromodulation in a rat model of the bladder micturition reflex; Am J Physiol Renal Physiol. 2012; F477-486; 302.
Su, X, et al.; Optimization of Neuromodulation for Bladder Control in a Rat Cystitis Model; Neuromodulation; 2016; 101-107; 19.
Su, X, et at.; Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex; BMC Urol; 2015; 50; 15.
Su, X, et al.; Quantification of effectiveness of bilateral and unilateral neuromodulation in the rat bladder rhythmic contraction model; BMC Urol; 2013; 34; 13.
Su, X, et al.; Role of the endogenous opioid systme in modulation of urinary bladder activity by spinal nerve stimulation; Am J Physiol Renal Physiol; 2013; F52-60; 305.
Sullivan, J. et al.; Overactive detrusor; Curr Opin Urol; 199; 291-296; 9.
Sullivan, J, et al.; The overactive bladder: neuropharmacological basis of clinical management; Curr Opin Obstet Gynecol; 1999; 477-483; 11.
Sun, Y, et al.; Effects of neural blocking agents on motor activity and secretion in the proximal and distal rat colon; evidence of marked segmental differences in nicotinic receptor activity; Scand J Gastroenterol; 2000; 380-388; 35.
Suskind, AM, et al.; Physician Use of Sacral Neuromodulation Among Medicare Beneficiaries With Overactive Bladder and Urinary Retention; Urology; 2015; 30-34; 86.
Suskind, AM, et al.; Understanding the dissemination of sacral neuromodulation; Surg Innov; 2013; 625-630; 20.
Sutherland, RS, et al.; Vesicourethral function in mice with genetic disruption of neuronal nitric oxide synthase; J Urol; 1997; 1109-1116; 157.
Svensson, L, et al.; Neuromodulation of experimental Shigella infection reduces damage to the gut mucosa; Microbes Infect; 2004; 256-264; 6.
Swinn, MJ, et al.; The cause and natural history of isolated urinary retention in young women; J Urol; 2002; 151-156; 167.
Tai, C, et al.; Bladder inhibition by intermittent pudendal nerve stimulation in cat using transdermal amplitude-modulated signal (TAMS); Neurourol Urodyn; 2012; 1181-1184; 31.
Tai, C, et al.; Inhibition of bladder overactivity by stimulation of feline pudendal nerve using transdermal amplitude-modulation signal (TAMS); BJU Int; 2012; 782-787; 109.
Canbaz Kabay, S, et al.; Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results; Neurourol Urodyn; 2015; Abstract.
Cardarelli, S, et al.; Efficacy of sacral neuromodulation on urological diseases: a multicentric research project; Urologia; 2012; 90-96; 79.
Cardot, V, et al.; [Guidelines for the treatment of urinary incontinence in women with refractory idiopathic vesical hyperactivity using sacral neuromodulation]; Prog Urol; 2010; S161-169; 20 Suppl 2;Abstract.
Carey, HV, et al.; Neuromodulation of intestinal transport in the suckling mouse; Am J Physiol; 1989; R481-486; 256; Abstract.
Carey, M, et al.; Sacral nerve root stimulation for lower urinary tract dysfunction: overcoming the problem of lead migration; BJU Int; 2001; 15-18; 87.
Carlson, JJ, et al.; Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States; Clin Ther; 2013; 414-424; 35.
Carlucci, L, et al.; Functional variability of sacral roots in bladder control; J Neurosurg Spine; 2014; 961-965; 21.
Carr, MC; Conservative nonsurgical management of spina bifida; Curr Urol Rep; 2010; 109-113; 11.
Carrington, EV, et al.; A systematic review of sacral nerve stimulation mechanisms in the treatment of fecal Incontinence and constipation; Neurogastroenterol Motil; 2014; 1222-1237; 26.
Chaabane, W, et al.; Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study; Neurourol Urodyn; 2011; 547-550; 30.
Chan, DK, et al.; Effective treatment of dyssynergic defecation using sacral neuromodulation in a patient with cerebral palsy; Female Pelvic Med Reconstr Surg; 2015; e27-29; 21;Abstract.
Chancellor, MB, et al.; Principles of Sacral Nerve Stimulation (SNS) for the Treatment of Bladder and Urethral Sphincter Dysfunctions; Neuromodulation; 2000; 16-26; 3.
Chandra, A, et al.; Neuromodulation of perineally transposed antropylorus with pudendal nerve anastomosis following total anorectal reconstruction in humans; Neurogastroenterol Motil; 2014; 1342-1348; 26.
Chapple, C, et al.; The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?; BJU Int; 2009; 1188-1190; 104.
Chapple, CR, et al.; Surgery for detrusor overactivity; World J Urol; 1998; 268-273; 16.
Chartier-Kastler, E, et al.; [Sacral neuromodulation with InterStim system: Results from the French national register]; Prog Urol; 2011; 209-217; 21;Abstract.
Chartier-Kastler, E, et al.; [Update on the second line management of idiopathic overactive bladder]; Prog Urol; 2009; 530-537; 19;Abstract.
Chartier-Kastler, E; Sacral neuromodulation for treating the symptoms of overactive bladder syndrome and non-obstructive urinary retention: >10 years of clinical experience; BJU Int; 2008; 417-423; 101.
Chatoor, D, et al.; Constipation and evacuation disorders; Best Pract Res Clin Gastroenterol; 2009; 517-530; 23.
Chen, G, et al.; Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease; Spinal Cord; 2014;Abstract.
Chen, G, et al.; The inhibitory effects of pudendal nerve stimulation on bladder overactivity in spinal cord injury dogs: is early stimulation necessary?; Neuromodulation; 2012; 232-237; discussion 237; 15.
Chen, ML, et al.; Electrical stimulation of somatic afferent nerves in the foot increases bladder capacity in healthy human subjects; J Urol; 2014; 1009-1013; 191.
Chen, SC, et al.; Pudendal neuromodulation improves voiding efficiency in diabetic rats; Neurourol Urodyn; 2013; 293-300; 32.
Chiarioni, G, et al.; Neuromodulation for fecal incontinence: an effective surgical intervention; World J Gastroenterol; 2013; 7048-7054; 19.
Choudhary, M, et al.; Inhibitory effects of tibial nerve stimulation on bladder neurophysiology in rats; Springerplus; 2016; 35; 5.
Colaco, M, et al.; Current guidelines in the management of interstitial cystitis; Transl Androl Urol; 2015; 677-683; 4.
Collins, SM; Is the irritable gut an inflamed gut?; Scand J Gastroenterol Suppl; 1992; 102-105; 192;Abstract.
Comiter, CV; Conscious Neuromodulation of the Bladder before Clinical Use; J Urol; 2015; 16-17; 194.
Comiter, CV; Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study; J Urol; 2003; 1369-1373; 169.
Corcos, J, et al.; Canadian Urological Association guidelines on urinary incontinence; Can J Urol; 2006; 3127-3138; 13;Abstract.
Cornu, JN; Actual treatment of overactive bladder and urge urinary incontinence; Minerva Urol Nefrol; 2013; 21-35; 65;Abstract.
Costa, JA, et al.; Spinal cord neuromodulation for voiding dysfunction; Clin Obstet Gynecol; 2000; 676-688; 43.
Craggs, M, et al.; Neuromodulation of the lower urinary tract; Exp Physiol; 1999; 149-160; 84.
Craggs, MD; Objective measurement of bladder sensation: use of a new patient-activated device and response to neuromodulation; BJU Int; 2005; 29-36; 96 Suppl 1.
Crock, LW, et al.; Central amygdala metabotropic glutamate receptor 5 in the modulation of visceral pain; J Neurosci; 2012; 14217-14226; 32.
Dahms, SE, et al.; Sacral neurostimulation and neuromodulation in urological practice; Curr Opin Urol; 2000; 329-335; 10.
Daneshgari, F, et al.; Future directions in pelvic neuromodulation; Urol Clin North Am; 2005; 113-115, viii; 32.
Daneshgari, F; Applications of neuromodulation of the lower urinary tract in female urology; Int Braz J Urol; 2006; 262-272; 32.
Daniels, DH, et al.; Sacral neuromodulation in diabetic patients: success and complications in the treatment of voiding dysfunction; Neurourol Urodyn; 2010; 578-581; 29.
Dasgupta, R, et al.; Changes in brain activity following sacral neuromodulation for urinary retention; J Urol; 2005; 2268-2272; 174.
Dasgupta, R, et al.; The management of female voiding dysfunction: Fowler's syndrome—a contemporary update; Curr Opin Urol; 2003; 293-299; 13.
Davis, T, et al.; Sacral neuromodulation outcomes for the treatment of refractory idiopathic detrusor overactivity stratified by indication: Lack of anticholinergic efficacy versus intolerability; Can Urol Assoc J; 2013; 176-178; 7.
De Boer, TA, et al.; [Male urinary incontinence]; Ned Tijdschr Geneeskd; 2008; 797-802; 152;Abstract.
De Gennaro, M, et al.; Current state of nerve stimulation technique for lower urinary tract dysfunction in children; J Urol; 2011; 1571-1577; 185.
De Gennaro, M, et al.; Percutaneous tibial nerve neuromodulation is well tolerated in children and effective for treating refractory vesical dysfunction; J Urol; 2004; 1911-1913; 171.
De Groat, WC, et al.; Impact of Bioelectronic Medicine on the Neural Regulation of Pelvic Visceral Function; Bioelectron Med; 2015; 25-36; 2015.
De Seze, M, et al.; [Peripheral electrical stimulation in neurogenic bladder]; Ann Readapt Med Phys; 2008; 473-478; 51;Abstract.
Deffieux, X, et al.; [Voiding dysfunction after surgical resection of deeply infiltrating endometriosis: pathophysiology and management]; Gynecol Obstet Fertil; 2007; S8-13; 35 Suppl 1;Abstract.
Del Popolo, G, et al.; [Standard pharmacological treatment and new therapies for overactive bladder]; Urologia; 2012; 42534; 79.
Denzinger, S, et al.; Does sacral neuromodulation lead to relevant reduction in the need for intermittent catheterization? A single-center experience on patients with chronic urinary retention; Neuromodulation; 2012; 586-591; discussion 591; 15.
Guys. JM, et al.; Sacral neuromodutation for neurogenic bladder dysfunction in children; J Urol; 2004; 1673-1676; 172.
Haddad, M, et al,; Sacral neuromodulation in children with urinary and fecal incontinence: a multicenter, open label, randomized, crossover study, J Urol: 2010; 696-701; 184.
Hamann, MF, et al.; [Urinary incontinence in men and women. Diagnostics and conservative therapy]; Urolege A; 2014; 1073-1084; quiz 1085-1076: 53.
Hartmann, KE, at al.; Treatment of overactive bladder in women; Evid Rep Technol Assess (Full Rep): 2009; 1-120. v:.
Hasan, ST, et al.; Neuromodulation in bladder dysfunction; Curr Opin Obstet Gynecol; 1998: 395-399; 10.
Hasan, ST, et al.; Surface localization of sacral foramina for neuromodulation of bladder function, An anatomical study; Eur Urol: 1996; 90-98; 29;Abstract.
Hasan, ST, et al.; Transcutaneous electrical nerve stimulation and temporary S3 neuromodulation in idiopathic detrusor instability; J Urol; 1996; 2005-2011; 155.
Hashim, H, et al.; Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations; Drugs; 2004; 1643-1656; 64.
Hashim, H, et al.; Novel uses for antidiuresis; Int J Clin Prat Suppl; 2007; 32-36; ;Abstract.
Hashim. H, et al.; Patient preferences for treating refractory overactive bladder in the UK; Int Urol Nephrol; 2015; 1619-1627: 47.
Hassouna, M, et al,; Dog as an animal model for neurostimulation; Neurourol Urodyn; 1994; 159-167; 13.
Hassouna, M. et al.; Update on sacral neuromodulation; indications and outcomes; Curr Urol Rep; 2003; 391-398; 4.
Hassouna, M; Sacral neuromodulation for overactive bladder: Is it worth It?: Can Urol Assoc J; 2013: E454; 7.
Hassouna, MM, et al.; Economic evaluation of sacral neuromodutation in overactive bladder: A Canadian perspective; Can Urol Assoc J; 2015; 242-247; 9.
Hedlund, H. et al.; Sacral neuromodulation in Norway: clinical experience of the first three years; Scand J Urol Nephrol Suppl; 2002; 87-95; ;Abstract.
Heinze, K, et al.; [Neuromodulation—new techniques]; Urologe A; 2015; 373-377; 54.
Hellstrom, PA, et al.; Sacral nerve stimulation lead implantation using the O-arm; BMC Urol; 2013; 48: 13.
Herbison. GP, et al.; Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults; Cochrane Database Syst Rev; 2009; Cd004202.
Hersh, L, et al.; Clinical management of urinary incontinence in women: Am Fam Physician; 2013; 634-640, 87.
Hijaz, A, et al.; Complications and troubleshooting of two-stage sacral neuromodulation therapy: a single-institution experience; Urology; 2006; 533-537; 68.
Hill, AJ, et al.; Resolution of Chronic Vulvar Pruritus With Replacement of a Neuromodulation Device; J Minim Invasive Gynecol; 2015: 889-891; 22.
Hindley, RG, et al.; The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate; BJU Int; 2001; 217-220; 88.
Hoag, N, et al.; Underactive Bladder: Clinical Features, Urodynamic Parameters, and Treatment; Int Neurourol J; 2015; 185-189; 19.
Hoch, M, et al.; [Chemical destruction of sacral nerve roots by alcohol injection for the treatment of overactive bladder]; Prog Urol; 2006; 584-587; 16;Abstract.
Hoda, MR, et al.; [Sacral neuromodulation in urology. The emperor's new clothes or effective high-tech medicine?]; Urologe A; 2010; 1254-1259: 49.
Hoebeke, P. et al.; Transcutaneous neuromodulation for the urge syndrome in children: a pilot study; J Urol; 2001; 2416-2419; 166.
Hohenfellner, M, et el.; [Sacral neuromodulation of the urinary bladder]: Urologe A; 2000: 55-63; 39.
Hohenfellner, M, et al.; Bilateral chronic sacral neuromodutation for treatment of low urinary tract dysfunction; J Urol; 1998; 821-824; 160.
Hohenfellner, M, et al.; Chronic sacral neuromodulation for treatment of neurogenic bladder dysfunction: long-term results with unilateral implants; Urology; 2001; 887-892: 58.
Hohenfellner, M. et al.; Sacral neuromodulation for treatment of lower urinary tract dysfunction: BJU Int: 2000; 10-19; discussion 22-13, 85 Suppl 3.
Hoque, T, et al.; Validation of internal controls for gene expression analysis in the intestine of rats infected with Hymenolepis diminuta; Parasitol Int; 2007; 325-329; 56.
Horrocks, EJ, et al.; Double-blind randomised controlled trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in the treatment of faecal incontinence: CONtrol of Faecal Incontinence using Distal NeuromodulaTion (the CONFIDeNT trial); Health Technol Assess; 2015; 1-164; 19.
Hotouras, A. et al.; Prospective clinical audit of two neuromodulatory treatments for fecal incontinence: sacral nerve stimulation (SNS) and percutaneous tibial nerve stimulation (PTNS); Surg Today: 2014: 2124-2130; 44.
Hoyle, CH, et al.; Ethylcholine mustard aziridinium on (AF64A) impairs cholinergic neuromuscular transmission in the guinea-pig ileum and urinary bladder, and cholinergic neuromodulation in the enteric nervous system of the guinea-pig distal colon; Gen Pharmacol; 1986; 543-548; 17.
Hubsher, CP, et al.; Sacral nerve stimulation for neuromodulation of the lower urinary tract; Can J Urol; 2012; 6480-6484; 19.
Hull, T, et al., Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence; Dis Colon Rectum; 2013; 234-245; 56.
Hull, TL; Sacral neuromodulation stimulation in fecal incontinence; Int Urogynecol J; 2010: 1565-1568; 21.
Humphreys, MR, et al.; Preliminary results of sacral neuromodulation in 23 children: J Urol; 2006; 2227-2231; 176.
Hyun, SJ, et al.; Comparative analysis between thoracic spinal cord and sacral neuromodulation in a rat spinal cord injury model; a preliminary report of a rat spinal cord stimulation model; Korean J Spine; 2013; 14-18; 10.
Iarumov, N, et al.; [Anal incontinence—new methods of surgical treatment using artificial bowel sphincter and sacral nerve stimulation]; Khirurgiia (Sofiia): 2007; 40-45; ;Abstract.
Indar, A, et al.; A dual benefit of sacral neuromodulation; Surg Innov; 2008; 219-222: 15.
Indinnimeo, M. et al.; Sacral neuromodulation for the treatment of fecal incontinence: analysis of cost-effectiveness; Dis Colon Rectum; 2010; 1661-1669, 53.
Ingber, MS, et al.; Neuromodulation and female sexual function: does treatment for refractory voiding symptoms have an added benefit?; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 1055-1059: 20.
Iqbal, F, et al.; Bilateral transcutaneous tibial nerve stimulation for chronic constipation; Colorectal Dis; 2016; 173-178; 18.
Ishigooka, M, et al.; Sacral nerve stimulation and diurnal urine volume; Eur Urol; 1999; 421-426; 36;Abstract.
Jacobs, SA, et al.; Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet; Neurourol Urodyn; 2014; 488-492; 33.
Jadav, AM, et al.; Does sacral nerve stimulation improve global pelvic function in women?; Colorectal Dis; 2013; 848-857; 15.
Jarrett, ME; Neuromodulation for constipation and fecal incontinence; Urol Clin North Am; 2005; 79-87; 32.
Jarvis; JC, et al.; Functionai electrical stimulation for control of internal organ function; Neuromodulation; 2001; 155-164; 4.
Jesus, LE, et al:, Psychosocial and respiratory disease related to severe bladder dysfunction and non-monosymptornatic enuresis; J Pediatr Urol; 2015;Abstract.
Majerus, SJ, et al.; Wireless, Ultra-Low-Power Implantable Sensor for Chronic Bladder Pressure Monitoring: ACM J Emerg Technol Comput Syst; 2012;8.
Mally, AD, et al.; Role of opioid and metabotropic glutamate 5 receptors in pudendal inhibition of bladder overactivity in cats; J Urol; 2013; 1574-1579; 189.
Malossi, J, et al.; Sacral neuromodulation for the treatment of bladder dysfunction; Curr Urol Rep; 2002; 61-66; 3.
Malouf, AJ, et al.; Short-term effets of sacral nerve stimulation for idiopathic slow transit constipation; World J Surg; 2002; 166-170; 26.
Mamopoulos, A, et al., Active sacral neuromodulator during pregnancy: a unique case report; Am J Obstet Gynecol: 2014; e4-5; 211.
Manriquez, V. et al.; Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial; Eur J Obstet Gynecol Reprod Biol; 2016; 42531; 196.
Marcelissen, T, et al.; Is the screening method of sacral neuromodulation a prognostic factor for long-term success?; J Urol; 2011; 583-587; 185.
Marcelissen, T, et al.; Sacral neuromodulation as a treatment for chornic pelvic pain; J Urol; 2011; 387-393; 186.
Marcelissen, TA, et al.; Long-term results of sacral neuromodulation with the tined lead procedure; J Urol; 2010; 1997-2000; 184.
Marcelissen, TA, et al.; Psychological and psychiatric factors as predictors for success in sacral neuromodulation treatment; BJU Int; 2011; 1834-1838; 108.
Marcelissen, TA, et al.; The effect of pulse rate changes on the clinical outcome of sacral neuromodulation; J Urol; 2011; 1781-1785; 185.
Marcelissen, TA, et al.; The use of bilaterai sacral nerve stimulation in patients with loss of unilateral treatment efficacy; J Urol; 2011; 976-980; 185.
Marinkovic, SP, et al.; Neuremodutation for Overactive Bladder Symptoms in Women Utilizing Either Motor or Sensory/Motor Provocation With a Minimum Nine-Year Follow-Up; Neuromodulation; 2015; 517-521; discussion 521; 18.
Martin Braun, P, et al.; [Continuous bilateral sacral neuromodulation as a minimally invasive implantation technique to patients with functional bladder changes]; Arch Esp Urol; 2003; 497-501; 56.
Martinson, M. et al.; Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation; J Urol; 2013; 210-216; 189.
Mason, MD, et al.; Prospective Evaluation of Sacral Neuromodulation in Children: Outcomes and Urodynamic Predictors of Success; J Urol; 2016.
Matsuta Y, et al.; Contribution of opioid and metabotropic glutamate receptor mechanisms to inhibition of bladder overactivity by tibial nerve stimulation; Am J Physiol Regul Integr Comp Physiol; 2013; R126-133; 305.
Matsuta, Y, et al.; Effect of methysergide on pudendal inhibition of micturition reflex in cats; Exp Neurol; 2013; 250-258; 247.
Matsuta, Y, et al.; Poststimulation inhibition of the mictuntion reflex induced by tibial nerve stimulation in rats; Physiol Rep; 2014; e00205; 2.
Mauroy, B, et al.; [Long-term results of interferential current stimulation in the treatment of bladder instability]; Prog Urol; 2001; 34-39; 11; Abstract.
Mayer, R; Neuromodulation—who, what, when, where and why?; J Urol; 2010; 17-18; 183.
Mayr, CA, et al.; Cost-effectiveness of novel therapies for overactive bladder; Expert Rev Pharmacoecon Outcomes Res; 2014; 527-535; 14.
Mazo, EB, et al.; [Temporary sacral and tibial neuromodulation in treating patients with ovractive urinary bladder]; Zh Vopr Neirokhir Im N N.Burdenko; 2002; 17-21; ;Abstract.
Mazo, EB, et al.; [Temporary sacral neuromodulation in patients with urge incontinence]; Urologiia: 2000; 42-46; ;Abstract.
Mazo, EB, et al.; [The role of somatosensory evoked potentials in prognosis of efficacy of tibial neuromodulation in patients with hyperactive urinary bladder]; Urologiia; 2005; 49-52; ;Abstract.
McAchran, SE, et al.; Sacral neuromodulation in the older woman; Clin Obstet Gynecol; 2007; 735-744; 50.
McKertich, K; Urinary incontinence-procedural and surgical treatments for women; Aust Fam Physician, 2008; 122-131; 37.
McNevin, MS, et al.; Outcomes associated with interstim therapy for medically refractory fecal incontinence; Am J Surg; 2014; 735-737; discussion 737-788; 207.
Mehnert, U, et al.; [Neuro-urological dysfunction of the lower urinary tract in CNS diseases: pathophysiology, epidemiology, and treatment options]; Urologe A; 2012; 189-197; 51.
Mehnert, U, et al.; The management of urinary incontinence in the male neurological patient; Curr Opin Urol; 2014; 586-592; 24.
Meissnitzer, T, et al.; CT-Guided Lead Placement for Selective Sacral Neuromodulation to Treat Lower Urinary Tract Dysfunctions; AJR Am J Rosentgenol; 2015; 1139-1142; 205.
Melenhorst, J, et al.; Sacral neuromodulation in patients with faecal incontinence: results of the first 100 permanent implantation; Colorectal Dis; 2007; 725-730; 9.
Meurette, G. et al.; Sacral nerve stimulation enhances epithelial barrier of the rectum: results from a porcine model; Neurogastroenterol Motil; 2012; 267-273, e110; 24.
Michelsen, HB, et al.; Rectal volume tolerability and anal pressures in patients with fecal incontinence treated with sacral nerve stimulation; Dis Colon Rectum; 2006; 1039-1044; 49.
Miller, JJ, et al.; Diagnosis and treatment of overactive bladder; Minerva Ginecol; 2005; 501-520; 57;Abstract.
Milne, JL; Behavioral therapies for overactive bladder: making sense of the evidence: J Wound Ostomy Continence Nurs; 2008; 93-101; quiz 102-103; 35;Abstract.
Minardi, D, et al.; Activity and expression of nitric oxide synthase in rat bladder after saral neuromodulation; Int J Immunopathol Pharmacol; 2008; 129-135; 21;Abstract.
Minardi, D, et al.; Lower urinary tract and bowel disorders and multiple sclerosis: role of sacral neuromodulation: a preliminary report; Neuromodulation; 2005; 176-181; 8.
Miotla, P, et al.; [Sacral nerve stimulation in the treatment of the lower urinary tract function disorders]; Ginekol Pol; 2011; 851-856; 82.
Mishra, NN; Clinical presentation and treatment of bladder pain syndrome/interstitial cystitis (BPS/IC) in India; Transl Androl Urol; 2015; 512-523; 4.
Moon, KH, et al.; Prospective Trial of Sacral Neuromodulation for Refractory Overactive Bladder Syndrome in Korean Patients; Low Urin Tract Symptoms; 2014; 175-179; 6.
Moutzouris, DA, et al.; Interstitial cystitis: an unsolved enigma: Clin J Am Soc Nephrol; 2009; 1844-1857; 4.
Murphy, AM, et al.; Treatment of overactive bladder: what is on the horizon?; Int Urogynecol J; 2013; 42503; 24.
Musco, S, et al.; Percutaneous Tibial Nerve Stimulation Improves Female Sexual Function in Women with Overactive Bladdere Syndrome: J Sex Med; 2016.
N. Patidar et al.; Transcutaneous posterior tibial nerve stimulation in pediatric overactivebladdeer; A preliminary report; Journal of Pediatric Urology; 2015; 351.e1-351.e6; 11.
Nakib, N, et al.; Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neuromodulation; Nat Clin Pract Urol; 2008; 118-119; 5.
Nambiar, A, et al.; Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO); Neurourol Urodyn; 2014; S21-25; 33 Suppl 3.
Natalin, R, et al.; Management of OAB in those over age 65; Curr Urol Rep; 2013; 379-385; 14,
Ng, CK, et al.; Refractory overactive bladder in men: update on novel therapies; Curr Urol Rep; 2006; 456-461; 7.
Nijman, RJ; Classification and treatment of functional incontinence in children; BJU Int; 2000; 37-42; discussion 45-36; 85 Suppl 3.
Krivoborodov, GG, et al.; [Tibial neuromodulation in the treatment of neurogenic detrusor hyperactivity in patients with Parkinson's disease]; Urologiia; 2006; 42435; ;Abstract.
Krolczyk, G, et al.; Effects of continuous microchip (MC) vagal neuromodulation on gastrointestinal function in rats; J Physiol Pharmacol; 2001; 705-715; 52.
Kubota, M, et al.; Effects of neuromodulation with sacral magnetic stimulation for intractable bowel or bladder dysfunction in postoperative patients with anorectal malformation: a preliminary report; Pediatr Surg Int; 2011; 599-603; 27.
Kumsar, S, et al.; Effects of sacral neuromodulation on isolated urinary bladder function in a rat model of spinal cord injury; Neuromodulation; 2015; 67-74; discussion 74-65; 18.
Kuo, HC; Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction: Urology; 2007; 57-61; discussion 61-52; 69.
Kuo, TL, et al.; Pelvic floor spasm as a cause of voiding dysfunction; Curr Opin Urol; 2015; 311-316; 25.
Kurpad, R, et al.; The evaluation and management of refractory neurogenic overactive bladder: Curr Urol Rep; 2014; 444; 15.
Kutzenberger, J: [Neurogenic urinary incontinence. Value of surgical management]; Urologe A; 2008; 699-706; 47.
La, TH, et al.; Intermittent sacral neuromodulation for idiopathic urgency urinary incontinence in women; Neurourol Urodyn; 2015;Abstract.
Laudano, MA, et al.; Disparities in the Use of Sacral Neuromodulation among Medicare Beneficiaries; J Urol; 2015; 449-453; 194.
Laviana, A, et al.; Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome; Neurosurg Clin N Am; 2014; 33-46; 25.
Lay, AH, et al.; The role of neuromodulation in patients with neurogenic overactive bladder; Curr Urol Rep; 2012; 343-347; 13.
Lazzeri, M, et al.; The challenge of overactive bladder therapy; alternative to antimuscarinic agents; Int Braz J Urol; 2006; 620-630; 32.
Le, NB, et al.; Expanding the Role of Neuromodulation for Overactive Bladder: New Indications and Alternatives to Delivery; Curr Bladder Dysfunct Rep; 2011; 25-30; 6.
Leclers, F, et al.; [Cystomanometric study of bladder sensation during sacral neuromodulation test]; Prog Urol; 2005; 238-243; 15;Abstract.
Lee, YY; What's New in the Toolbox for Constipation and Fecal Incontinence?; Front Med (Lausanne); 2014; 5; 1.
Leicht, W, et al.; [Botulinum toxin versus sacral neuromodulation for idiopathic detrusor overactivity]; Urologe A; 2012; 348-351; 51.
Leng, WW, et al.; How sacral nerve stimulation neuromodulation works; Urol Clin North Am; 2005; 42692; 32.
Leong, FC, et al.; Neuromodulation for the treatment of urinary incontinence; Mo Med; 2007; 435-439; 104;Abstract.
Leong, RK, et al.; Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder; BJU Int; 2011; 558-564; 108.
Leong, RK, et al.; Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review; Urol Int; 2010; 245-253; 84.
Leong, RK, et al.; PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy; Neurourol Urodyn; 2011; 1249-1252; 30.
Leong, RK, et al.; Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey; J Urol; 2011; 588-592; 185.
Levin, PJ, et al.; Psychosocial factors related to the use of InterStim(R) for the treatment of refractory overactive bladder; Female Pelvic Med Reconstr Surg; 2014; 272-275; 20;Abstract.
Levin, PJ, et al.; The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review; Int Urogynecol J; 2012; 1591-1597; 23.
Levy, RM; The evolving definitioin of neuromodulation; Neuromodulation; 2014; 207-210; 17.
Lewis, JM, et al.; Non-traditional management of the neurogenic bladder; tissue engineering and neuromodulation; ScientificWorldJournal; 2007; 1230-1241; 7.
Liao, KK, et al.; Effect of sacral neuromodulation on the spinal nociceptive reflex of patients with idiopathic overactive bladder; Neuromodulation; 2008; 50-55; 11.
Liberman, D, et al.; Concerns regarding sacral neuromodulation as a treatment option for medical-refractory overactive bladder; Can Urol Assoc J; 2011; 285-287; 5.
Lin, YT, et al.; Effects of pudendal neuromodulation on bladder function in chronic spinal cord-injured rats; J Formos Med Assoc; 2015.
Linares Quevedo, AI, et al.; [Posterior sacral root neuromodulation in the treatment of chronic urinary dysfunction]; Actas Urol Esp; 2002; 250-260; 26;Abstract.
Lippmann, QK, et al.; Successful use of sacral neuromodulation in a 12-year-old with cerebral palsy and neurogenic bladder; Neuromodulation; 2014; 396-398; 17.
Lombardi, G. et al.; Clinical concomitant benefits on pelvic floor dysfunctions after sacral neuromodulation in patients with incomplete spinal cord injury; Spinal Cord; 2011; 629-636; 49.
Lombardi, G, et al.; Clinical female sexual outcome after sacral neuromodulation implant for lower urinary tract symptom (LUTS); J Sex Med; 2008; 1411-1417; 5.
Lombardi, G, et al.; Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms; Spinal Cord; 2009; 486-491; 47.
Lombardi, G, et al.; Clinical outcome of sacral neuromodulation in incomplete spinal cord-injured patients suffering from neurogenic bowel dysfunctions; Spinal Cord; 2010; 154-159; 48.
Lombardi, G, et al.; Intravesical electrostimulation versus sacral neuromodulation for incomplete spinal cord patients suffering from neurogenic non-obstructive urinary retention; Spinal Cord; 2013; 571-578; 51.
Lombardi, G, et al.; Sacral neuromodulation and female sexuality; Int Urogynecol J; 2015; 1751-1757; 26.
Lombardi, G, et al.; Sacral neuromodulation for lower urinary tract dysfunction and impact on erectile function; J Sex Med; 2008; 2135-2140; 5.
Lombardi, G, et al.; Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year-follow-up single-centre experience; Spinal Cord; 2014; 241-245; 52.
Lopez-Delgado, A, et al.; Effect on anal pressure of percutaneous posterior tibial nerve stimulation for faecal incontinence; Colorectal Dis; 2014; 533-537; 16.
Lowette, K, et al.; Role of corticosterone in the murine enteric nervous system during fasting: Am J Physiol Gastrointest Liver Physiol; 2014; G905-913; 307.
Lyon, TD, et al.; Pudendal but not tibial nerve stimulation inhibits bladder contractions induced by stimulation of pontine micturition center in cats; Am J Physiol Regul Integr Comp Physiol; 2016; R366-374; 310.
M. Matsushita et al.; Primary somatosensory evoked magnetic fields elicited by sacralsurface electrical stimulation; Neuroscience Letters; 2008; 77?80; 431.
Madersbacher, H, et al.; What are the causes and consequences of bladder overdistension? ICI-RS 2011; Neurourol Urodyn; 2012; 317-321; 31.
Madersbacher, H; Overactive bladder—a practical approach to evaluation and management; J Med Liban; 2004; 220-226; 52;Abstract.
Maeda, Y, et al.; Sacral nerve stimulation for faecal incontinence and constipation: a European consensus statement; Colorectal Dis; 2015; O74-87; 17.
Maher, CF, et al.; Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis; J Urol; 2001; 884-886; 165.
Maher, RM, et al.; A novel externally applied neuromuscular stimulator for the treatment of stress urinary incontinence in women—a pilot study; Neuromodulation; 2013; 590-594; discussion 594; 16.
Majerus, SJ, et al.; Low-power wireless micromanometer system for acute and chronic bladder-pressure monitoring; IEEE Trans Biomed Eng; 2011; 763-767; 58.
Abdel Raheem, A, et al.; Voiding dysfunction in women: How to manage it correctly; Arab J Urol; 2013; 319-330; 11.
Abraham, N, et al.; Urgency after a sling: review of the management; Curr Urol Rep; 2014; 400; 15.
Abrams, P, et al.; The role of neuromodulation in the management of urinary urge incontinence; BJU Int; 2003; 355-359; 91.
Abrams, P; The role of neuromodulation in the management of urinary urge incontinence; BJU Int; 2004; 1116; 93.
Allahdin, S, et al.; An overview of treatment of overactive bladder syndrome in women; J Obstet Gynaecol; 2012; 217-221; 32.
Alo, KM, et al.; Sacral nerve root stimulation for the treatment of urge incontinence and detrusor dysfunction utilizing a cephalocaudal intraspinal method of lead insertion: a case report; Neuromodulation; 2001; 53-58; 4.
Alo, KM, et al.; Selective Nerve Root Stimulation (SNRS) for the Treatment of Intractable Pelvic Pain and Motor Dysfunction: A Case Report; Neuromodulation; 2001; 19-23; 4.
Al-Shaiji, TF, et al.; Pelvic electrical neuromodulation for the treatment of overactive bladder symptoms; Adv Urol; 2011; 757454; 2011.
Al-Zahrani, AA, et al.; Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center; J Urol; 2011; 981-986; 185.
Amarenco, G, et al.; Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder; J Urol; 2003; 2210-2215; 169.
Amend, B, et al.; [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A]; Urologe A; 2010; 245-252; 49.
Amend, B, et al.; Prolonged percutaneous SNM testing does not cause infection-related explanation; BJU Int; 2013; 185-491; 111.
Amoroso, L, et al.; Sacral-neuromodulation CT-guided; Radiol Med; 2005; 421-429; 109;Abstract.
Amundsen, CL, et al.; Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure?; Urology; 2005; 746-750; 66.
Amundsen, CL, et al.; Sacral neuromodulation in an older, urge-incontinent population; Am J Obstet Gynecol; 2002; 1462-1465; discussion 1465; 187.
Amundsen, Cl, et al.; The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial; Contemp Clin Trials; 2014; 272-283; 37.
Anger, JT, et al.; The effect of sacral neuromodulation on anticholinergic use and expenditures in a privately insured population; Neuromodulation; 2014; 72-74; discussion 74; 17.
Antolak, SJ, Jr., et al.; Therapeutic pudendal nerve blocks using corticosteroids cure pelvic pain after failure of sacral neuromodulation; Pain Med; 2009; 186-189; 10.
Antolak, SJ, Jr.; Re: Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study; J Urol; 2003; 1956; author reply 1956; 170.
Anton, PA; Stress and mind-body impact on the course of inflammatory bowel diseases; Semin Gastrointest Dis; 1999; 14-19; 10;Abstract.
Aoun, F, et al.; [Lower urinary tract dysfunction following radical hysterectomy]; Prog Urol; 2015; 1184-1190; 25; Abstract.
Apostolidis, A; Neuromodulation for intractable OAB; Neurourol Urodyn; 2011; 766-770; 30.
Arlandis, S, et al.; Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder; Value Health; 2011; 219-228; 14.
Arnold, J, et al.; Overactive bladder syndrome—management and treatment options; Aust Fam Physician; 2012; 878-883; 41.
Arrabal-Polo, MA, et al.; Clinical efficacy in the treatment of overactive bladder refractory to anticholinergics by posterior tibial nerve stimulation; Korean J Urol; 2012; 483-486; 53.
Atiemo, HO, et al.; Evaluation and management of refractory overactive bladder; Curr Urol Rep; 2006; 370-375; 7.
Atnip, S, et al.; A unique approach to severe constipation; Urol Nurs; 2011; 348-350; 31.
Badawi, JK, et al.; [Current diagnostics and therapy of the overactive bladder and urge incontinence]; Dtsch Med Wochenschr; 2005; 1503-1506; 130;Abstract.
Badlani, GH; Update on lower urinary tract symptoms; ScientificWorldJournal; 2009; 499-500; 9.
Baeten, CG; Status of sacral neuromodulation for refractory constipation; Colorectal Dis; 2011; 19-22; 13 Suppl 2.
Balchandra, P, et al.; Women's perspective: intra-detrusor botox versus sacral neuromodulation for overactive plodder symptoms after unsuccessful anticholinergic treatment; Int Urogynecol J; 2014; 1059-1064; 25.
Banakhar, M, et al.; Effect of sacral neuromodulation on female sexual function and quality of life: Are they correlated?; Can Urol Assoc J; 2014; E762-767; 8.
Banakhar, M, et al.; Sacral Neuromodulation for Genitourinary Problems; Prog Neurol Surg; 2015; 192-199; 29; Abstract.
Banakhar, MA, et al.; Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem; Ther Adv Urol; 2012; 179-185; 4.
Bannowsky, A, et al.; [Sacral neuromodulation in treatment of functional disorders of the lower urinary tract. An overview of basic principles, indications, outcomes]; Urologe A; 2003; 1357-1365; 42.
Bannowsky, A, et al.; Urodynamic changes and response rates in patients treated with permanent electrodes compared to conventional wire electrodes in the peripheral nerve evaluation test; World J Urol; 2008; 623-626; 26.
Banyo, T; [The role of electrical neuromodulation in the therapy of chronic lower urinary tract dysfunction]; Ideggyogy Sz; 2003; 68-71; 56;Abstract.
Barnett, G, et al.; Re: Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation: M. Martinson, S. MacDiarmid and E. Black J Urol 2013; 189: 210-216; J Urol; 2013; 1444-1445; 190.
Baron, M, et al.; [Does urinary sacral neuromodulation improve bowel symptoms other than fecal incontinence: A systematic review]; Prog Urol; 2016;Abstract.
Barroso U Jr et al.; Electrical nerve stimulation for overactive bladder in children;Nature Reviews Urology; 2011; 402-407; 8.
Barroso, U, Jr., et al.; Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children; J Urol; 2013; 673-677; 190.
Bartley, J, et al.; Neuromodulation for overactive bladder; Nat Rev Urol; 2013; 513-521; 10.
Bartley, JM, et al.; Understanding clinic options for overactive bladder; Curr Urol Rep; 2013; 541-548; 14.
Batla, A, et al.; Lower urinary tract dysfunction in patients with functional movement disorders; J Neurol Sci; 2016; 192-194; 361.
Bayrak, O, et al.; Botulinum toxin injections for treating neurogenic detrusor overactivity; Turk J Urol; 2015; 221-227; 11.
Bemelmans, BL, et al.; Neuromodulation by implant for treating lower urinary tract symptoms and dysfunction; Eur Urol; 1999; 81-91; 36;Abstract.
Beneton, C, et al.; [The medical treatment of overactive bladder]; Neurochirurgie; 2003; 369-376; 49;Abstract.
Benson, JT, et al.; Pudendal neuralgia, a severe pain syndrome; Am J Obstet Gynecol; 2005; 1663-1668; 192.
Benson, JT; New therapeutic options for urge incontinence; Curr Womens Health Rep; 2001; 61-66; 1;Abstract.
Benson-Cooper, S, et al.; Introduction of sacral neuromodulation for the treatment of faecal incontinence; N Z Med J; 2013; 47-53; 126.
Related Publications (1)
Number Date Country
20170312512 A1 Nov 2017 US
Provisional Applications (1)
Number Date Country
61828981 May 2013 US
Divisions (1)
Number Date Country
Parent 14893946 US
Child 15650228 US